



Airdoc 鷹瞳

Beijing Airdoc Technology Co., Ltd.
北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

Stock Code 股份代號：2251

2024

Interim Report

中期報告

CONTENTS 目錄

	Page	頁次
Corporate Information	2	公司資料
Financial Summary	5	財務概要
Management Discussion and Analysis	6	管理層討論與分析
Other Information	38	其他資料
Independent Review Report	59	獨立審閱報告
Interim Condensed Consolidated Statement of Profit or Loss	61	中期簡明綜合損益表
Interim Condensed Consolidated Statement of Comprehensive Income	62	中期簡明綜合收益表
Interim Condensed Consolidated Statement of Financial Position	63	中期簡明綜合財務狀況表
Interim Condensed Consolidated Statement of Changes in Equity	65	中期簡明綜合權益變動表
Interim Condensed Consolidated Statement of Cash Flows	66	中期簡明綜合現金流量表
Notes to Interim Condensed Consolidated Financial Information	70	中期簡明綜合財務資料附註
Definitions and Glossary of Technical Terms	100	釋義及技術詞彙表



CORPORATE INFORMATION

公司資料

BOARD OF DIRECTORS

Executive Directors

Mr. ZHANG Dalei (張大磊)
(Chairman and chief executive officer)
Ms. WANG Lin (王林)
Dr. HE Chao (和超)
Mr. QIN Yong (秦勇)

Independent Non-executive Directors

Mr. NG Kong Ping Albert (吳港平)
(resigned on August 28, 2024)
Dr. WU Yangfeng (武陽豐)
Dr. HUANG Yanlin (黃彥林)

SUPERVISORS

Mr. WEI Yubo (魏宇博)
Ms. BAI Huihui (白惠惠)
Dr. LUO Ting (羅婷)

AUDIT COMMITTEE

Mr. NG Kong Ping Albert (吳港平) *(Chairman)*
(resigned on August 28, 2024)
Dr. HUANG Yanlin (黃彥林)
Dr. WU Yangfeng (武陽豐)

REMUNERATION AND APPRAISAL COMMITTEE

Dr. HUANG Yanlin (黃彥林) *(Chairman)*
Mr. NG Kong Ping Albert (吳港平)
(resigned on August 28, 2024)
Ms. WANG Lin (王林)

NOMINATION COMMITTEE

Mr. ZHANG Dalei (張大磊) *(Chairman)*
Dr. HUANG Yanlin (黃彥林)
Dr. WU Yangfeng (武陽豐)

董事會

執行董事

張大磊先生
(主席兼首席執行官)
王林女士
和超博士
秦勇先生

獨立非執行董事

吳港平先生
(於2024年8月28日辭任)
武陽豐博士
黃彥林博士

監事

魏宇博先生
白惠惠女士
羅婷博士

審核委員會

吳港平先生 *(主席)*
(於2024年8月28日辭任)
黃彥林博士
武陽豐博士

薪酬與考核委員會

黃彥林博士 *(主席)*
吳港平先生
(於2024年8月28日辭任)
王林女士

提名委員會

張大磊先生 *(主席)*
黃彥林博士
武陽豐博士

CORPORATE INFORMATION

公司資料

STRATEGY COMMITTEE

Mr. ZHANG Dalei (張大磊) (*Chairman*)
Mr. NG Kong Ping Albert (吳港平)
(*resigned on August 28, 2024*)
Dr. WU Yangfeng (武陽豐)

ESG COMMITTEE

Mr. ZHANG Dalei (張大磊) (*Chairman*)
Ms. WANG Lin (王林)
Dr. HE Chao (和超)

AUTHORIZED REPRESENTATIVES

Mr. ZHANG Dalei (張大磊)
Ms. SO Lai Shan (蘇麗珊)

JOINT COMPANY SECRETARIES

Ms. YANG Wenting (楊文婷)
Ms. SO Lai Shan (蘇麗珊)
(*ACG (CS, CGP) HKACG (CS, CGP)*)

HEAD OFFICE, REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

Room 21, 4th Floor, Building 2, A2 Yard
West Third Ring North Road
Haidian District
Beijing
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 1901, 19/F, Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong

戰略委員會

張大磊先生(主席)
吳港平先生
(於2024年8月28日辭任)
武陽豐博士

環境、社會及管治委員會

張大磊先生(主席)
王林女士
和超博士

授權代表

張大磊先生
蘇麗珊女士

聯席公司秘書

楊文婷女士
蘇麗珊女士(特許公司治理公會會士、
香港公司治理公會會士)

中國的總部、註冊辦事處和主要營業地點

中國
北京市
海淀區
西三環北路
甲2號院2號樓4層21室

香港主要營業地點

香港
銅鑼灣
希慎道33號
利園一期19樓1901室

CORPORATE INFORMATION

公司資料

H SHARE REGISTRAR

Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong

HONG KONG LEGAL ADVISER

Kirkland & Ellis
26/F, Gloucester Tower
The Landmark
15 Queen's Road Central
Hong Kong

PRC LEGAL ADVISER

Zhong Lun Law Firm
22-31/F, South Tower of CP Center
20 Jin He East Avenue
Chaoyang District
Beijing
PRC

AUDITOR

Ernst & Young
Certified Public Accountants
Registered Public Interest Entity Auditor
27/F, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

STOCK CODE

2251

COMPANY WEBSITE

www.airdoc.com

H股證券登記處

卓佳證券登記有限公司
香港
夏慤道16號
遠東金融中心17樓

香港法律顧問

凱易律師事務所
香港
皇后大道中15號
置地廣場
告羅士打大廈26樓

中國法律顧問

中倫律師事務所
中國
北京市
朝陽區
金和東路20號院
正大中心南塔22-31層

核數師

安永會計師事務所
執業會計師
註冊公眾利益實體核數師
香港
鰂魚涌
英皇道979號
太古坊一座27樓

股份代號

2251

公司網站

www.airdoc.com

FINANCIAL SUMMARY

財務概要

Six months ended June 30,
截至6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Revenue	收入	93,710	82,502
Cost of sales	銷售成本	(39,954)	(31,138)
Gross profit	毛利	53,756	51,364
Loss before tax	除稅前虧損	(82,730)	(40,529)
Loss for the period	期內虧損	(81,488)	(41,017)
Loss per share	每股虧損		
Basic and diluted (RMB)	基本及攤薄(人民幣元)	(0.79)	(0.36)

		As of June 30, 2024 截至2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	As of December 31, 2023 截至2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Financial Position	財務狀況		
Non-current assets	非流動資產	529,749	402,985
Current assets	流動資產	1,017,620	1,281,927
Non-current liabilities	非流動負債	13,951	16,891
Current liabilities	流動負債	61,791	110,237
Net assets	資產淨值	1,471,627	1,557,784
Total equity attributable to equity shareholders of the Company	本公司權益股東應佔權益 總額	1,455,242	1,540,383
Non-controlling interests	非控股權益	16,385	17,401

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

BUSINESS OVERVIEW

As an industry pioneer, we are focused on leveraging AI technology to provide comprehensive solutions for early detection, diagnosis and health risk assessment of chronic fundus and ophthalmic diseases, while also offering eye health management services such as myopia prevention and visual training. Our proprietary AI-empowered retina-based deep algorithm platform holds a leading position in the industry, making us one of the first to provide AI-empowered retina-based early detection, diagnosis and health risk assessment solutions in China. Our pipeline includes AI-based SaMDs, health risk assessment solutions and compatible AI hardware devices, designed to cater to medical institutions and consumer healthcare environments, based on which we developed an integrated solution that combines both software and hardware components. Additionally, we have launched AI-empowered treatment products targeting myopia, strabismus, and amblyopia in children and adolescents, achieving a one-stop solution that ranges from detection to assessment to treatment. This not only enables us to expand our commercial activities from detection to treatment, but also strengthens our channel management and synergistic effects, which broadens the market coverage of our products, extending beyond the clinical departments of hospitals to serve a wider range of primary healthcare institutions, consumer health environments, and eye health management settings.

Upholding the mission of “Accessible and Affordable to Everyone”, we are steadfast in expanding our service sites, enhancing the volume of detections and treatments, and thereby realizing substantial growth in revenue. In the process of our continual efforts in optimizing marketing strategy, during the Reporting Period, the number of our active service sites grew from 3,331 to 5,950, representing a year-over-year increase of 78.6%. Through our SaMDs and health risk assessment solutions, we detected 2.96 million cases in the first half of 2024. Additionally, our revenue increased from RMB82.5 million for the six months ended June 30, 2023 to RMB93.7 million for the Reporting Period, representing a year-over-year growth of 13.6%.

業務概覽

作為行業先鋒，鷹瞳科技專注於運用人工智能技術為慢性眼底疾病和眼科疾病的早期檢測、診斷以及健康風險評估提供全方位的解決方案，同時也涵蓋近視預防和視覺訓練等眼健康管理服務。我們自主研发的人工智能視網膜影像深度算法平台處於行業領先地位，並且是中國首批提供基於該技術的早期檢測、診斷和風險評估服務的公司之一。我們的產品管線包括為醫療機構和大健康領域提供的眼底輔助診斷人工智能軟件(SaMD)、健康風險評估系統以及相應的智能硬件設備，打造了集軟件和硬件於一體的解決方案。此外，我們還推出了針對兒童和青少年近視及斜弱視問題的人工智能治療產品，實現了從檢測、評估到治療的一站式解決方案。這不僅使我們能夠將商業活動從檢測擴展至治療，還增強了我們的渠道經營及協同效應，擴大了產品的市場覆蓋範圍，不限於醫院臨床科室，還能服務於更廣泛的基層醫療機構、大健康場景和眼健康管理場景。

我們秉承「讓健康無處不在」的使命，不斷拓展服務網點，提升檢測與治療量，並基於此實現規模性的收入增長。在持續優化銷售策略的過程中，報告期內，我們的活躍服務網點同比從3,331個增加到5,950個，增長78.6%。通過SaMD和健康風險評估方案，於2024年上半年我們共檢測了2.96百萬病例。此外，我們的收入也有增長，從2023年6月30日止六個月的人民幣82.5百萬元增長至報告期的人民幣93.7百萬元，增長率達到13.6%。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Our revenue growth is mainly attributed to the outstanding performance of Airdoc Medical (鷹瞳醫療) and Airdoc Eye Health (鷹瞳眼健康) of our three main business pillars. Specifically, revenue from Airdoc Medical increased from RMB29.8 million to RMB36.5 million, with a growth rate of 22.1%, which was driven by the expansion of our retinal detection services to more hospitals and primary healthcare institutions. Revenue from Airdoc Eye Health rose from RMB31.0 million to RMB38.0 million, with a growth rate of 22.7% stemming from our enhanced coverage of optical chains and persistent efforts in deepening the integration of diagnosis and treatment, which strategically extended our products and services to post-diagnostic treatment. Among the 2.96 million cases detected within the Reporting Period, we identified 15,842 significant positive cases, with a cumulative total of over 70,000 significant positive cases identified, thereby making a notable contribution to the early detection of severe illness among our vast user base.

1. Our Portfolio

We continued to deepen the strategy of integrated diagnosis and treatment, establishing a comprehensive medical AI product matrix of Retinal AI, myopia prevention and control AI, and visual training AI. Retinal AI products address the largely unmet medical needs for early detection and diagnosis of chronic diseases and fundus complications, and our self-developed AI-empowered retina-based early detection, diagnosis and health risk assessment solutions are potentially capable of covering a wide range of diseases and lesions. Our retinal AI products include SaMDs for detection and diagnosis, health risk assessment solutions, and proprietary AI-empowered hardware devices, forming an integrated solution of AI-based software and hardware. Our visual training AI products have been enhanced with AI-empowered eye tracking and training guidance modules, receiving recognition from both ophthalmologists and customers. In terms of our myopia prevention and control AI, leveraging more advanced R&D capabilities than our peers, we have developed non-invasive light management products, strengthening our potential advantages in this area and addressing customer needs while adhering to regulatory requirement.

這一收入增長主要歸功於我們的三大核心業務板塊中鷹瞳醫療和鷹瞳眼健康的出色表現。其中，鷹瞳醫療的收入從人民幣29.8百萬元增長至人民幣36.5百萬元，增長率為22.1%，這主要得益於我們將視網膜檢測業務擴展至更多醫院和基層醫療機構；鷹瞳眼健康的收入從人民幣31.0百萬元增長至人民幣38.0百萬元，增長率為22.7%，這來源於我們增強視光連鎖覆蓋範圍，並且不斷深化診療一體化服務，策略性地將產品及服務擴展到檢後治療。在報告期內的2.96百萬檢測病例中，我們識別出15,842例重大陽性案例，累計識別重大陽性案例達到7萬多例，為廣大用戶早期發現重症做出了重要貢獻。

1. 我們的產品組合

我們在診斷及治療一體化的戰略上不斷繼續深入，形成了眼底視網膜AI、近視防控AI、視覺訓練AI的醫療AI產品矩陣。眼底視網膜AI產品解決慢性疾病及眼底併發症的早期檢測及診斷的巨大醫療需求缺口問題，開發的人工智能視網膜影像識別的早期檢測、診斷及健康風險評估解決方案，有望涵蓋廣泛的疾病及病灶。眼底視網膜AI產品涵蓋用於檢測和診斷的軟件醫療器械、健康風險評估解決方案以及專有人工智能硬件設備，形成一個基於人工智能的軟件及硬件一體化的解決方案。視覺訓練AI產品增加了AI眼動和AI訓練指導模塊，受到專業醫生及客戶的認可。近視防控AI方面，借助擁有比同行更為先進的研發能力，我們研發了無創光線管理產品，增強了在這方面的潛在優勢，在符合監管要求的同時填補客戶剛需。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

The following diagram sets forth key details of our portfolio as of the date of this report:

下圖載列截至本報告日期我們產品組合的主要詳情：

Product Type 產品類型	Product 產品	Indication 適應症	Class of Medical Device 醫療器械類型	R&D Stage 研發階段		Registration Stage 註冊階段			Expected timeline for the next milestone 下一個里程碑的預期時間表	NMPA Registration Certificate Application 國家藥監局註冊及申請情況
				Early Stage of Development ¹ 開發初期 ¹	Late Stage of Development ² 開發後期 ²	Registrational Trial 註冊實驗	NMPA Submission 向國家藥監局提交申請	NMPA Approval 國家藥監局批准		
SaMDs for Detection and Diagnosis 用於檢測和診斷的SaMD	Airdoc AIRFUNDUS	Ver. 1.0 1.0版本	Diabetic retinopathy 糖尿病視網膜病變	Class III 第三類	[Progress bar from Early Stage to NMPA Approval]					Approved in August 2020 2020年8月獲批
			Hypertensive retinopathy 高血壓性視網膜病變		[Progress bar from Early Stage to NMPA Approval]					
		Ver. 2.0 2.0版本	Retinal vein occlusion 視網膜靜脈阻塞	Class III 第三類	[Progress bar from Early Stage to NMPA Approval]					To apply in Q4 2024 2024年第四季申請
		AMD 年齡相關性黃斑變性		[Progress bar from Early Stage to NMPA Approval]						
	Ver. 3.0 3.0版本	Pathological myopia 病理性近視	Class III 第三類	[Progress bar from Early Stage to NMPA Approval]					Q2 2025 2025年第二季度	To apply in H2 2025 2025年下半年申請
		Retinal detachment 視網膜脫落		[Progress bar from Early Stage to NMPA Approval]						
	Other individual products 其他獨立產品		Glaucoma detection 青光眼檢測	Class II 第二類	[Progress bar from Early Stage to NMPA Approval]					Approved in June 2020 2020年6月獲批
			Cataracts detection 白內障檢測	Class II 第二類	[Progress bar from Early Stage to NMPA Approval]					Approved in January 2022 2022年1月獲批
			Strabismus and amblyopia 斜視、弱視	Class II 第二類	[Progress bar from Early Stage to NMPA Approval]					
			Other products ³ 其他產品	Class II 第二類	[Progress bar from Early Stage to NMPA Approval]					

Product Type 產品類型	Indication 適應症	R&D Stage 研發階段		Commercialization Stage 商業化階段
		Early Stage of Development ¹ 開發初期 ¹	Late Stage of Development ² 開發後期 ²	
Health Risk Assessment Solutions ³ (HRS) 健康風險評估方案 ³ (HRS)	55 types of lesions and diseases ³ 55種病社病病病	[Progress bar from Early Stage to Late Stage]		[Progress bar from Commercialization to Commercialization]
	ICVD (prediction) ICVD (預測)	[Progress bar from Early Stage to Late Stage]		[Progress bar from Commercialization to Commercialization]
	Retinal vein occlusion (prediction) 視網膜靜脈阻塞 (預測)	[Progress bar from Early Stage to Late Stage]		[Progress bar from Commercialization to Commercialization]
	Dementia 癡呆症	[Progress bar from Early Stage to Late Stage]		[Progress bar from Commercialization to Commercialization]
	Hyperthyroidism 甲狀腺機能亢進	[Progress bar from Early Stage to Late Stage]		[Progress bar from Commercialization to Commercialization]
	Parkinson's disease 帕金森病	[Progress bar from Early Stage to Late Stage]		[Progress bar from Commercialization to Commercialization]
	Atrial fibrillation 房顫	[Progress bar from Early Stage to Late Stage]		[Progress bar from Commercialization to Commercialization]
	Diabetic nephropathy 糖尿病腎病	[Progress bar from Early Stage to Late Stage]		[Progress bar from Commercialization to Commercialization]
	Pregnancy-induced hypertension syndrome (eclampsia prediction) 孕高壓 (子癇預測)	[Progress bar from Early Stage to Late Stage]		[Progress bar from Commercialization to Commercialization]

Product Type 產品類型	Product 產品	Class of Medical Device 醫療器械類型	R&D Stage 研發階段		Registration Stage 註冊階段			Expected timeline for the next milestone 下一個里程碑的預期時間表	NMPA Registration Certificate Application 國家藥監局註冊及申請情況
			Early Stage of Development ¹ 開發初期 ¹	Late Stage of Development – Pilot Product ² 開發後期 – 試驗生產 ²	Registrational Trial 註冊實驗	NMPA Submission 向國家藥監局提交申請	NMPA Approval 國家藥監局批准		
Proprietary Hardware Device 自研硬件設備	AI-FUNDUSCAMERA-P	Class II 第二類	[Progress bar from Early Stage to NMPA Approval]					Approved in March 2021 2021年3月獲批	
	AI-FUNDUSCAMERA-D	Class II 第二類	[Progress bar from Early Stage to NMPA Approval]					Approved in July 2022 2022年7月獲批	
	AI-FUNDUSCAMERA-M	Class II 第二類	[Progress bar from Early Stage to NMPA Approval]					Have applied in Q4 2023 2023年第四季申請	
	Myopia light therapy device 近視光療治療儀	Class II 第二類	[Progress bar from Early Stage to NMPA Approval]					First approved in July 2018 2018年7月首次獲批	
	Myopia light therapy device 近視光療治療儀	Class III 第三類	[Progress bar from Early Stage to NMPA Approval]						

Our Core Product
我們的核心產品

- | | |
|--|--|
| <ol style="list-style-type: none"> 1. Early stage of development denotes the process of data collection, data labelling and model training. 2. Late stage of development denotes the process of data supplementation, algorithm training iteration and algorithm validation. 3. No regulatory approval or registration is required for the sale of our health risk assessment solutions in consumer healthcare and eye health environments. | <ol style="list-style-type: none"> 1. 開發初期指數據收集、數據標記及模型訓練過程。 2. 開發後期指數據補充、算法訓練迭代及算法驗證過程。 3. 在大健康和眼健康場景中，銷售我們的健康風險評估解決方案無需獲得監管批准或註冊。 |
|--|--|

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

- | | |
|--|--|
| <p>4. During the Reporting Period, we offered health risk assessment solutions with the ability to detect risk indicators, including risk assessments of retinal abnormalities, retinal vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease and anemia.</p> | <p>4. 於報告期內，我們提供具有檢測健康風險指標能力的健康風險評估解決方案，包括對視網膜異常、視網膜血管異常、玻璃體異常、視網膜腫瘤、視神經病變、黃斑病變、先天性視網膜異常、心血管異常及貧血症進行的風險評估。</p> |
| <p>5. Early stage of development denotes the process of product planning, product definition, engineering verification and design verification.</p> | <p>5. 開發初期指產品規劃、產品定義、工程驗證及設計驗證過程。</p> |
| <p>6. Pilot production denotes the process of production verification.</p> | <p>6. 試點生產指生產驗證過程。</p> |
| <p>7. Other individual products include five other SaMDs designed for the detection and auxiliary diagnosis of diseases and lesions, covering ICVD and ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial hypertension retinopathy and anemia.</p> | <p>7. 其他獨立產品包括其他五款SaMD旨在檢測及輔助診斷疾病及病灶，涵蓋了ICVD及ASCVD、妊娠期糖尿病視網膜病變、妊娠期高血壓性視網膜病變、顱內高壓相關視乳頭水腫視網膜病變及貧血症。</p> |

Retinal AI

Our retinal AI products include SaMDs for detection and auxiliary diagnosis, health risk assessment solutions and proprietary smart hardware devices.

SaMDs for Detection and Auxiliary Diagnosis

Airdoc-AIFUNDUS, our core product, is an AI-based SaMD available in three versions. Version 1.0 has obtained the Class III medical device certificate from the NMPA, which can assist in the diagnosis of diabetic retinopathy, with leading performance and compatibility with most fundus cameras on the market. Version 2.0 has completed clinical trials and applied for registration for multiple diseases. Version 3.0 is designed for the auxiliary diagnosis of pathological myopia and retinal detachment. In addition, our glaucoma detection SaMD and cataracts detection SaMD have obtained Class II device registration certificates from the Shanghai branch of the NMPA in June 2020 and January 2022, respectively.

眼底視網膜AI

我們的眼底視網膜AI產品包括用於檢測及輔助診斷的SaMD、健康風險評估方案和獨有的智能硬件設備。

用於檢測及輔助診斷的SaMD

核心產品Airdoc-AIFUNDUS屬人工智能SaMD，分三個版本。1.0版獲國家藥監局三類器械註冊證，能夠輔助糖尿病視網膜病變診斷，性能領先且兼容市面上大多數眼底相機。2.0版針對多種病症，完成臨床試驗並申請註冊。3.0版專為病理性近視及視網膜脫落的輔助診斷而設計。此外，青光眼檢測SaMD及白內障檢測SaMD分別於2020年6月、2022年1月獲上海市藥監局二類器械註冊證。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Health Risk Assessment Solutions

Our health risk assessment solutions are based on AI-empowered retina-based technology to provide end users with comprehensive health assessments and risk indicator detection across a spectrum of diseases. We provide customized solutions for different medical and healthcare settings, covering 55 types of lesions and disease risks. We have successfully marketed these solutions to a range of healthcare providers, including health checkup centers, and plan to further expand the coverage to encompass additional health risks.

Proprietary AI-empowered Hardware Devices

We have three in-house developed fundus cameras that are compatible with our auxiliary diagnosis SaMDs and health risk assessment solutions, enabling us to provide integrated healthcare solutions that combine hardware and software. These AI-powered hardware devices are capable of addressing pain points of conventional fundus cameras while reducing costs. AI-FUNDUSCAMERA-P is a portable, automatic and self-service fundus camera that can complete the retinal image capture automatically without the need for an operator, which has obtained the Class II medical device certificate from the Shanghai branch of the NMPA and commercialized in March 2021. AI-FUNDUSCAMERA-D is a fully automatic and fully self-service desktop fundus camera with excellent image quality and low cost, which has obtained the certificate in July 2022 and started the commercialization of the desktop version. AI-FUNDUSCAMERA-M, a multimodal health scanner integrated with more biosensors that can obtain a variety of physiological data, has been completed at the end of 2023.

健康風險評估解決方案

健康風險評估解決方案基於人工智能視網膜影像識別技術向終端用戶提供全面的健康評估和風險指標檢測，涵蓋多種病症。針對不同醫療健康場景，提供定製化方案，現覆蓋55種病灶和疾病風險。我們已成功將該等解決方案已售予多類醫療健康供應商，包括體檢中心等，並計劃擴大覆蓋範圍，以涵蓋更多健康風險。

獨有的人工智能硬件設備

我們擁有三款適配輔助診斷SaMD及健康風險評估解決方案的自主研發眼底相機，可提供軟硬件結合的醫療健康服務整體方案。硬設備由人工智能技術驅動，能解決現有眼底相機痛點，同時降低成本。AI-FUNDUSCAMERA-P是便攜、自動及自助的眼底相機，無需操作人員即可自動採集視網膜影像，2021年3月獲上海市藥監局二類醫療器械證書並商業化。AI-FUNDUSCAMERA-D是全自動自助台式眼底相機，影像質量佳且成本低，2022年7月獲證，並開啟了台式版本商業化。AI-FUNDUSCAMERA-M是整合更多生物傳感器的多模態健康掃描儀，能獲取多種生理數據，已於2023年底完成研發。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Myopia Prevention and Control AI

In the field of myopia prevention and control, we have introduced a series of AI-empowered therapeutic products that offer more effective prevention and management measures for myopia in children and adolescents. Our myopia prevention and control product employs non-invasive light management technology to safely and quickly prevent and control myopia, and mitigate the progression of myopia. This device has been registered as a Class II medical device and has received widespread recognition among the medical community and consumers for its significant treatment effects. This innovative product won the “Special Commendation Gold Awards” at the Salon International des Inventions de Genève (International Exhibition of Inventions in Geneva) in 2023. The NMPA promulgated in June 2023 a new regulation which reclassified myopia treatment device as Class III medical device and prohibits the production and sale of laser myopia treatment devices that have not obtained the Class III medical device certification since July 1, 2024. In accordance with the aforesaid requirements of the NMPA, our AI-based laser myopia prevention and control product is currently undergoing the process of upgrading from Class II medical device certification to Class III medical device certification. Save as discussed in the subsection headed “Trade Receivables – Impairment of trade receivables” of the Financial Review section below, the aforesaid regulatory change has limited impact on the Group’s business and financial conditions, primarily because (i) the production and sale of the Group’s other myopia treatment devices was not affected by such regulatory change; and (ii) as of the date of this report, the Company did not identify any significant increase in credit risk associated with the trade receivables with respect to the laser myopia treatment devices from other customers. We are committed to upholding long-termism and professional dedication to ensure our product quality and product registration.

近視防控AI

在近視防控的領域，我們推出了由AI賦能的治療類產品系列，為兒童青少年提供了更有效的近視預防和管理方法。我們的近視防控產品採用無創光線管理技術，能夠安全且快捷地防控近視，緩解近視的加深。此設備已通過醫療器械二類認證，並在醫學界和消費者中獲得了廣泛認可，其治療效果顯著。這一創新產品在2023年度日內瓦國際發明展上榮獲「特別表彰金獎」。國家藥監局於2023年6月頒佈一項新法規，將近視治療儀重新歸類為第三類醫療器械，並自2024年7月1日起禁止生產及銷售未取得第三類醫療器械認證的激光近視治療儀。根據上述國家藥監局的要求，我們的激光近視防控AI產品正在進行由二類醫療器械認證升級為三類醫療器械資質的過程。除下文財務回顧一節「應收賬款 – 應收賬款減值」分節所討論者外，上述監管變化對本集團業務及財務狀況的影響有限，主要由於(i)本集團其他近視治療儀的生產及銷售並未受該監管變化的影響；及(ii)截至本報告日期，本公司並未發現與其他客戶激光近視治療儀應收賬款相關的信貸風險顯著增加。我們秉承長期主義和專業精神做好產品質量和註冊。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Visual Training AI

Our AI-based visual training product has been registered as a Class II medical device and can be widely used in hospitals for the treatment of strabismus and amblyopia. The product includes a comprehensive range of visual training programs of nearly 500 types of training content, covering stimulation training, precision training, binocular visual training, fusion training and stereoscopic visual training, fully supporting all stages of strabismus and amblyopia treatment, aiming to enhance patients' visual functions. We provide treatments in both hospital and home settings, achieving seamless integration between the two and significantly enhancing the convenience of patient training.

During the Reporting Period, we have added an AI eye movement module and an AI training guide module to our digital therapy for visual training AI. AI eye movement can cost-effectively utilize AI algorithms to track pupil size, blink frequency, and gaze trajectory to simulate training of the human eye's gaze, sweep, and follow functions. Airdoc eye tracking algorithm realizes end-to-end sight line estimation based on deep learning, estimates sight line direction or fixation point of human eyes through facial keypoints, pupil and depth information, eye corner positions and other information, and maps the three-dimensional gaze vector of human eyes to the two-dimensional position of fixation point on the screen, thereby realizing predictive tracking. This technique can be applied not only to visual eye movement examination and training, but also to reading ability examination and training. The AI training guidance module utilizes the built-in camera to monitor training behaviors using AI behavior management algorithms. It provides real-time guidance based on the training content, including appropriate screen distance, correct training posture without tilting the head or having uneven shoulders, proper wearing of red-blue glasses or covering, and whether the training is focused. This technology aims to address the issue of lack of guidance from professional doctors

視覺訓練AI

我們研發的視覺訓練AI產品已獲得二類醫療器械註冊認證，可廣泛應用於醫院治療斜弱視的場合。該產品包含了一系列全面的視覺訓練方案近500種訓練內容，涵蓋刺激訓練、精細訓練、同時視訓練、融合訓練及立體視訓練等，全面支持斜弱視治療的各個階段，旨在提高患者的視覺功能。我們提供的治療方式分為到院訓練和家庭訓練兩種，實現醫院與家庭的無縫對接，極大提升了患者訓練的便捷性。

報告期內，我們的視覺訓練AI數字療法增加了AI眼動和AI訓練指導模塊。AI眼動能夠利用AI算法低成本的追蹤瞳孔大小、眨眼頻率、視線軌跡，模擬訓練人眼的注視、掃視和追隨功能。鷹瞳眼動追蹤算法基於深度學習實現端到端的視線估計，通過人臉關鍵點、瞳孔及深度信息、眼角位置信息等估計人眼的視線方向或者注視點，將人眼三維方視線向量與屏幕二維注視點位置映射並實現預測追蹤。該技術不光可以應用於視覺眼動的檢查和訓練，還可應用於閱讀能力的檢查和訓練。AI訓練指導模塊利用原生攝像頭，通過AI行為管理算法監控訓練行為，根據訓練的內容給出即時性指導，包括距離屏幕遠近適宜、是否正確訓練姿勢沒有歪頭/高低肩、是否正確佩戴紅藍眼鏡或遮蓋、是否在專注的訓練，通過該技術期望解決家庭訓練沒有專業醫生或視光師指導的問題，提升訓練效

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

or optometrists during home training to enhance the training effectiveness. Airdoc's training program recommendation algorithm recommends personalized training plans based on examination, training and review data accumulated from historical patients, adjusts the training plans and detailed parameters based on patient training data and review results, and recommends training plans that patients are more interested in based on their training behavior to improve training compliance and effectiveness.

WARNING UNDER RULE 18A.08(3) OF THE LISTING RULES: WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET OUR CORE PRODUCT, AIRDOC-AIFUNDUS.

2. Our R&D and Technologies

Our Retinal AI was approved by the NMPA as the first Class III AI-empowered retina-based auxiliary diagnosis product in China. Our AI-empowered retina-based early detection, diagnosis and health risk assessment technology has been fully validated in terms of scientific theory, clinical trial data and clinical pathways, and is supported by the results of the FDA-approved proof-of-concept clinical trial for MOA-equivalent products. We have also published in prestigious peer-reviewed scientific journals such as the Lancet series, the British Journal of Ophthalmology and British Journal of Dermatology, and have presented over 20 papers at influential artificial intelligence conferences such as Medical Image Computing and Computer-Assisted Intervention (MICCAI). In addition, the high performance of our products has been reported in prestigious peer-reviewed scientific journals such as the Natural series. In response to the demand for affordable and efficient solutions applicable to chronic diseases, we believe that our AI-empowered early detection and diagnostic solutions address the need by strengthening diagnostic capabilities, improving treatment compliance, and providing non-invasive, accurate, rapid, effective and scalable diagnostic solutions.

果。鷹瞳訓練方案推薦算法，基於歷史患者沉澱的檢查、訓練和複查數據推薦個性化訓練方案，根據患者訓練數據和複查結果調整訓練方案和細節參數，根據患者訓練行為推薦患者更感興趣的訓練方案，以提高訓練依從性及有效性。

上市規則第18A.08(3)條規定的警示聲明：我們可能最終無法開發及銷售我們的核心產品AIRDOC-AIFUNDUS。

2. 我們的研發及技術

我們的眼底視網膜AI獲得了中國首款國家藥監局批准的第三類人工智能視網膜影響識別輔助診斷產品。我們的人工智能視網膜影像識別早期檢測、診斷及健康風險評估技術，在科學理論、臨床試驗數據及臨床途徑方面經充分驗證，並獲FDA批准的MOA等效產品概念驗證臨床試驗結果的支持。我們還在《柳葉刀》系列、《英國眼科學雜誌》及《英國皮膚病學雜誌》等權威同行評審科學期刊上發表了，及在一些頗具影響力的人工智能學術會議（例如Medical Image Computing and Computer-Assisted Intervention (MICCAI)）上發表了超過20篇論文。此外，《自然》系列等多種權威同行評審科學期刊均報道過我們產品的高性能。針對適用於慢性病的價格低廉和高效的解決方案的需求，我們相信通過加強診斷能力、提高治療依從性以及提供無創、準確、快速、有效且可擴展的診斷解決方案，我們的人工智能早期檢測及診斷解決方案能滿足相關需求。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Since our Airdoc-AIFUNDUS built-in algorithms are already highly adaptable, they are compatible with a wide range of fundus camera brands and models. Different fundus cameras have different image characteristics, which vary in brightness, color, noise level and viewing angle. We have trained Airdoc-AIFUNDUS with images from a variety of fundus cameras to ensure consistent and accurate analysis results without the need to consider the specific camera model being used. In addition, we have utilized the data augmentation feature to generate more differentiated images and trained Airdoc-AIFUNDUS for greater compatibility.

Our Airdoc-AIFUNDUS (1.0) has been trained on data from 15 different organizations in China, making it applicable to a wider range of populations. Our data varies in terms of gender, age, geographic region, and other demographic characteristics, covering a significant portion of the national population. By training our Airdoc-AIFUNDUS with such diverse data and conducting multi-dimensional analysis on our product performance across different customers types, we can ensure that our products are always effective for all customers, thereby expanding the applicability of our products across markets.

由於我們的Airdoc-AIFUNDUS內置算法可實現高度適應性，因此可與廣泛的眼底相機品牌及型號兼容。不同的眼底相機具有不同的影像特性，在亮度、顏色、噪聲水平及視角方面存在差異。我們已使用來自各種眼底相機的影像對Airdoc-AIFUNDUS進行了訓練，以確保可在無需考慮所使用具體照相機型號的情況下，擁有一致且準確的分析結果。此外，我們利用數據增強功能生成更具差異性的影像，並對Airdoc-AIFUNDUS進行了訓練，以實現更高的兼容性。

我們的Airdoc-AIFUNDUS (1.0)經過了中國15個不同機構的數據的訓練，可適用於更廣泛的人群。我們的數據在性別、年齡、地理區域及其他人口特徵方面都各不相同，覆蓋了全國人口的很大一部分。通過使用此等多樣化數據訓練我們的Airdoc-AIFUNDUS及對不同類型的客戶進行產品性能的多維分析，我們可以確保我們的產品始終如一地對所有客戶有效，從而擴展我們產品於各市場上的適用性。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Our Airdoc-AIFUNDUS includes an automatic quality control feature that verifies retinal area, focus, color balance and exposure with multiple independent detectors. This feature can assess each captured image in real time and alert the user when the image quality is inadequate, ensuring that usable images are captured before departure of the patient. Traditional quality control relies on the operator's experience to assess the quality of retinal images, which has many drawbacks. For example, operators may lack the specialized training necessary to assess image quality; it can be time-consuming to assess all captured images, and maintaining consistency in assessment standards among different operators is challenging. Our automated real-time image quality control addresses these issues by improving accessibility and efficiency, enhancing diagnostic quality and reducing reliance on experienced physicians.

During the Reporting Period, we published the research results of a collaborative study in the *Journal of Cataract and Refractive Surgery (JCRS)*, the official journal of the American Society of Cataract and Refractive Surgery (ASCRS) and the European Society of Cataract and Refractive Surgeons (ESCRS). The study, conducted in collaboration with Professor Wang Xiaoying (王曉瑛) from the Eye and ENT Hospital of Fudan University (復旦大學附屬眼耳鼻喉科醫院), leveraging AI technologies, explores the impact of vault and other ocular biometric parameters on predicting refractive errors after Implantable Collamer Lens (ICL) implantation surgery. It proposes and validates a postoperative refractive power prediction method that is more accurate compared to existing calculation methods. This research allows for a more in-depth quantitative analysis of the correlation between vault and refractive power, aiding ophthalmologists in selecting the most suitable ICL for each individual.

我們的Airdoc-AIFUNDUS包含自動質量控制功能，能通過多個獨立探測器來驗證視網膜區域、聚焦、色彩平衡及曝光。該功能實時評估每一張捕捉到的影像，並在影像質量不合格時提醒用戶，從而確保在患者離開前捕捉到可用的影像。傳統的質量控制依賴於操作者的經驗來評估視網膜影像的質量，存在許多缺陷。例如，操作者可能缺乏評估影像質量所必需的專業培訓，需要相當長的時間來評估所有捕獲的圖像，而且不同操作者之間很難保持評估標準的一致性。我們的自動實時影像質量控制解決了該等問題，通過提高可及性和效率，提升診斷質量及減少對經驗豐富的醫生的依賴。

報告期內，我們在美國白內障和屈光手術協會(ASCRS)及歐洲白內障和屈光外科醫師協會(ESCRS)官方雜誌—《白內障與屈光手術雜誌(JCRS)》上發表一項合作研究成果。該研究乃與復旦大學附屬眼耳鼻喉科醫院王曉瑛教授合作進行，利用人工智能技術，探討了拱高(vault)以及其他眼生物測量參數對植入式隱形眼鏡(ICL)植入術後預測屈光誤差的影響。該研究提出並驗證了一種相比現有計算方法更為準確的術後屈光度預測方法。該研究能夠更深入的定量分析拱高和屈光度的關聯，有助於眼科醫生為每個個體選擇最適合的ICL。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

During the Reporting Period, we published another collaborative research results in *iScience*, a prestigious sub-journal of *Cell*. The study, conducted in collaboration with Professor Zhao Peiquan (趙培泉) from the Department of Ophthalmology at Xinhua Hospital affiliated with Shanghai Jiao Tong University School of Medicine (上海交通大學醫學院附屬新華醫院), innovatively introduced a novel semi-supervised deep learning model that enhances the model's classification performance using a small amount of labeled data and a large amount of unlabeled data, aiming to reduce the data annotation cost required for automatic staging of retinopathy of prematurity. The results demonstrate that this method can achieve good classification performance while significantly reducing the need for annotations in clinical scenarios.

During the Reporting Period, our in-house developed AI eye movement technology was expected to cost-effectively applying eye trackers into the realm of ophthalmic visual health. With AI training guidance based on ordinary RGB cameras, we aim to establish an Airdoc-featured AI visual training digital therapy, thus forming a competitive advantage.

During the Reporting Period, we were granted 20 new patents, including 14 inventions, three utility models, and three appearance designs. To date, we have 258 patents, including 122 inventions, 60 utility models, and 76 appearance designs. We also possess 94 software copyrights.

報告期內，我們於《Cell》知名子刊《iScience》上發表另一項合作研究成果。該研究乃與上海交通大學醫學院附屬新華醫院眼科趙培泉教授合作進行，創新性地引入一種新的半監督深度學習模型，使用少量標註數據和大量未標註數據來提升模型的分類性能，旨在減少早產兒視網膜病變自動分期所需的數據標註成本。結果表明，該方法能夠在大幅減少臨床場景下標註需求的同時，達到良好的分類效果。

在報告期內，我們自主研發的AI眼動技術有望低成本的將眼動儀應用於眼科視覺健康領域，基於普通RGB攝像頭的AI訓練指導，我們旨在構建鷹瞳特色的AI視覺訓練數字療法，從而形成競爭優勢。

報告期內，我們獲得20項新專利，包括14項發明、三項實用新型及三項外觀設計。迄今為止，我們擁有專利258項，其中發明122項、實用新型60項及外觀設計76項，亦擁有94項軟件版權。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

3. Commercialization Development

Our portfolio of Retinal AI products, based on AI-empowered retina-based technology, provides early detection, diagnosis and health risk assessment solutions with the potential to cover a wide range of application scenarios and multiple chronic diseases. Our AI-based myopia prevention and control products and AI-based visual training products, combined with Retinal AI, synergistically empower the formation of an integrated AI-empowered diagnostic and therapeutic eye health solution for all age groups throughout their lifetime. This solution ranges from AI-based examination and fitting to AI-based assessment and predictive analysis to the prevention, correction and control of myopia, as well as AI-based strabismic and amblyopic visual training. Given the diverse range of healthcare scenarios in which our products can be applied to, we have developed a flexible and multi-channel sales and marketing strategy to cover various commercialization pathways in medical institutions, consumer healthcare environments and eye health management settings.

During the Reporting Period, our customer count increased to 418, and the number of active service sites using our SaMDs and health risk assessment solutions grew from 3,331 to 5,950, representing a 78.6% increase year-over-year. During our provision of SaMDs or health risk assessment solutions, we charge our customers on a pay-per-use basis based on the actual amount of testing services we provided. For the Reporting Period, we charged an average of RMB21.05 per use, which is calculated by dividing our revenue from the provision of AI-based software solutions by the uses, representing a year-over-year increase of 0.9% from RMB20.87 per use for the same period in 2023.

3. 商業化發展

我們的眼底視網膜AI產品組合基於人工智能視網膜影像識別技術，提供早期檢測、診斷及健康風險評估解決方案，有潛力覆蓋廣泛的應用場景及多種慢性疾病；近視防控AI及視覺訓練AI產品與眼底視網膜AI相結合，聯動賦能，形成了從AI檢查驗配、AI評估與預測分析，到近視的預防、矯正和控制，以及斜、弱視AI視覺訓練，這樣的一體化AI賦能診療的全年齡段全生命週期的眼健康解決方案。由於多種醫療健康場景均可使用我們的產品，我們開發出了一套靈活、多渠道的銷售及營銷策略以涵蓋醫療機構、大健康場景及眼健康管理場景的多種商業化管道。

於報告期期間，我們的客戶數量增長到418個，使用我們的SaMD及健康風險評估解決方案的活躍服務網點數量從3,331增加到5,950個，同比增長78.6%。就我們提供的SaMD或健康風險評估解決方案而言，根據我們提供檢測服務的實際用量，我們向客戶按次收費。於報告期內，我們平均每次檢測收費為人民幣21.05元（通過提供人工智能軟件解決方案的收入除以檢測次數計算得出），較2023年同期的每次檢測人民幣20.87元同比增長0.9%。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

During the Reporting Period, we continued empowering our Airdoc Eye Health business by AI technology, relevant products of which can detect over 30 eye health risks, including vascular, neural, hemorrhages, plaques and other abnormal manifestations. Through GenAI (generative artificial intelligence) technology, such products are able to predict retinal changes and refractive progression. Through monitoring progression parameters, we achieved precise and personalized eye health management, producing visual reports suitable for eyewear fitting and eye health management settings. This not only enhances the sense of value, but also significantly reduces professional reliance, helping optometry institutions achieve improvements in both professional eye health capabilities and business performance. Moreover, we made full use of AI technological advantages to achieve an all-around process from AI recognition and analysis to digital management and to on-the-ground support, providing efficient and intelligent solutions for Airdoc Eye Health business. As of June 30, 2024, our Airdoc Eye Health business covered 2,073 service sites, representing a 51.2% increase year-over-year; among which, our myopia AI-based prevention and control products recorded 1,672.7 thousand uses, representing an increase of 87.9% from the end of 2023, providing services to 16.0 thousand registered users, and our visual training AI products recorded 918.9 thousand trainings, providing trainings to 9.0 thousand homebased registered users and 69.0 thousand in-hospital registered users. Moreover, our AI-based visual training products have covered over 800 hospitals nationwide and helped more than 300.0 thousand patients recover.

在報告期內，我們繼續用AI賦能鷹瞳眼健康業務，相關產品可檢測出包含血管類、神經類，以及出血、斑塊等異常表現在內的30多項的眼健康風險，並結合GenAI(生成式人工智能)技術，對視網膜變化和屈光進展進行預測，通過對進展參數的監測實現精準化、個性化的眼健康管理，產出適用於配鏡及眼健康管理場景的可視化報告，在提升價值感的同時，大大降低在專業領域對人的依賴，助力機構專業眼健康能力和業務業績的雙線提升，充分利用人工智能的技術優勢，實現從AI識別分析到數字化管理，再到落地支持的全方位流程，為眼健康業務提供高效、智能的解決方案。截至2024年6月30日，我們的鷹瞳眼健康業務覆蓋2,073個網點，同比增長51.2%；其中，我們的近視防控AI產品使用次數達到167.27萬，相比2023年底增長87.9%，服務用戶數量達到1.6萬；視覺訓練AI產品訓練次數為91.89萬，家庭訓練服務用戶數量為0.9萬，到院訓練服務用戶數量為6.9萬，並且，我們的視覺訓練AI產品已經覆蓋全國800餘家醫院，幫助30餘萬名患者康復。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

As of June 30, 2024, our marketing team consists of 84 members, providing customers with a full life cycle of customized support. Our sales and marketing team, which comprises functions of sales, marketing, product solutions and customer success, covers different geographical regions and commercialization channels. We provide our sales and marketing personnel with comprehensive trainings covering corporate culture, product knowledge, medical theories and marketing strategies to further enhance their professional capabilities.

Airdoc Medical

Airdoc Medical covers medical institutions which include hospitals, primary healthcare institutions (such as community clinics) and health checkup centers. Aiming to be of great help to doctors and address the issue of unavailable experienced retinal specialists in underserved regions, our solution for Airdoc Medical primarily serves the clinical needs for detection and auxiliary diagnosis of certain indications with quantitative measurements, such as the total size and number of hemorrhages and exudates.

For our sales to hospitals, we seek to include our Airdoc-AIFUNDUS (1.0) in the pricing guidance in most provinces in China, upon which hospitals can charge patients separately for such medical service. As of the date of this report, the pricing guidance related to our products had been issued by local governmental authorities in Beijing, Hebei, Shandong, Shanxi, Anhui and Jiangsu, pursuant to which our Airdoc-AIFUNDUS can be utilized as a new charging item. For primary healthcare institutions and health checkup centers, we also market our health risk assessment solutions as we see strong opportunities there.

截至2024年6月30日，我們營銷團隊有84名成員組成的，為客戶提供全生命週期的定製化支持。我們的銷售及營銷團隊由銷售、市場營銷、產品解決方案和客戶成功等職能組成，覆蓋不同地理區域及商業化管道。我們為銷售及營銷人員提供全面培訓，包括企業文化、產品知識、醫學理論及營銷策略等以進一步提升專業能力。

鷹瞳醫療

鷹瞳醫療覆蓋包括醫院、基層醫療機構(如社區診所)及體檢中心在內的醫療機構。為了成為醫生的極大助力，解決醫療資源欠缺地區資深視網膜專家數量不足的問題，我們鷹瞳醫療的解決方案主要滿足檢測及輔助診斷某些適應症的臨床需求，提供諸多定量測量指標，如出血及滲出總面積及數量。

對於面向醫院的銷售，我們致力將Airdoc-AIFUNDUS (1.0)納入中國大部分省份的定價指引，據此，醫院可就該等醫療服務向患者單獨收費。截至本報告日期，北京、河北、山東、山西、安徽及江蘇的地方政府機關已發佈我們產品相關的定價指引，據此，我們的Airdoc-AIFUNDUS可作為新增收費項目。對於基層醫療機構及體檢中心而言，由於我們謹此預見到巨大機遇，因此亦向其銷售我們的健康風險評估解決方案。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

We are dedicated to increasing the penetration of our products in both hospitals and primary healthcare institutions. During the Reporting Period, we sold our Airdoc-AIFUNDUS (1.0) to hospitals and primary healthcare institutions, witnessing a significant growth in the number of service sites covered and detections conducted. The number of active hospital service sites we covered reached 244, representing a year-over-year increase of 70.6%, with the number of detections conducted reaching 125.0 thousand, up by 106.0% year-over-year. The number of active primary healthcare institution service sites we covered reached 1,533, representing a year-over-year increase of 192.0%, with the number of detections conducted reaching 409.0 thousand, up by 324.6% year-over-year. In addition, we also implemented our AI-based solutions in over 296 health checkup centers across China. Among them, some health checkup centers have achieved a repurchase rate of over 50% for our SaMD products. Based on GenAI large language model technology, we have also supported iKang launching an AI digital human “ikkie”, iKang’s first AI based health butler, offering interactive medical knowledge Q&A on physical examination knowledge, disease consultation, report result interpretation and intelligent answering, covering all stages before, during and after examinations, thereby providing users with a real-time, intelligent, precise and connected new experience. During the Reporting Period, we recorded revenue of RMB36.5 million from Airdoc Medical through the sales of our Airdoc-AIFUNDUS (1.0), representing a 22.1% increase year-over-year.

我們致力於擴大產品在等級醫院和基層醫療機構的覆蓋。於報告期內，我們將Airdoc-AIFUNDUS (1.0)銷售給醫院和基層醫療機構的網點數量和檢測數量都有較大的增長。其中，醫院的覆蓋活躍網點數量達到了244家，同比增長70.6%；檢測次數達到了12.5萬，同比增長106.0%。基層醫療機構的覆蓋活躍網點數達到了1,533家，同比增長192.0%；檢測次數達到40.9萬，同比增長324.6%。此外，全國超過296個體檢中心部署了我們的人工智能解決方案，其中，部分體檢中心對我們軟件產品的復購率達到了50%以上。我們還基於GenAI大語言模型技術支持愛康集團推出智能AI數字人「ikkie」—愛康集團首個AI健康管家，實現了體檢知識、疾病諮詢、報告解讀、智能問答的交互式醫療知識問答，服務覆蓋檢前、檢中、檢後全環節，為用戶提供實時、智能、精準、連接的全新體驗。於報告期間，我們通過銷售Airdoc-AIFUNDUS (1.0)視網膜相機，來自鷹瞳醫療的收入達到人民幣36.5百萬元，較同期增長22.1%。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Our rapid growth of business under Airdoc Medical settings is attributable to the social benefits and social values generated from our industry upgrades empowered by AI technology and the new trends in industry development led by us. We also introduced our products to the physical examination, endocrinology, ophthalmology, obstetrics and gynecology, and cardiology departments of several hospitals, for example, the Chinese People's Liberation Army General Hospital (301 Hospital), Peking University First Hospital, Beijing Anzhen Hospital, Sichuan Provincial People's Hospital, Shanghai First Maternity and Infant Hospital and Zhongshan Hospital affiliated to Fudan University.

We undertook a project in relation to the technology application scenarios in Beijing Zhongguancun Science City, and developed and deployed our diabetes retinopathy auxiliary diagnosis SaMD, namely Airdoc-AIFUNDUS (1.0), and follow-up algorithms on the Beijing Haidian District Government Affairs Cloud (北京市海澱區政務雲). It is the first time to match our fundus AI algorithm with the China-made Cambricon Technologies' GPU chip, and at the same time, it has also established a new model of AI-based regional primary healthcare screening, follow-up and referral, linking 29 community health service centers in Haidian District, Beijing. In order to optimize the management of the diabetic (chronic disease) population in the region and to improve the early diagnosis rate of diabetic retinopathy, the departments of ophthalmology and physical examination of Beijing Haidian Hospital have applied a system with our technology to cover the community hospitals in the region for retinal disease screening. During the Reporting Period, 5,297 cases have been detected.

我們在鷹瞳醫療場景下業務的高速增長，得益於我們以AI技術賦能行業升級，引領行業發展新趨勢所帶來的社會效益和社會價值。同時，我們的產品已經進入醫院的體檢科、內分泌科、眼科以及婦產科、心內科科室，涉及的部分醫院有解放軍總醫院(301醫院)、北京大學第一醫院、北京安貞醫院、四川省人民醫院、上海第一婦嬰保健院、復旦大學附屬中山醫院等。

我們承接的北京市中關村科學城科技應用場景的項目，在北京市海澱區政務雲上開發部署了糖尿病視網膜病變輔助診斷軟件Airdoc-AIFUNDUS (1.0)及隨訪算法。這次實踐首次將眼底AI算法與國產芯片寒武紀GPU相匹配，同時還構建了以北京市海澱區29家社區衛生服務中心聯動的AI區域基層醫療篩查、隨訪及轉診新模式。為優化全區糖尿病(慢病)人群的管理，提升糖尿病視網膜病變的早期診斷率，北京海澱醫院眼科與體檢科應用帶有我們技術的系統，輻射全區社區醫院，用於視網膜疾病篩查。報告期內，已經檢測人數達到5,297例。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

During the Reporting Period, we also participated in the Shandong Province's Pilot Project for Integrated Management, Prevention and Treatment of Chronic Diseases — Management of Three Highs (high blood pressure, high blood sugar and high cholesterol) and Prevention of Six Diseases. At present, the screening area covers more than 60 community health service centers, health service stations, township health centers and village health clinics in the Qingdao West Coast New Area (Huangdao), City North District, Laixi City, Pingdu City, and part of Licang District and Chengyang District. Approximately 65,000 person-times screenings have been conducted.

Airdoc Health

Airdoc Health covers a wide range of consumer healthcare environments, such as insurance companies and pharmacies, to which we offer our health risk assessment solutions that focus on chronic diseases. As the concept of health management is on the rise, more types of business settings have emerged as the entry point of daily health management for specific populations, and they are keen to better serve their end users' specific healthcare needs. We empower consumer healthcare environments to provide the AI-enabled assessment of risk factors for chronic diseases and continuous health monitoring, allowing high-quality healthcare accessible in a much wider range of business settings and to a much larger base of end users.

報告期內，我們還參與山東省三高（高血壓、高血糖及高膽固醇）共管六病同防醫防融合慢性病管理試點項目，目前篩查範圍覆蓋了青島西海岸新區（黃島）、市北區、萊西市、平度市、李滄區及城陽區部分區域的60多家的社區衛生服務中心、衛生服務站、鄉鎮衛生院、村衛生室，共計篩查約6.5萬人次。

鷹瞳健康

鷹瞳健康覆蓋了眾多大健康場景，如保險公司及醫藥公司，我們向該客戶群體提供聚焦於慢性疾病的健康風險評估解決方案。隨著健康管理理念的興起，越來越多類型的商業場景涌現出來成為特定人群日常健康管理的入口，該等商業場景也急於更好地滿足其終端用戶特定的健康服務需求。我們賦能大健康場景以提供人工智能驅動的慢性疾病風險因素評估及健康持續監測服務，從而讓更多的終端用戶在更多的商業場景下可以享受到高質量的健康服務。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

In the business setting of insurance, we assist insurance companies in evaluating the health conditions of their insurance applicants and insured members in an accurate, efficient and continuous manner. During the Reporting Period, we provided our solutions to top commercial insurance companies, including Taikang Life Insurance Company Limited, Ping An Insurance (Group) Company of China, Ltd., China Life Insurance Company Limited, New China Life Insurance Co., Ltd. and Ping An Health Insurance Co., Ltd. (“**Ping An Health Insurance**”). Among them, our Retinal AI — AI health risk assessment solutions was first included as a health management service into the multiple innovative and high-quality value-added services in a million coverage medical insurance launched by Ping An Health Insurance. This service helps the insured individuals screen and assess various retinal diseases and chronic disease risks, enabling better management of their health conditions. During the Reporting Period, we recorded revenue of RMB19.3 million from Airdoc Health.

With the progress of our overseas CE mark registration activities, we actively explored the overseas market during the Reporting Period, making business progress in Chile, Spain, the Czech Republic, Thailand, the Philippines, Indonesia, South Africa and Malaysia. During the Reporting Period, our overseas revenue reached RMB4.6 million, accounting for 4.9% of our total revenue for the Reporting Period.

During the Reporting Period, we deployed the “Retina Primary Screening Fundus Camera Detection and Health Management Solution” in more than 400 branches of Hebei Postal Savings Bank, providing advanced fundus health monitoring services for its customer base, and have served more than 145,000 customers in total.

在保險業務場景下，我們協助保險公司準確、高效及持續地評估其投保人及受保人的健康狀況。於報告期內，我們為包括泰康人壽保險股份有限公司、中國平安保險(集團)股份有限公司、中國人壽保險股份有限公司、新華人壽保險股份有限公司和平安健康保險股份有限公司(以下簡稱「**平安健康保險**」)在內的頂尖商業保險公司提供解決方案。其中，我們在平安健康保險推出的百萬醫療險創新升級的多項優質增值服務中，首次納入了我們的眼底視網膜AI-視網膜影像人工智能健康風險評估作為健康管理服務，幫助被保人篩查和評估多種視網膜疾病和慢病隱患，更好地管理自己的健康狀況。於報告期內，我們來自鷹瞳健康的收入達到人民幣**19.3**百萬元。

隨著我們海外CE標誌的註冊業務的進展，報告期內，我們積極佈局海外市場業務，並在智利、西班牙、捷克、泰國、菲律賓、印度尼西亞、南非及馬來西亞，均取得了業務進展。於報告期內，我們來自海外的收入達到人民幣**4.6**百萬元，佔我們報告期內總收入的**4.9%**。

報告期間，我們在河北省郵政儲蓄銀行，全省超過**400**個營業網點落地部署了「視網膜初級篩查眼底攝像檢查與健康管理解決方案」，為郵政儲蓄客戶群體提供先進的眼底健康監測服務，已累計服務客戶的數量超過**145,000**名。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Airdoc Eye Health

Airdoc Eye Health covers various eye health management settings, such as optometry centers and government sponsored vision screening projects, to which we offer our health risk assessment solutions that focus on retinal conditions. Particularly, myopia prevention and control has not only become a nationwide activity advocated by the government but also an issue that is given priority by parents to solve when their children spend more time in screens due to the extensive use of mobile devices. Through our Airdoc Eye Health solutions, we are keen to address the needs for eye health evaluation as well as myopia control and prevention for the younger generation. For optometry centers, we provide our customers with a comprehensive analysis of their end customers' retinal conditions, enabling them not only to identify risk factors that may lead to impaired vision, but also provide customized professional eyeglasses prescriptions. During the Reporting Period, our solutions were deployed in optometry chain institutions through our effective distributors, and the number of service sites covered reached 2,073, representing a year-over-year increase of 51.2%. During the Reporting Period, we recorded revenue of RMB38.0 million from the Airdoc Eye Health. Our myopia prevention and control and visual training businesses not only enable us to achieve the integration of diagnosis and treatment but also bring synergies and additional value to Airdoc Eye Health business, which will also benefit our overall business operations for a long term.

鷹瞳眼健康

鷹瞳眼健康覆蓋各類眼健康管理場景，如視光中心及政府贊助視力篩查項目，我們向該客戶群體提供聚焦於視網膜狀況的健康風險評估解決方案。尤其是近視防控，不僅已經成為政府倡導的全國性活動，也是家長在孩子大量使用移動設備而面臨螢幕時間增加時會優先解決的問題。通過鷹瞳眼健康解決方案，我們致力於滿足年輕一代對眼健康評估及近視防控的需求。就視光中心而言，我們向客戶提供針對其終端客戶視網膜狀況的全面分析，使其不僅能夠識別可能導致視力受損的風險因素，亦能提供定製化專業配鏡處方。於報告期內，通過我們有效的分銷商，我們的解決方案已視光連鎖機構部署，所覆蓋的服務網點數量為2,073個，同比增長51.2%。於報告期內，我們錄得來自鷹瞳眼健康業務的收入為人民幣38.0百萬元。我們的近視防控及視覺訓練業務，不僅使我們實現了診療一體化，還為我們眼健康業務帶來協同效應及額外價值，這也將使我們的整體業務營運長期受益。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

4. Production Capability

Cost control and quality assurance have always been crucial to us. We have two manufacture bases located in Changping District, Beijing and the High-tech Development Zone in Changsha, Hunan, respectively. In particular, the Hunan manufacturing base occupies a site area of nearly 5,000 square meters with complete testing and production equipment, started production after obtaining the Medical Device Production License in October 2022 and received ISO13485 medical device quality management system certification in 2023. Our factories strictly implement the 6S lean management system and ERP production management system to ensure manufacture efficiency and compliance with all required safety measures and requirements of laws and regulations. Currently, our Changsha manufacture base has a professional management team of nearly 30 members operating four production lines and a cleanroom, capable of producing various types of devices and product R&D, with a capacity of approximately 100,000 fundus cameras per year.

During the Reporting Period, we invested in establishing a reliability laboratory in the Changsha factory. This laboratory currently possesses 15 types of equipment, including high- and low-temperature impact testing machines, salt mist testing machines, ultraviolet (UV) testing machines, and sand and dust testing chambers, and is capable of undertaking over 20 experimental projects, fully meeting various experimental needs for R&D and production. By establishing the Changsha factory, we can strengthen cost and quality control and are therefore confident that we will keep maintaining competitive advantages in the future.

4. 生產力

成本控制及質量保證對我們而言一直至關重要。我們擁有2個製造基地，分別位於北京昌平區和湖南長沙高新技術開發區。其中湖南製造基地，佔地近5,000平米，擁有完善的測試和生產設備，於2022年10月獲得醫療器械生產許可證後開始投產，並在2023年獲得ISO13485醫療器械質量管理體系認證。我們的工廠嚴格執行6S精益管理體系及ERP生產管理系統，確保生產效率並符合所有必須的安全措施和法律法規的要求。目前我們的長沙生產基地專業管理團隊近30人，運營四條生產線、無塵車間，能夠製造多種類型的設備和具備產品研發實驗的能力，產能約為100,000台眼底相機/年。

報告期內，我們在長沙工廠投入建立的可靠性實驗室，目前擁有涵蓋高低溫衝擊實驗機，鹽霧實驗機，紫外線(UV)測試機，沙塵實驗箱等各類設備共計15種，可承接實驗項目達20餘項，完全滿足研發、生產等各類實驗需求。通過設立長沙工廠，我們能夠加強成本及質量控制並相信我們於未來將繼續保持競爭優勢。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

5. Future and Outlook

We target to continue the expansion of our sales channels, aiming for a significant boost in sales growth across Airdoc Medical, Airdoc Health and Airdoc Eye Health. We aim to continue increasing our sales by integrating large language model (LLM) technologies into our main service process. Furthermore, we plan to introduce new business initiatives by combining diagnosis and treatment services for myopia, strabismus and amblyopia, outlining our future strategy. We have fully prepared for a comprehensive entry into the overseas market. We believe our products will be well accepted by overseas markets because of our continued efforts in expanding our business footprints in overseas markets, such as Malaysia, Singapore, Thailand, the United Arab Emirates and South Africa. We expect that sales from these new markets will gradually increase.

GenAI is the trend of the moment, with its applications becoming increasingly integrated into everyday life. We continue to invest in the R&D of GenAI-related technologies by further incorporating it into our products and services. We are actively formulating strategies to introduce GenAI in our auxiliary diagnosis, disease detection and personalized medical advices, bridging doctors and patients conveniently and efficiently without constraints of time and space.

With the perfection of our laboratory in Changsha manufacture base, we will have more competitive edges in terms of our three main products, namely Retinal AI, myopia prevention and control AI, and visual training AI. At the same time, we will continue our efforts in reducing costs and improving gross profit margins. Looking ahead, we will continue investing in R&D, integrating comprehensive AI-based therapy solutions into our existing diagnostic technologies. We will also remain committed to increasing production capacity, expanding global coverage, and launching the next-generation products that are “accessible and affordable to everyone”.

5. 未來及前景

我們的目標為繼續拓寬我們的銷售管道，力爭大幅提升鷹瞳醫療、鷹瞳健康及鷹瞳眼健康的銷售增長。我們力爭通過將大語言模型(LLM)技術融入我們的主要服務流程，繼續提高銷售額。此外，我們計劃通過結合近視、斜視及弱視的診斷及治療服務推出新業務舉措以勾畫我們的未來戰略。我們已為全面進入海外市場做好充分準備。由於我們不斷努力擴大我們於海外市場的業務足跡，如馬來西亞、新加坡、泰國、阿拉伯聯合酋長國及南非，我們相信我們的產品將獲海外市場接納。我們預計於該等新市場的銷售額將逐步增加。

GenAI是當下的趨勢，其應用日益融入日常生活。我們持續投入GenAI相關技術研發，將其進一步納入我們的產品及服務。我們正積極制定戰略，於輔助問診、疾病檢測及個性化醫療建議中引入GenAI，方便高效地連接醫生及患者，且不受時間及空間限制。

隨著長沙製造基地實驗室的完善，我們的眼底視網膜AI、近視防控AI和視覺訓練AI三大版塊產品將更具有競爭優勢。同時，我們將繼續努力精簡成本，提高毛利率。展望未來，我們將持續投入研發力量，將全面的人工智能治療解決方案整合至我們現有的診斷技術中。我們亦將繼續致力於提高產能，擴大全球覆蓋率，並推出「讓健康無處不在」的下一代產品。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

FINANCIAL REVIEW

Revenue

During the Reporting Period, we primarily generated revenue from provision of AI-based software solutions, which represented our provision of SaMD and health risk assessment solutions to medical institutions and healthcare providers, including hospitals, community clinics, health checkup centers, insurance companies, optometry centers and pharmacies. We also generated revenue from the sales of hardware devices, representing the fundus cameras we sold together with our software, as well as the sales of AI-based myopia prevention and control products and visual training products. Depending on customer needs, we may sell our software as a standalone product or as a bundle with hardware developed by us or third parties.

Our revenue increased by 13.6% from RMB82.5 million for the six months ended June 30, 2023 to RMB93.7 million for the six months ended June 30, 2024. This increase was primarily attributable to (i) a 22.1% year-over-year increase in the business of Airdoc Medical, resulting from a growth in coverage of hospitals and primary healthcare institutions; and (ii) a 22.7% year-over-year growth in the business of Airdoc Eye Health, driven by sales of our myopia prevention and control products; partially offset by a slight decrease in the revenue from Airdoc Health.

Cost of Sales

Our cost of sales primarily consists of (i) employee benefits expenses; (ii) hardware devices costs, representing the cost of sales of in-house fundus camera and in-house myopia prevention and control products, and the purchase cost of fundus cameras from third parties. We provide integrated healthcare solutions that combine hardware and software and do not sell hardware devices separately to our customers; (iii) depreciation expenses primarily relate to the depreciation of hardware devices; and (iv) cloud service fees, representing the service fees we paid to cloud service suppliers to support our AI-based software solutions.

財務回顧

收入

於報告期內，我們的收入主要來源於提供人工智能軟件解決方案，即我們向醫療機構及醫療健康供應商（包括醫院、社區診所、體檢中心、保險公司、視光中心及藥房）提供SaMD及健康風險評估解決方案。我們的收入亦來源於銷售硬件設備（即連同我們的軟件一起銷售的眼底相機），以及銷售近視防控AI產品及視覺訓練產品。根據客戶需求，我們可將軟件作為單獨產品出售或與我們自研或第三方的硬件捆綁銷售。

我們的收入由截至2023年6月30日止六個月的人民幣82.5百萬元增加13.6%至截至2024年6月30日止六個月的人民幣93.7百萬元。該增加主要由於(i)醫院及基層醫療機構的覆蓋率均有所增長，鷹瞳醫療業務同比增長22.1%；及(ii)受近視防控產品銷售額的推動，鷹瞳眼健康業務同比增長22.7%；部分由鷹瞳健康的收入略微下降所抵銷。

銷售成本

我們的銷售成本主要包括(i)僱員福利開支；(ii)硬件設備成本，為內部眼底相機及內部近視防控產品的銷售成本，以及從第三方購買眼底相機的成本。我們提供硬件和軟件相結合的醫療健康整體解決方案，不單獨向客戶銷售硬件設備；(iii)折舊開支，主要與硬件設備折舊有關；及(iv)雲服務費用，為我們向雲服務供應商支付的用以支持人工智能軟件解決方案的服務費。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Our cost of sales increased by 28.3% from RMB31.1 million for the six months ended June 30, 2023 to RMB40.0 million for the six months ended June 30, 2024, primarily due to (i) an increase in sales of our hardware devices and related accessories as we commenced mass production for our in-house fundus cameras and myopia prevention and control products; (ii) an increase in operating expenses as a result of the increase in number of our service sites; (iii) an increase in the cost of cloud services for the higher volume of services we provided during the Reporting Period; and (iv) a corresponding increase in equipment maintenance costs due to the growth in the number of service sites.

Gross Profit and Gross Profit Margin

Based on the factors described above, the gross profit of the Group increased from RMB51.4 million for the six months ended June 30, 2023 to RMB53.8 million for the six months ended June 30, 2024. Gross profit margin is calculated as gross profit divided by revenue. The overall gross profit margin of the Group decreased from 62.3% for the six months ended June 30, 2023 to 57.4% for the six months ended June 30, 2024, primarily due to the increased proportion of revenue consumed by equipment maintenance costs and cloud service fees.

Other Income and Gains

Our other income and gains decreased from RMB49.8 million for the six months ended June 30, 2023 to RMB17.7 million for the six months ended June 30, 2024, primarily due to a reduction in interest income and investment gains from financial assets, as well as lower foreign exchange gains due to fluctuations in the exchange rate of United States dollars against Renminbi Yuan.

我們的銷售成本由截至2023年6月30日止六個月的人民幣31.1百萬元增加28.3%至截至2024年6月30日止六個月的人民幣40.0百萬元，主要由於(i)隨著我們開始量產我們的內部眼底相機及近視防控產品，我們的硬件設備及相關配件的銷售額增加；(ii)運營開支因服務網點數量增加而增加；(iii)於報告期內提供的服務量增加導致雲服務成本增加；及(iv)服務網點數量增加導致設備維護成本相應增加。

毛利及毛利率

根據上述因素，本集團毛利由截至2023年6月30日止六個月的人民幣51.4百萬元增加至截至2024年6月30日止六個月的人民幣53.8百萬元。毛利率按毛利除以收入計算。本集團整體毛利率由截至2023年6月30日止六個月的62.3%減少至截至2024年6月30日止六個月的57.4%，主要由於設備維護成本及雲服務費用於收入中所佔比例有所增加。

其他收入及收益

我們的其他收入及收益由截至2023年6月30日止六個月的人民幣49.8百萬元減少至截至2024年6月30日止六個月的人民幣17.7百萬元，主要由於金融資產的利息收入及投資收益減少，以及美元兌人民幣的匯率波動導致匯兌收益有所減少。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

R&D Expenses

Our R&D expenses decreased by 13.3% from RMB56.5 million for the six months ended June 30, 2023 to RMB49.0 million for the six months ended June 30, 2024, primarily attributable to streamlined R&D processes that led to cost optimizations.

The following table summarizes a breakdown of our R&D expenses for the periods indicated.

研發開支

我們的研發開支由截至2023年6月30日止六個月的人民幣56.5百萬元減少13.3%至截至2024年6月30日止六個月的人民幣49.0百萬元，主要由於研發流程的簡化優化了成本。

下表概列於所示期間我們的研發開支明細。

Six months ended June 30, 截至6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Employee benefits expenses	僱員福利開支	36,590	39,809
Product development expenses	產品開發開支	3,915	8,529
Product registration expenses	產品註冊開支	2,356	3,175
Depreciation expenses	折舊開支	4,690	3,195
Others	其他	1,435	1,809
Total	合計	48,986	56,517

Selling and Distribution Expenses

Our selling and distribution expenses primarily consist of employee benefits expenses for our in-house sales and marketing team and marketing expenses.

Our selling and distribution expenses decreased by 13.8% from RMB44.3 million for the six months ended June 30, 2023 to RMB38.2 million for the six months ended June 30, 2024, primarily due to the implementation of centralized management in sales and marketing activities and targeted campaign strategies, which resulted in more efficient allocation of marketing and promotional resources.

銷售及分銷開支

我們的銷售及分銷開支主要包括我們內部銷售及營銷團隊的僱員福利開支及營銷開支。

我們的銷售及分銷開支由截至2023年6月30日止六個月的人民幣44.3百萬元減少13.8%至截至2024年6月30日止六個月的人民幣38.2百萬元，主要由於在銷售及營銷活動中實施集中管理及有針對性的活動策略，從而更有效地分配營銷及促銷資源。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Administrative Expenses

Our administrative expenses mainly consist of employee benefits expenses for our employees involved in administrative and supportive functions and professional service expenses.

Our administrative expenses increased by 7.2% from RMB39.2 million for the six months ended June 30, 2023 to RMB42.0 million for the six months ended June 30, 2024, primarily due to the increase in the share-based payments.

Income Tax

We recorded income tax credit of RMB1.2 million for the six months ended June 30, 2024 (June 30, 2023: a charge of RMB488,000).

Loss for the Period

We recorded a loss of RMB81.5 million for the six months ended June 30, 2024, compared with a loss of RMB41.0 million for the six months ended June 30, 2023. The increase in loss for the period was primarily due to (i) a loss allowance of RMB23.7 million made for the Reporting Period by the Company due to a recent regulatory change, and (ii) an increase of RMB11.4 million in the share-based payments made during the Reporting Period. The loss allowance was made for a batch of laser myopia treatment device sold to a client of our Group, because the relevant business of the client was affected by a recent regulatory change, which reclassified laser myopia treatment device as Class III medical devices and prohibits the sales of laser myopia treatment device that have not obtained the Class III medical device certification since July 1, 2024. Other businesses of the Group were not affected by such regulatory change. For further details, please see the subsection headed “Trade Receivables” below.

行政開支

我們的行政開支主要包括我們行政管理和支持職能僱員的僱員福利開支及專業服務開支。

我們的行政開支由截至2023年6月30日止六個月的人民幣39.2百萬元增加7.2%至截至2024年6月30日止六個月的人民幣42.0百萬元，主要由於股份支付增加。

所得稅

截至2024年6月30日止六個月，我們錄得所得稅抵免人民幣1.2百萬元（2023年6月30日：計入人民幣488,000元）。

期內虧損

我們於截至2024年6月30日止六個月錄得虧損人民幣81.5百萬元，而截至2023年6月30日止六個月為虧損人民幣41.0百萬元。期內虧損增加主要由於(i)本公司因近期監管變化而於報告期內作出虧損撥備人民幣23.7百萬元，及(ii)於報告期內股份支付增加人民幣11.4百萬元。由於客戶的相關業務受到近期法規變化的影響，該法規將激光近視治療儀重新歸類為第三類醫療器械，並自2024年7月1日起禁止銷售未取得第三類醫療器械認證的激光近視治療儀，故就向本集團客戶出售的一批激光近視治療儀作出虧損撥備。本集團的其他業務並未受到有關法規變化的影響。有關進一步詳情，請參閱下文「應收賬款」分節。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Property, Plant and Equipment

Our property, plant and equipment primarily consist of (i) hardware devices, representing fundus cameras which have been deployed or will be deployed at our customers' service site to be used together with our software; (ii) furniture and others; and (iii) leasehold improvement.

Our property, plant and equipment increased to RMB20.2 million as of June 30, 2024 from RMB18.0 million as of December 31, 2023, which was primarily due to the provision of increased fundus cameras, which is in line with the Company's integrated hardware-software approach and market expansion strategy.

Inventories

Our inventories primarily consist of raw materials for manufacturing our in-house fundus cameras and the third-party fundus cameras we purchased for the bundled sales together with our software and in-house myopia prevention and control products. We assign specific personnel to regularly monitor our inventories and endeavor to keep an optimal inventory level in line with the expected usages in the near term.

Our inventories decreased to RMB28.2 million as of June 30, 2024 from RMB40.1 million as of December 31, 2023, which was primarily due to effective inventory management that aligned production with sales, thereby reducing inventory levels.

物業、廠房及設備

我們的物業、廠房及設備主要包括(i)硬件設備，指已部署或將部署在我們客戶的服務網點以配合我們的軟件一同使用的眼底相機，(ii)辦公設備及其他；及(iii)租賃物業裝修。

我們的物業、廠房及設備由截至2023年12月31日的人民幣18.0百萬元增加至截至2024年6月30日的人民幣20.2百萬元，主要由於為契合本公司軟硬件一體化方法及市場擴張戰略，提供的眼底相機增加。

存貨

我們的存貨主要包括用於製造內部眼底相機的原材料及我們為捆綁銷售我們的軟件及內部近視防控產品而購買的第三方眼底相機。我們指派特定人員定期監控我們的存貨，並致力於維持最佳存貨水平，使之符合近期的預期用量。

我們的存貨由截至2023年12月31日的人民幣40.1百萬元減少至截至2024年6月30日的人民幣28.2百萬元，主要由於有效的存貨管理使生產與銷售保持一致，從而降低存貨水平。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Trade Receivables

Our trade receivables decreased to RMB58.2 million as of June 30, 2024 from RMB79.6 million as of December 31, 2023, which was primarily due to provisions made for aging receivables, partially offset by a relatively quicker pace of payment collection from customers.

An impairment of trade receivables amounted to approximately RMB24.7 million was made for the six months ended June 30, 2024, which was primarily related to the loss allowance made for a contract of sales of laser myopia treatment devices.

Impairment of trade receivables

In the fourth quarter of 2022 (“Q4 2022”), the Group entered into a contract with Customer A (the same Customer A referred to in note 3 to the interim condensed consolidated financial information as set out in this report) for the sale of a batch of laser myopia treatment devices (the “**Sold Devices**”). The Group recognized the corresponding sales revenue and the associated trade receivables in Q4 2022 as the Sold Devices were delivered to and accepted by Customer A and the controls of the Sold Devices was transferred to the Customer A by the end of Q4 2022.

In June 2023, the NMPA issued the “Notice on Regulating the Registration Management of Laser Myopia and Amblyopia Treatment Devices (關於規範激光近視弱視治療儀類產品註冊管理工作的通知)” (Medical Device Notice No. [2023] 354) (the “**Notice**”), which stipulates that, with effect from July 1, 2024 (the “**Effective Date**”), myopia treatment devices that have not obtained Class III medical device certification would no longer be permitted for production and sales in the PRC.

應收賬款

我們的應收賬款由截至2023年12月31日的人民幣79.6百萬元減少至截至2024年6月30日的人民幣58.2百萬元，主要由於就賬齡應收款項計提撥備，部分由客戶回款相對較快的速度所抵銷。

截至2024年6月30日止六個月，應收賬款減值約為人民幣24.7百萬元，主要與激光近視治療儀銷售合約的虧損撥備有關。

應收賬款減值

於2022年第四季度（「**2022年第四季度**」），本集團與客戶A（即本報告所載中期簡明綜合財務資料附註3所提述的同一客戶A）就銷售一批激光近視治療儀（「**已售出設備**」）訂立合約。由於已售出設備已交付予客戶A並由其驗收，且已售出設備的控制權已於2022年第四季度末轉移予客戶A，故本集團於2022年第四季度確認相應銷售收入及相關應收賬款。

於2023年6月，國家藥監局發佈「關於規範激光近視弱視治療儀類產品註冊管理工作的通知」（藥械准字[2023]354號）（「**通知**」），通知規定，自2024年7月1日（「**生效日期**」）起，未獲得第三類醫療器械認證的近視治療儀，不得在中國生產及銷售。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Since the sale of the Sold Devices, the Group has engaged in ongoing communications with Customer A regarding the settlement of the outstanding trade receivables with respect to the Sold Devices. Notwithstanding the promulgation of the Notice, based on the following considerations: (i) the Group has consistently received timely and regular payments from Customer A for other trade receivables, without any delays or defaults, (ii) Customer A has maintained a sound financial position, supported by ongoing assessments of its creditworthiness, (iii) the Group received partial payments totaling RMB2.62 million from Customer A specifically related to the Sold Devices as of December 31, 2023, which was consistent with the Group's established commercial practices and the payment expectations with Customer A in respect of the Sold Devices, and (iv) the Notice had no immediate impact on Customer A's ability to resell the Sold Devices, the Group did not identify any significant increase in credit risk associated with the trade receivables with respect to the Sold Devices from Customer A in the second half of 2023.

During the first half of 2024, the Company noticed that as the effective date of the Notice was approaching, Customer A's ability to resell the Sold Devices was materially and adversely impacted, affecting its ability to repay the trade receivables through the resale of the Sold Devices.

As of June 30, 2024, the outstanding trade receivables from Customer A with respect to the Sold Devices amounted to RMB23.7 million. Despite the Group's efforts, Customer A has been unable to repay the outstanding amount. Considering that the deterioration of the business performance and reduced cash flows of Customer A's myopia treatment devices business, as well as the approaching of the Effective Date, the Group assessed that the expected credit loss ("ECL") associated with the trade receivables from Customer A had increased significantly, and the possibility of recovering the relevant trade receivables became remote. Consequently, the Company recognized an impairment loss of RMB23.7 million (the "Impairment") for the total outstanding trade receivables from Customer A with respect to the Sold Devices.

自銷售已售出設備以來，本集團一直與客戶A就結算有關已售出設備的未償還應收賬款進行持續溝通。儘管已頒佈通知，惟基於以下考慮：(i)本集團一直持續收到客戶A就其他應收賬款按時及定期支付的款項，並無任何延誤或拖欠，(ii)客戶A一直維持穩健的財務狀況，並獲對其信用度持續評估的支持，(iii)截至2023年12月31日，本集團已收到客戶A就已售出設備支付的部分款項合共人民幣2.62百萬元，符合本集團的既定商業慣例及與客戶A就已售出設備的付款預期一致，及(iv)通知對客戶A轉售已售出設備的能力並無直接影響，本集團並無發現於2023年下半年就已售出設備應收客戶A的應收賬款的信貸風險顯著增加。

於2024年上半年，本公司注意到隨著通知生效日期臨近，客戶A轉售已售出設備的能力受到重大不利影響，影響其透過轉售已售出設備償還應收賬款的能力。

截至2024年6月30日，客戶A就已售出設備的未償還應收賬款為人民幣23.7百萬元。儘管本集團作出努力，客戶A仍未能償還欠款。鑒於客戶A近視治療儀業務的經營績效惡化及現金流量減少，以及生效日期臨近，本集團評估客戶A的應收賬款相關的預期信貸虧損（「預期信貸虧損」）大幅增加，收回相關應收賬款的可能性變得渺茫。因此，本公司就應收客戶A有關已售出設備的未償還應收賬款總額確認減值虧損人民幣23.7百萬元（「減值」）。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

The assessment and determination of the Impairment

The Impairment was assessed and determined following a thorough and systematic evaluation process in accordance with IFRS 9 Financial Instruments, which requires the Group to measure the ECL on trade receivables at each reporting date. The Group employs a provision matrix for the assessment of ECL on its trade receivables. In cases where there is evidence of a significant increase in credit risk or impairment indicators for specific customers, the Group performs individual assessments of loss allowances for those trade receivables.

During the year ended December 31, 2023, based on the reasons set out in “Impairment of trade receivables” above, the Group did not identify any significant increase in credit risk associated with the trade receivables from Customer A with respect to the Sold Devices. Accordingly, based on the Company’s accounting policy, the credit risk on the trade receivables from Customer A with respect to the Sold Devices was assessed using the provision matrix, and no individual impairment allowance was required to be recognized.

During the Reporting Period, based on the factors set out in “Impairment of trade receivables” above, there was a significant increase in credit risk related to the trade receivables from Customer A with respect to the Sold Devices. In accordance with IFRS 9 and the Company’s accounting policy and after assessing the aforesaid factors, the Company determined that, an impairment should be made for the trade receivables from Customer A with respect to the Sold Devices of RMB23.7 million.

In addition to the provision matrix, for Customer A whose credit risk increased significantly, the Group has made individual loss allowances. Details of which are set out in note 12 to the interim condensed consolidated financial information as set out in this report.

減值評估及釐定

減值乃根據國際財務報告準則第9號金融工具經全面及系統的評估程序評估及釐定，該準則要求本集團於各報告日期計量應收賬款的預期信貸虧損。本集團採用撥備矩陣評估其應收賬款的預期信貸虧損。如有證據顯示特定客戶的信貸風險或減值跡象顯著增加，本集團便會對該等應收賬款的虧損撥備進行單獨評估。

截至2023年12月31日止年度，基於上文「應收賬款減值」所載原因，本集團並無發現客戶A有關已售出設備的應收賬款相關的信貸風險顯著增加。因此，根據本公司的會計政策，已使用撥備矩陣評估客戶A有關已售出設備的應收賬款信貸風險，且無需確認個別減值撥備。

於報告期內，基於上文「應收賬款減值」所載因素，客戶A有關已售出設備的應收賬款相關信貸風險顯著增加。根據國際財務報告準則第9號及本公司的會計政策，經評估上述因素後，本公司認為應就客戶A有關已售出設備的應收賬款人民幣23.7百萬元計提減值。

除撥備矩陣外，就信貸風險顯著增加的客戶A而言，本集團已作出個別虧損撥備。其詳情載於本報告所載之中期簡明綜合財務資料附註12。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Prepayments, Other Receivables and Other Assets

Our prepayments, other receivables and other assets increased to RMB22.8 million as of June 30, 2024 from RMB17.4 million as of December 31, 2023, which was primarily due to higher balances of prepaid expenses earmarked for R&D as well as general operational purposes.

Financial Assets at Fair Value Through Profit or Loss

Our financial assets at fair value through profit or loss mainly represented fund investments and wealth management products subscribed for from certain financial institutions to improve cash utilization efficiency. Our financial assets at fair value through profit or loss increased from RMB266.9 million as of December 31, 2023 to RMB445.8 million as of June 30, 2024, primarily due to subscription of certain wealth management products as a supplemental means to improve utilization of our idle cash on a short-term basis.

Cash and Cash Equivalents

Our cash and cash equivalents decreased to RMB547.8 million as of June 30, 2024 from RMB891.5 million as of December 31, 2023, which was primarily due to purchase of other financial assets, and the use of cash in the ordinary course of business during the Reporting Period.

Trade Payables

Our trade payables decreased to RMB7.9 million as of June 30, 2024 from RMB17.5 million as of December 31, 2023, which was primarily due to stringent raw material procurement aligned with our sales demands.

預付款項、其他應收款項及其他資產

我們的預付款項、其他應收款項及其他資產由截至2023年12月31日的人民幣17.4百萬元增加至截至2024年6月30日的人民幣22.8百萬元，主要由於為研發以及一般營運目的預留的預付開支結餘增加。

以公允價值計量且其變動計入當期損益的金融資產

我們以公允價值計量且其變動計入當期損益的金融資產主要指基金投資以及為提高現金使用效率而從若干金融機構認購的理財產品。我們以公允價值計量且其變動計入當期損益的金融資產由截至2023年12月31日的人民幣266.9百萬元增加至截至2024年6月30日的人民幣445.8百萬元，主要由於認購若干理財產品作為短期內提高閒置現金使用率的補充措施。

現金及現金等價物

我們的現金及現金等價物由截至2023年12月31日的人民幣891.5百萬元減少至截至2024年6月30日的人民幣547.8百萬元，主要由於報告期內購買其他金融資產，及日常業務過程中現金使用所致。

應付賬款

我們的應付賬款由截至2023年12月31日的人民幣17.5百萬元減少至截至2024年6月30日的人民幣7.9百萬元，主要由於我們根據銷售需求更嚴格地採購原材料所致。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Liquidity and Source of Funding

Our policy is to regularly monitor our liquidity requirements and our compliance with lending covenants, to ensure that it maintains sufficient reserves of cash and adequate committed lines of funding from major financial institutions to meet its liquidity requirements in the short and longer term.

As of June 30, 2024, our current assets were RMB1,017.6 million which mainly includes cash and cash equivalents of RMB547.8 million, time deposits of RMB18.6 million and other financial assets of RMB342.1 million. As of June 30, 2024, our current liabilities were RMB61.8 million which mainly includes trade payables of RMB7.9 million, other payables and accruals of RMB37.9 million and contract liabilities of RMB12.5 million.

Borrowings

As of June 30, 2024, we did not have any bank loans or other borrowings (as of December 31, 2023: nil).

流動資金及資金來源

我們的政策為定期監控我們的流動資金需求及借貸契諾遵守情況，以確保本集團維持足夠的現金儲備及獲大型金融機構提供充足的承諾資金額度，以滿足我們的短期及長期的流動資金需求。

截至2024年6月30日，我們的流動資產為人民幣1,017.6百萬元，主要包括現金及現金等價物人民幣547.8百萬元、定期存款人民幣18.6百萬元以及其他金融資產人民幣342.1百萬元。截至2024年6月30日，我們的流動負債為人民幣61.8百萬元，主要包括應付賬款人民幣7.9百萬元、其他應付款項及應計費用人民幣37.9百萬元及合約負債人民幣12.5百萬元。

借款

截至2024年6月30日，我們概無任何銀行貸款或其他借款（截至2023年12月31日：無）。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Contract Liabilities

Our contract liabilities represent our obligations to transfer services to our customers as we entered into services agreements with our customers for AI-based software solutions and sales of hardware devices for which we have received advanced payments from such customers under the relevant customer service agreements or work orders.

Our contract liabilities decreased to RMB12.5 million as of June 30, 2024 from RMB23.7 million as of December 31, 2023, which was primarily due to the accelerated revenue recognition as a result of improved contract fulfillment and faster service delivery.

Net Current Assets

Our net current assets decreased to RMB955.8 million as of June 30, 2024 from RMB1,171.7 million as of December 31, 2023.

Gearing Ratio

Gearing ratio is calculated by using interest-bearing borrowings and lease liabilities less cash and cash equivalents, divided by total equity and multiplied by 100%. As of June 30, 2024, we were in a net cash position and thus gearing ratio is not applicable.

Treasury Policy

We adopt a prudent financial management approach for our treasury policy to ensure that our liquidity structure comprising assets, liabilities and other commitments is able to always meet our capital requirements.

合約負債

我們的合約負債是指我們向客戶轉移服務的義務，原因是我們與客戶就人工智能軟件解決方案和硬件設備銷售訂立了服務協議，據此，我們根據相關的客戶服務協議或工作訂單，從該等客戶收取預付款。

我們的合約負債由截至2023年12月31日的人民幣23.7百萬元減少至截至2024年6月30日的人民幣12.5百萬元，主要由於履約改善及服務交付加快，收入確認加速。

流動資產淨值

我們的流動資產淨值由截至2023年12月31日的人民幣1,171.7百萬元減少至截至2024年6月30日的人民幣955.8百萬元。

資產負債比率

資產負債比率的計算方法是用有息借款及租賃負債減去現金及現金等價物，除以總權益，再乘以100%。截至2024年6月30日，我們處於淨現金狀況，因此資產負債比率並不適用。

庫務政策

我們就庫務政策採取審慎的財務管理方法，以確保我們由資產、負債及其他承擔組成的流動資金架構能夠始終滿足我們的資金需求。

OTHER INFORMATION 其他資料

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY OF ITS ASSOCIATED CORPORATIONS

As of June 30, 2024, the interests and short positions of the Directors, Supervisors or chief executives of the Company and their associates in any of the Shares, underlying Shares and debentures of our Company or its associated corporation (within the meaning of Part XV of the SFO), as recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, to be recorded in the register referred to therein, or as otherwise required to be notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

董事、監事和最高行政人員於本公司或其任何相聯法團的股份、相關股份及債權證中的權益及淡倉

截至2024年6月30日，本公司董事、監事或最高行政人員及彼等聯繫人士於本公司或其相聯法團的任何股份、相關股份及債權證（定義見證券及期貨條例第XV部）中，擁有根據證券及期貨條例第352條記錄於本公司須備存的登記冊內之權益及淡倉，或須登記於其所述之登記冊內之權益及淡倉，或根據標準守則須知會本公司及聯交所之權益及淡倉如下：

Interests in Shares or underlying Shares of the Company

於本公司股份或相關股份的權益

Name of Director	Position	Nature of interest	Number and class of Shares	Long Position/ Short Position	Approximate percentage of interest in the relevant class of Shares of our Company ⁽¹⁾ 於本公司相關股份類別的權益概約百分比 ⁽¹⁾	Approximate percentage of interest in our Company
董事姓名	職務	權益性質	股份數目及類別	好倉／淡倉		於本公司的權益概約百分比
Mr. Zhang 張先生	Executive Director and chief executive officer 執行董事兼首席執行官	Beneficial owner 實益擁有人	9,109,466 H Shares ⁽²⁾	Long Position 好倉	17.05%	8.80%
			12,074,198 Unlisted Shares 未上市股份	Long Position 好倉	24.08%	11.66%
		Interest in a controlled corporation ⁽³⁾ 受控法團權益 ⁽³⁾	1,371,845 H Shares	Long Position	2.57%	1.32%
			H股 2,335,363 Unlisted Shares 未上市股份	好倉 Long Position	4.66%	2.25%
		Interest of a party to an agreement ⁽⁴⁾ 協議訂約方權益 ⁽⁴⁾	474,859 H Shares	Long Position	0.89%	0.46%
			H股 1,398,058 Unlisted Shares 未上市股份	好倉 Long Position	2.79%	1.35%
Ms. WANG Lin 王林女士	Executive Director 執行董事	Beneficial owner 實益擁有人	100,000 H Shares ⁽⁵⁾ H股 ⁽⁶⁾	Long Position 好倉	0.19%	0.10%

OTHER INFORMATION

其他資料

Name of Director	Position	Nature of interest	Number and class of Shares	Long Position/ Short Position	Approximate percentage of interest in the relevant class of Shares of our Company ⁽¹⁾ 於本公司相關股份類別的權益概約百分比 ⁽¹⁾	Approximate percentage of interest in our Company 於本公司的權益概約百分比
董事姓名	職務	權益性質	股份數目及類別	好倉／淡倉		
Dr. HE Chao 和超博士	Executive Director 執行董事	Beneficial owner 實益擁有人	54,405 H Shares ⁽⁶⁾ H股 ⁽⁶⁾	Long Position 好倉	0.10%	0.05%
Mr. QIN Yong 秦勇先生	Executive Director 執行董事	Beneficial owner 實益擁有人	96,116 H Shares ⁽⁷⁾ H股 ⁽⁷⁾	Long Position 好倉	0.18%	0.09%

Notes:

附註：

- | | |
|--|---|
| (1) The percentage is calculated based on the number of relevant class of Shares in issue as of June 30, 2024. | (1) 該百分比乃根據截至2024年6月30日已發行的相關股份類別數量計算。 |
| (2) Including (i) 5,799,128 H Shares directly held by him and (ii) 3,310,338 Incentive Shares granted to him yet unvested under the 2022 Equity Incentive Scheme. | (2) 包括(i)彼直接持有的5,799,128股H股及(ii)根據2022年股權激勵計劃授予彼但尚未歸屬的3,310,338股激勵股份。 |
| (3) As of June 30, 2024, Mr. Zhang was the general partner of Airdoc Universe. Therefore, Mr. Zhang was deemed to be interested in the Shares held by Airdoc Universe under the SFO. | (3) 截至2024年6月30日，張先生是鬱金香宇宙的普通合夥人。因此，根據證券及期貨條例，張先生被視為於鬱金香宇宙持有的股份中擁有權益。 |
| (4) As of June 30, 2024, pursuant to the Concert Party Agreement, Mr. Zhang agreed to act in concert with Mr. Gao and Mr. Chen by aligning their votes at Shareholders' meetings of the Company. Therefore, Mr. Zhang was deemed to be interested in an aggregate of 573,859 H Shares held by his concert parties. | (4) 截至2024年6月30日，根據一致行動人士協議，張先生、高先生及陳先生同意在本公司股東大會上通過調整其投票來實現一致行動。因此，張先生被視為於其一致行動人士持有的合共573,859股H股中擁有權益。 |
| (5) Including (i) 25,000 H Shares directly held by her, and (ii) 75,000 Incentive Shares granted to her yet unvested under the 2022 Equity Incentive Scheme. | (5) 包括(i)彼直接持有的25,000股H股，及(ii)根據2022年股權激勵計劃授予彼但尚未歸屬的75,000股激勵股份。 |
| (6) Representing 54,405 Incentive Shares granted to him yet unvested under the 2022 Equity Incentive Scheme. | (6) 指根據2022年股權激勵計劃授予彼但尚未歸屬的54,405股激勵股份。 |
| (7) Including (i) 21,116 H Shares directly held by him, and (ii) 75,000 Incentive Shares granted to him yet unvested under the 2022 Equity Incentive Scheme. | (7) 包括(i)彼直接持有的21,116股H股，及(ii)根據2022年股權激勵計劃授予彼但尚未歸屬的75,000股激勵股份。 |

Save as disclosed above, as of June 30, 2024, to the best knowledge of the Company, none of the Directors, Supervisors or chief executives of the Company or their associates had or was deemed to have any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations as recorded in the register required to be kept, pursuant to Section 352 of the SFO, to be recorded in the register referred to therein, or as otherwise required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

除上文所披露者外，截至2024年6月30日，據本公司所知，概無本公司董事、監事或最高行政人員或彼等聯繫人士於本公司或其任何相聯法團的股份、相關股份或債權證中，擁有根據證券及期貨條例第352條記錄於本公司須備存的登記冊內之權益及淡倉，或須登記於其所述之登記冊內之權益及淡倉，或根據標準守則須知會本公司及聯交所之權益及淡倉。

OTHER INFORMATION

其他資料

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As of June 30, 2024, so far as the Directors or chief executives of the Company are aware, the following persons (other than the Directors or chief executives of the Company or their associates) had interests and/or short positions in the Shares or underlying Shares as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

Interests in Shares or underlying Shares of the Company

主要股東於股份及相關股份之權益及淡倉

截至2024年6月30日，就本公司董事或最高行政人員所知，以下人士（本公司董事或最高行政人員或彼等聯繫人士除外）擁有根據證券及期貨條例第336條記錄於本公司須備存之登記冊所載之股份或相關股份的權益及／或淡倉：

於本公司股份或相關股份的權益

Name of Substantial Shareholders	Nature of interest	Number of Shares		Long Position/ Short Position	Approximate percentage of interest in the relevant class of Shares of our Company	Approximate percentage of interest in our Company
主要股東姓名／ 名稱	權益性質	股份數目	股份類別	好倉／淡倉	於本公司相關 股份類別的權益 概約百分比	於本公司的權益 概約百分比
Mr. Gao ⁽¹⁾ 高先生 ⁽¹⁾	Beneficial owner 實益擁有人	79	H shares H股	Long Position 好倉	0.00%	0.00%
		441,678	Unlisted Shares 未上市股份	Long Position 好倉	0.88%	0.43%
	Interest of a party to an agreement 協議訂約方權益	7,645,753	H shares H股	Long Position 好倉	14.31%	7.38%
		15,365,940	Unlisted Shares 未上市股份	Long Position 好倉	30.64%	14.84%
Mr. Chen ⁽²⁾ 陳先生 ⁽²⁾	Beneficial owner 實益擁有人	474,780	H Shares H股	Long Position 好倉	0.89%	0.46%
		956,380	Unlisted Shares 未上市股份	Long Position 好倉	1.91%	0.92%
	Interest of a party to an agreement 協議訂約方權益	7,171,052	H Shares H股	Long Position 好倉	13.42%	6.92%
		14,851,239	Unlisted Shares 未上市股份	Long Position 好倉	29.61%	13.34%

OTHER INFORMATION

其他資料

Name of Substantial Shareholders	Nature of interest	Number of Shares	Class of Shares	Long Position/ Short Position	Approximate percentage of interest in the relevant class of Shares of our Company 於本公司相關股份類別的權益概約百分比	Approximate percentage of interest in our Company 於本公司的權益概約百分比
主要股東姓名/ 名稱	權益性質	股份數目	股份類別	好倉/淡倉		
Fosun International ⁽³⁾ 復星國際 ⁽³⁾	Interest in a controlled corporation	6,292,835	H Shares H股	Long Position 好倉	11.78%	6.08%
	受控法團權益	3,424,168	Unlisted Shares 未上市股份	Long Position 好倉	6.83%	3.31%
	Interest of a party to an agreement 協議訂約方權益	114,253	H Shares H股	Long Position 好倉	0.21%	0.11%
Yadong Beichen ⁽³⁾⁽⁴⁾ 亞東北辰 ⁽³⁾⁽⁴⁾	Beneficial owner	6,292,835	H Shares H股	Long Position 好倉	11.78%	6.08%
	實益擁有人	3,424,168	Unlisted Shares 未上市股份	Long Position 好倉	6.83%	3.31%
	Interest of a party to an agreement 協議訂約方權益	114,253	H Shares H股	Long Position 好倉	0.21%	0.11%
MIALKOS Tomasz Jakub	Beneficial owner	9,188,300	H Shares	Long Position	17.20%	8.87%
MIALKOS Tomasz Jakub	實益擁有人		H股	好倉		
Ping An Insurance ⁽⁵⁾ 平安保險 ⁽⁵⁾	Interest in a controlled corporation 受控法團權益	7,169,737	Unlisted Shares 未上市股份	Long Position 好倉	14.30%	6.92%
Ping An Healthtech ⁽⁵⁾ 平安醫療科技 ⁽⁵⁾	Beneficial owner 實益擁有人	7,169,737	Unlisted Shares 未上市股份	Long Position 好倉	14.30%	6.92%
Lake Bleu Capital (Hong Kong) Limited ⁽⁵⁾ 清池資本(香港)有限 公司 ⁽⁵⁾	Investment manager 投資經理	4,785,236	H Shares H股	Long Position 好倉	8.96%	4.62%
Lake Bleu Prime ⁽⁵⁾ Lake Bleu Prime ⁽⁵⁾	Beneficial owner 實益擁有人	3,394,300	H Shares H股	Long Position 好倉	6.35%	3.28%

OTHER INFORMATION

其他資料

Name of Substantial Shareholders	Nature of interest	Number of		Long Position/ Short Position	Approximate percentage of interest in the relevant class of Shares of our Company	Approximate percentage of interest in our Company
		Shares	Class of Shares		於本公司相關股份類別的權益 概約百分比	於本公司的權益 概約百分比
主要股東姓名/ 名稱	權益性質	股份數目	股份類別	好倉/淡倉		
LBC Sunshine ⁽⁵⁾ 清池資本陽光 ⁽⁵⁾	Beneficial owner 實益擁有人	1,390,936	H Shares H股	Long Position 好倉	2.60%	1.34%
Niagara Falls Holding Limited Niagara Falls Holding Limited	Beneficial owner 實益擁有人	4,117,900	H Shares H股	Long Position 好倉	7.71%	3.98%
XU Yanhua ⁽⁶⁾ 徐彥華 ⁽⁶⁾	Interest in a controlled corporation 受控法團權益	6,076,019	Unlisted Shares 未上市股份	Long Position 好倉	12.12%	5.87%
Suqian Airdoc ⁽⁶⁾ 宿遷鷹瞳 ⁽⁶⁾	Beneficial owner 實益擁有人	3,756,431	Unlisted Shares 未上市股份	Long Position 好倉	7.49%	3.63%

Notes:

附註：

- (1) As of June 30, 2024, pursuant to the Concert Party Agreement, Mr. Gao agreed to act in concert with Mr. Zhang and Mr. Chen by aligning their votes at Shareholders' meetings of the Company. On June 7, 2024, Airdoc Universe disposed of 91,100 H Shares, and Mr. Zhang is deemed to be interested in shares held by it as its general partner under the SFO. Mr. Chen disposed of 50,000 H Shares. Therefore, Mr. Gao was deemed to be interested in an aggregate of 7,967,353 H Shares held by Mr. Zhang and Mr. Chen.
- (1) 截至2024年6月30日，根據一致行動人士協議，高先生、張先生及陳先生同意於本公司股東大會上通過調整其投票來實現一致行動。於2024年6月7日，鬱金香宇宙已出售91,100股H股，根據證券及期貨條例，張先生被視為於其作為普通合夥人持有的股份中擁有權益。陳先生已出售50,000股H股。因此，高先生被視為於張先生及陳先生持有的合共7,967,353股H股中擁有權益。
- (2) As of June 30, 2024, pursuant to the Concert Party Agreement, Mr. Chen agreed to act in concert with Mr. Zhang and Mr. Gao by aligning their votes at Shareholders' meetings of the Company. On June 7, 2024, Airdoc Universe disposed of 91,100 H Shares, and Mr. Zhang is deemed to be interested in shares held by it as its general partner under the SFO. Mr. Chen disposed of 50,000 H Shares and was therefore deemed to be interested in an aggregate of 7,383,652 H Shares held by Mr. Zhang and Mr. Chen.
- (2) 截至2024年6月30日，根據一致行動人士協議，陳先生、張先生及高先生同意於本公司股東大會上通過調整其投票來實現一致行動。於2024年6月7日，鬱金香宇宙已出售91,100股H股，根據證券及期貨條例，張先生被視為於其作為普通合夥人持有的股份中擁有權益。陳先生已出售50,000股H股，因此被視為於張先生及陳先生持有的合共7,383,652股H股中擁有權益。

OTHER INFORMATION 其他資料

- (3) As of June 30, 2024, Yadong Beichen was held by Shanghai Ruikun Venture Capital Co., Ltd. (上海銳坤創業投資有限公司) (“**Shanghai Ruikun**”) and Shanghai Fosun Industrial Investment Co., Ltd. (上海復星產業投資有限公司) (“**Shanghai Fosun**”) as to 64.1% and 35.9%, respectively. Shanghai Ruikun was owned as to 98% by Shanghai Fosun High Technology Group Finance Co., Ltd. (上海復星高科技(集團)有限公司) (“**Fosun High Technology**”) which was wholly owned by Fosun International Limited (復星國際有限公司) (“**Fosun International**”), a company whose shares are listed on the Stock Exchange (stock code: 656). Shanghai Fosun was wholly owned by Fosun High Technology. Therefore, each of Shanghai Ruikun, Shanghai Fosun, Fosun High Technology and Fosun International was deemed to be interested in the shares in which Yadong Beichen was interested under the SFO.
- (3) 截至2024年6月30日，亞東北辰由上海銳坤創業投資有限公司(「上海銳坤」)及上海復星產業投資有限公司(「上海復星」)分別持有64.1%及35.9%的權益。上海復星高科技(集團)有限公司(「復星高科技」)擁有上海銳坤98%的權益，而其本身又由復星國際有限公司(「復星國際」)(一家股份於聯交所上市的公司(股份代號：656))全資擁有。上海復星由復星高科技全資擁有。因此，根據證券及期貨條例，上海銳坤、上海復星、復星高科技及復星國際均被視為於亞東北辰擁有權益的股份中擁有權益。
- (4) As of June 30, 2024, pursuant to the voting proxy arrangement between Ningbo Xingbangyu Business Management Consulting Partnership (Limited Partnership) (寧波星邦鬱企業管理諮詢合夥企業(有限合夥)) (“**Xingbangyu**”) and Yadong Beichen, Xingbangyu conferred the voting right of the Shares held by it on Yadong Beichen. Therefore, Yadong Beichen was deemed to be interested in the 114,253 H Shares held by Xingbangyu under the SFO.
- (4) 截至2024年6月30日，根據寧波星邦鬱企業管理諮詢合夥企業(有限合夥)(「星邦鬱」)及亞東北辰之間的投票代理安排，星邦鬱將其所持股份的投票權授予亞東北辰。因此，根據證券及期貨條例，亞東北辰被視為於星邦鬱持有的114,253股H股中擁有權益。
- (5) As of June 30, 2024, Lake Bleu Capital (Hong Kong) Limited was the investment manager of Lake Bleu Prime Healthcare Master Fund Limited (“**Lake Bleu Prime**”) and LBC Sunshine Healthcare Fund II. Limited Partnership, which holds 3,394,300 H Shares and 1,390,936 H Shares, respectively. Therefore, Lake Bleu Capital (Hong Kong) Limited is deemed to be interested in the Shares in which Lake Bleu Prime Healthcare Master Fund Limited and LBC Sunshine Healthcare Fund II. Limited Partnership were interested under the SFO.
- (5) 截至2024年6月30日，清池資本(香港)有限公司是Lake Bleu Prime Healthcare Master Fund Limited(「**Lake Bleu Prime**」)和清池資本陽光二號基金的投資經理，分別持有3,394,300股H股及1,390,936股H股。因此，根據證券及期貨條例，清池資本(香港)有限公司被視為於Lake Bleu Prime Healthcare Master Fund Limited及清池資本陽光二號基金擁有權益的股份中擁有權益。
- (6) As of June 30, 2024, Ms. XU Yanhua (徐彥華), an employee of our Group, was the general partner of Suqian Airdoc and Suqian Zhongyou, each as an employee incentive platform of our Company. Therefore, Ms. XU Yanhua is deemed to be interested in the 3,756,431 and 2,319,588 Unlisted Shares respectively held by Suqian Airdoc and Suqian Zhongyou under the SFO.
- (6) 截至2024年6月30日，本集團僱員徐彥華女士為宿遷鷹瞳及宿遷眾佑(均為本公司僱員激勵平台)的普通合夥人。因此，根據證券及期貨條例，徐彥華女士被視為於宿遷鷹瞳及宿遷眾佑分別持有的3,756,431股及2,319,588股未上市股份中擁有權益。

Save as disclosed above, as of June 30, 2024, to the best knowledge of the Company, no person, other than the Directors, Supervisors or chief executives of the Company whose interests are set out in the subsection above, had any interests or short positions in the Shares or underlying Shares as recorded in the register required to be kept under section 336 of the SFO.

除上文所披露者外，截至2024年6月30日，據本公司所深知，除本公司董事、監事或最高行政人員(彼等權益載於上文分節中)外，並無任何人士擁有根據證券及期貨條例第336條規定備存之登記冊所載之股份或相關股份的任何權益或淡倉。

OTHER INFORMATION

其他資料

CORPORATE GOVERNANCE

The Company is committed to maintaining high standard of corporate governance to safeguard the interests of the Shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company has adopted the code provisions of the Corporate Governance Code as its own code of corporate governance. The Board is of the view that the Company has complied with all applicable code provisions of the Corporate Governance Code for the Reporting Period, except for the following:

Under the code provision C.2.1 of the Corporate Governance Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Under the current organization structure of the Company, Mr. Zhang is the chairman of the Board, chief executive officer and founder of the Company. With extensive experience in the medical devices industry and having served in the Company since its establishment, Mr. Zhang is in charge of overall management, business and strategic development of the Group. The Board considers that vesting the roles of the chairman of the Board and the chief executive officer in the same person is beneficial to the business operations and management of the Group. The balance of power and authority is ensured by the operation of the Board, which comprises experienced and diverse individuals. As of June 30, 2024, the Board comprised four executive Directors (including Mr. Zhang) and three independent non-executive Directors, and therefore has a strong independent element in its composition.

企業管治

本公司致力於維持高水準的企業管治，以維護股東利益、提升企業價值、制定業務策略及政策，並提高透明度及問責性。

本公司已採納企業管治守則之守則條文作為其自身的企業管治守則。董事會認為本公司於報告期已遵守企業管治守則內所有適用守則條文，惟以下情況除外：

根據企業管治守則的守則條文第C.2.1條，主席與首席執行官的角色應分開，不應由同一人擔任。在本公司現有組織架構下，張先生為本公司董事會主席、首席執行官兼創始人。張先生擁有豐富的醫療器械行業經驗，自本公司成立以來一直任職於本公司，負責本集團的整體管理、業務及戰略發展。董事會認為，由同一人兼任董事會主席及首席執行官職務有利於本集團的業務營運及管理。董事會的運作確保權力及授權達到平衡，董事會由經驗豐富且多元化的人士組成。截至2024年6月30日，董事會由四名執行董事（包括張先生）及三名獨立非執行董事組成，因此其組成具備強有力的獨立性。

OTHER INFORMATION 其他資料

On August 28, 2024, Mr. NG Kong Ping Albert (吳港平) (“**Mr. Albert Ng**”) resigned as an independent non-executive Director and ceased to be the chairman of the Audit Committee and a member of the remuneration and appraisal committee of the Company. Due to the resignation of Mr. Albert Ng, the Company does not meet the requirements that (i) the Board must include at least three independent non-executive Directors, one of whom must have appropriate professional qualifications or accounting or related financial management expertise, and one of whom must be ordinarily resident in Hong Kong, as required under Rule 3.10 and Rule 19A.18(1) of the Listing Rules, respectively; (ii) the independent non-executive Directors must represent at least one-third of the Board as required under Rule 3.10A of the Listing Rules; and (iii) the Audit Committee must comprise a minimum of three members (at least one of whom is an independent non-executive director with appropriate professional qualifications or accounting or related financial management expertise as required under Rule 3.10(2) of the Listing Rules) and chaired by an independent non-executive Director as required under Rule 3.21 of the Listing Rules. For further information, please see the announcement of the Company dated August 28, 2024.

To comply with the aforesaid requirements, the Company has identified a suitable candidate, Mr. NG Ho Yin Owen (吳浩然), to fill the vacancy of independent non-executive Director in order to fulfill the requirements of the Listing Rules. For further information, please see the announcement of the Company dated September 20, 2024.

The Board will continue to review and monitor the practices of the Company with an aim of maintaining a high standard of corporate governance and assess whether separation of the roles of chairman of the Board and chief executive officer is necessary.

於2024年8月28日，吳港平先生（「吳先生」）辭任獨立非執行董事，並不再擔任本公司審核委員會的主席及薪酬與考核委員會的成員。由於吳先生的辭任，本公司未能滿足以下要求：(i)分別根據上市規則第3.10條及第19A.18(1)條所載的規定，董事會必須包括至少三名獨立非執行董事，其中一名獨立非執行董事必須具備適當的專業資格或會計或相關的財務管理專長，且其中一名獨立非執行董事必須常居香港；(ii)根據上市規則第3.10A條所載的規定，獨立非執行董事必須至少佔董事會成員的三分之一；及(iii)根據上市規則第3.21條所載的規定，審核委員會須至少由三名成員組成，其中至少一名為上市規則第3.10(2)條所規定具備適當的專業資格或會計或相關的財務管理專長的獨立非執行董事，並由獨立非執行董事擔任主席。有關進一步資料，請參閱本公司日期為2024年8月28日的公告。

為符合上述要求，本公司已物色合適人選，即吳浩然先生填補獨立非執行董事的空缺，以符合上市規則的規定。有關進一步資料，請參閱本公司日期為2024年9月20日的公告。

董事會將繼續檢討及監督本公司的運作，以維持高水平的企業管治，並評估董事會主席與首席執行官的角色是否需要有所區分。

OTHER INFORMATION

其他資料

COMPLIANCE WITH THE MODEL CODE

The Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors, Supervisors and the Company's senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company's securities. Having made specific enquiry of all Directors and Supervisors, all of them have confirmed that they have complied with the Model Code during the Reporting Period and up to the date of this report. No incident of non-compliance of the Model Code by the employees who are likely to be in possession of inside information of the Company was noted by the Company.

COMPLIANCE WITH RELEVANT LAWS AND REGULATIONS

The Group's operations are carried out in the PRC, while its Shares are listed on the Stock Exchange. The businesses operated by the Group are subject to the laws of relevant jurisdiction in the PRC and Hong Kong. During the Reporting Period and up to the date of this report, as far as the Board and management are aware, the Group has complied with relevant laws and regulations that have a significant impact on the business and operation of the Group in the applicable jurisdictions.

遵守標準守則

本公司已採納標準守則作為董事、監事及本公司高級管理人員在因其職位或僱傭關係而可能擁有有關本公司證券的內幕消息的情況下買賣本公司證券的行為守則。經向全體董事及監事作出具體查詢後，全體董事及監事確認彼等於報告期內及直至本報告日期均已遵守標準守則。本公司並無發現可能掌握本公司內幕消息的僱員存在不遵守標準守則的情況。

遵守相關法律法規

本集團於中國開展業務營運，同時股份於聯交所上市。本集團經營的業務須遵守中國及香港相關司法管轄區法律。於報告期內及直至本報告日期，就董事會及管理層所知，本集團已遵守對本集團於適用司法管轄區業務及營運有重大影響的相關法律法規。

OTHER INFORMATION 其他資料

During the Reporting Period and up to the date of the interim report, none of the Group and the Directors, Supervisors and senior management of the Company were subject to any investigation initiated or administrative penalties imposed by the CSRC, banned from entering the market, identified as inappropriate candidates, publicly condemned by stock exchanges, subject to mandatory measures, transferred to judicial organs or held criminally responsible, and none were involved in any other litigation, arbitration or administrative proceedings which would have a material adverse impact on our business, financial condition or results of operations.

SHARE CAPITAL AND SHARES ISSUED

Details of movements in the share capital of the Company for the six months ended June 30, 2024 and details of the Shares issued for the six months ended June 30, 2024 are set out in note 18 to the interim condensed consolidated financial information as set out in this report.

DEBENTURE ISSUED

The Group did not issue any debenture for the six months ended June 30, 2024.

EQUITY-LINKED AGREEMENTS

No equity-linked agreements that will or may result in the Company issuing shares or that require the Company to enter into any agreements that will or may result in the Company issuing shares were entered into by the Company during the Reporting Period or subsisted at the end of the Reporting Period.

於報告期內及直至本中期報告日期，概無本集團及董事、監事、本公司高級管理人員受到中國證監會立案調查或行政處罰、被禁止上市、被認定為被證券交易所公開譴責、採取強制措施、移送司法機關或追究刑事責任的不適當人選，並無涉及其他對公司業務、財務狀況或經營業績產生重大不利影響的訴訟、仲裁或行政程序。

股本及已發行股份

本公司截至2024年6月30日止六個月的股本變動詳情及截至2024年6月30日止六個月已發行股份詳情載於本報告所載中期簡明綜合財務資料附註18。

已發行債權證

截至2024年6月30日止六個月，本集團未發行任何債權證。

股票掛鈎協議

本公司概無於報告期內訂立或訂立於報告期末仍然存續的、將導致或可能導致本公司發行股份或要求本公司訂立任何協議以導致或可能導致本公司發行股份之股票掛鈎協議。

OTHER INFORMATION

其他資料

SIGNIFICANT INVESTMENTS, MATERIAL ACQUISITIONS AND DISPOSALS

重大投資、重大收購及出售事項

As of June 30, 2024, the Group held certain investment and wealth management products, which carries a value of 5% or more of the Group's total assets, the details of which are set out as follows:

截至2024年6月30日，本集團持有若干投資及理財產品，其價值佔本集團資產總值之5%或以上，詳情載列如下：

No.	Name of investment/ wealth management product	Principal amount	Fair value as of June 30, 2024 截至2024年 6月30日的 公允價值 (RMB'000) (人民幣千元)	Unrealized gain for the Reporting Period ⁽⁴⁾ 報告期內 未變現收益 ⁽⁴⁾ (RMB'000) (人民幣千元)	Size relative to the total assets of the Group 相對於本集團 資產總值的規模 (%)
1.	China Merchants Bank structured deposits ⁽¹⁾ 招商銀行結構性存款 ⁽¹⁾	RMB140,000,000 人民幣140,000,000元	140,505	505	9.08
2.	New China Innovation Fund ⁽²⁾ New China Innovation Fund ⁽²⁾	US\$15,000,000 15,000,000美元	109,108	671	7.05
3.	IndexCap Med&Tech I L.P. ⁽³⁾ IndexCap Med&Tech I L.P. ⁽³⁾	US\$14,500,000 14,500,000美元	103,695	637	6.70

Notes:

附註：

- (1) Representing the structured deposits subscribed for by the Company from China Merchants Bank Co., Ltd. during the Reporting Period. (1) 指本公司於報告期內向招商銀行股份有限公司認購的結構性存款。
- (2) Representing the wealth management product subscribed for by the Company from New China Innovation Fund SPC on January 25, 2022. (2) 指本公司於2022年1月25日向New China Innovation Fund SPC認購的理財產品。
- (3) Representing the limited partnership interest in IndexCap Med&Tech I L.P. subscribed for by a wholly-owned subsidiary of the Company on January 24, 2023. For further details of the transaction, please refer to the announcements of the Company dated January 24, 2023 and February 6, 2023, respectively. (3) 指本公司全資附屬公司於2023年1月24日認購IndexCap Med&Tech I L.P.的有限合夥權益。有關交易之進一步詳情，請參閱本公司日期分別為2023年1月24日及2023年2月6日的公告。
- (4) The relevant investment and wealth management products did not record any realized gains or receive any dividend for the Reporting Period. (4) 於報告期內，相關投資及理財產品並無錄得任何已變現收益或收取任何股息。

OTHER INFORMATION 其他資料

The Group has always adopted a prudent investment strategy and would closely monitor the market changes and adjust its investment portfolio as and when necessary. The Group intended to hold these investments as needed aiming to generating a stable income. Save as disclosed above, there were no other significant investments nor material acquisitions or disposals of subsidiaries and affiliated companies by the Group for the Reporting Period.

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

As of the date of this interim report, we did not have any existing plan for material investments or acquisition of capital assets.

CAPITAL COMMITMENTS

As of June 30, 2024, we recorded capital commitment of RMB37.6 million for the purchase of other financial assets and capital contributions (as of December 31, 2023: RMB49.2 million).

CONTINGENT LIABILITIES

As of June 30, 2024, we did not have any contingent liabilities.

CHARGE ON ASSETS

As of June 30, 2024, we did not have any charge on assets.

FOREIGN EXCHANGE EXPOSURE

Our financial statements are expressed in RMB, but certain of its cash and cash equivalents are denominated in foreign currencies, and are exposed to foreign currency risk. We have established a foreign exchange exposure monitoring policy and will consider hedging against significant foreign exchange exposure of the Group should the need arise.

本集團一貫採取審慎的投資策略，密切監察市場變化，並於必要時調整其投資組合。本集團擬根據需要持有該等投資，旨在產生穩定收入。除上文所披露者外，於報告期內，本集團並無進行其他重大投資或重大收購或出售附屬公司及聯屬公司。

重大投資或資本資產的未來計劃

截至本中期報告日期，我們並無任何重大投資或收購資本資產的現有計劃。

資本承擔

截至2024年6月30日，我們就購買其他金融資產及出資錄得資本承擔人民幣37.6百萬元(截至2023年12月31日：人民幣49.2百萬元)。

或有負債

截至2024年6月30日，我們概無任何或有負債。

資產押記

截至2024年6月30日，我們並無任何資產押記。

外匯風險

我們的財務報表以人民幣列示，但我們的若干現金及現金等價物以外幣計價，並面臨外幣風險。我們已制定外匯風險監控政策，並將在有需要時考慮對沖本集團的重大外匯風險。

OTHER INFORMATION

其他資料

EMPLOYEE AND REMUNERATION POLICIES

As of June 30, 2024, we had 254 full-time employees. The total remuneration cost (share-based compensation included) incurred by the Group for the six months ended June 30, 2024 was RMB102.9 million. The remuneration package of our employees includes salary and bonus, which are generally determined by their qualifications, industry experience, position and performance. We make contributions to social insurance and housing provident funds as required by the PRC laws and regulations. We have adopted the 2022 Equity Incentive Scheme on January 13, 2023 to incentivize our employees.

The Remuneration and Appraisal Committee was set up for reviewing the Company's emolument policy and structure for all remuneration of the Directors, Supervisors and senior management of the Company, having regard to the Company's operating results, individual performance of the Directors, Supervisors and senior management and comparable market practices.

We provide formal and comprehensive company-level and department-level trainings to our new employees, followed by on-the-job training. We also provide trainings and development programs to our employees from time to time to ensure their awareness and compliance with our various policies and procedures.

For the six months ended June 30, 2024, we did not experience any material labor disputes or strikes that may have a material and adverse effect on our business, financial condition or results of operations, or any difficulty in recruiting employees.

僱員及薪酬政策

截至2024年6月30日，我們有254名全職僱員。截至2024年6月30日止六個月，本集團產生的總薪酬成本（包括股份支付）為人民幣102.9百萬元。本公司僱員的薪酬待遇包括薪金及花紅，一般視彼等的資歷、行業經驗、職位及表現而定。我們按照中國法律法規的要求繳納社會保險及住房公積金。我們已於2023年1月13日採納2022年股權激勵計劃，以激勵我們的僱員。

本公司設立薪酬與考核委員會，結合本公司經營業績，董事、監事及高級管理人員的個人表現，以及可資比較市場慣例，審議董事、監事及本公司高級管理人員全部薪酬的薪酬政策和薪酬結構。

我們於在職培訓前向新僱員提供正式全面的公司級與部門級培訓。我們亦不時為僱員提供培訓及發展規劃，以確保彼等瞭解並遵守我們的各類政策及流程。

截至2024年6月30日止六個月，我們未發生任何可能對我們的業務、財務狀況或經營業績造成重大不利影響的重大勞資糾紛或罷工，亦未在招聘員工方面遇到任何困難。

OTHER INFORMATION 其他資料

USE OF NET PROCEEDS FROM GLOBAL OFFERING

The Company's Shares were listed on the Stock Exchange on November 5, 2021. After finalization and the settlement of the listing expenses, including the relevant expenses incurred by work done by professional parties, the finalized net proceeds from the Global Offering amounted to HK\$1,550.7 million. Accordingly, the planned applications of the net proceeds as disclosed in the section headed "Future Plans and Use of Proceeds" of the prospectus of the Company issued on October 26, 2021 are adjusted pro rata as set forth in the table below. Throughout the Reporting Period and up to the date of this interim report, the planned applications and allocation percentage remained unchanged. As of June 30, 2024, approximately HK\$800.8 million of the net proceeds of the Global Offering had been utilized as follows:

全球發售所得款項淨額用途

本公司股份於2021年11月5日在聯交所上市。經最終確定及結清上市開支(包括專業人士完成工作所產生的相關開支)後，全球發售的最終所得款項淨額為1,550.7百萬港元。因此，本公司於2021年10月26日發佈的招股章程內「未來計劃及所得款項用途」一節披露的所得款項淨額的計劃用途已如下表所示按比例調整。於整個報告期內及直至本中期報告日期，計劃用途及分配比例維持不變。截至2024年6月30日，全球發售所得款項淨額的約800.8百萬港元已作如下用途：

		Planned Applications (HK\$ million)	Percentage of total net proceeds (%)	Actual usage for the six months ended June 30, 2024 (HK\$ million)	Actual usage up to June 30, 2024 (HK\$ million)	Unutilized proceeds as of June 30, 2024 (HK\$ million)	Expected time of full utilization of remaining balance
		計劃用途 (百萬港元)	佔所得款項總淨額之百分比 (%)	截至2024年6月30日止六個月的實際使用量 (百萬港元)	截至2024年6月30日的實際使用量 (百萬港元)	截至2024年6月30日未動用所得款項 (百萬港元)	餘額悉數動用之預期時間
Optimization, development and commercialization of our Core Product	我們核心產品的優化、開發和商業化	775.4	50	115.5	369.1	406.3	2026
Research and development and manufacturing of our hardware devices	我們硬件設備的研發和製造	294.6	19	32.2	175.5	119.1	2026
Ongoing and future R&D of our health risk assessment solutions	我們正在進行的及未來的健康風險評估解決方案的研發	155.1	10	44.6	91.7	63.4	2026
Development of our portfolio to diversify our AI-empowered retina-based early detection, diagnosis and health risk assessment solutions	我們產品組合的開發，以豐富我們人工智能視網膜影像識別的早期檢測、診斷及健康風險評估解決方案	93.0	6	3.5	29.6	63.4	2024
Collaborations with academic and research institutions on joint research projects	與學術及研究機構就聯合研究項目進行的合作	77.5	5	1.4	17.6	59.9	2024
Working capital and other general corporate purposes	營運資金和其他一般公司用途	155.1	10	26.9	117.3	37.8	2024
Total	合計	1,550.7	100	224.2	800.8	749.9	

OTHER INFORMATION

其他資料

On August 28, 2024, after careful consideration and detailed evaluation of the Group's R&D progress, operation level and business strategies, the Board resolved to change in the use of the net proceeds from the Global Offering and reallocation of the unutilized amount of the net proceeds as of July 31, 2024 of approximately HK\$723.7 million in total, which is subject to further approval by the Shareholders. For further details, please see relevant announcement of the Company dated August 28, 2024.

EVENTS AFTER THE REPORTING PERIOD

On August 28, 2024, the Board resolved to approve the 2024 full circulation of the shares of the Company, pursuant to which a total of 50,151,012 Unlisted Shares can be converted into H Shares and listed on the Stock Exchange, which is subject to further approval by the Shareholders. For details, please see relevant announcement of the Company dated August 28, 2024.

Save as disclosed herein and in the note 23 to the interim condensed consolidated financial information as set out in this report, there are no important events affecting the Group occurred after the Reporting Period and up to the date of this report.

INTERIM DIVIDENDS

The Board does not recommend the payment of interim dividends for the six months ended June 30, 2024 to the Shareholders (June 30, 2023: nil).

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any listed securities of the Company (including sale of treasury Shares) during the six months ended June 30, 2024 and up to the date of this interim report. As of June 30, 2024, the Company did not hold any treasury Shares.

於2024年8月28日，經審慎考慮及詳細評估本集團的研發進度、營運水平及業務戰略後，董事會議決變更全球發售所得款項淨額用途及重新分配截至2024年7月31日合共約723.7百萬港元的所得款項淨額未動用金額，該事項有待股東進一步批准。有關進一步詳情，請參閱本公司日期為2024年8月28日的相關公告。

報告期後事項

於2024年8月28日，董事會議決批准本公司股份的2024年全流通，據此，合共50,151,012股未上市股份可轉換為H股並於聯交所上市，該事項有待股東進一步批准。有關詳情，請參閱本公司日期為2024年8月28日的相關公告。

除本報告及本報告所載中期簡明綜合財務資料附註23所披露者外，於報告期後及直至本報告日期止概無發生影響本集團的重大事件。

中期股息

董事會並不建議向股東派付截至2024年6月30日止六個月的中期股息(2023年6月30日：無)。

購買、出售或贖回本公司的上市證券

於截至2024年6月30日止六個月及直至本中期報告日期，本公司或其任何附屬公司均未購買、出售或贖回本公司的任何上市證券(包括出售庫存股份)。截至2024年6月30日，本公司並無持有任何庫存股份。

OTHER INFORMATION 其他資料

SHARE INCENTIVES SCHEME

Incentives granted prior to the Listing

Airdoc Universe, Suqian Airdoc and Suqian Zhongyou were established in the PRC as our employee incentive platforms, and respectively held approximately 3.58%, 3.87% and 2.24% of the total issued Shares of the Company as of the date of this interim report. For further details of the employee incentive platforms, please refer to the Prospectus.

2022 Equity Incentive Scheme

On January 13, 2023, the Board resolved to adopt the 2022 Equity Incentive Scheme, which was subsequently approved by the Shareholders at the extraordinary general meeting of the Company held on March 30, 2023. Further details of the 2022 Equity Incentive Scheme are set out in the circular of the Company dated March 10, 2023 and the 2023 annual report. The 2022 Equity Incentive Scheme shall be valid and effective for a period of five years commencing from March 30, 2023. The maximum number of Incentive Shares grantable under the 2022 Equity Incentive Scheme shall not exceed 6,214,080 H Shares, which shall be satisfied by the H Shares to be purchased in the open market by trustee.

2024 Equity Incentive Scheme

On August 28, 2024, the Board resolved to adopt the 2024 Equity Incentive Scheme, which is subject to further approval by the Shareholders. For further details, please see the announcement of the Company dated August 28, 2024.

股份激勵計劃

於上市前授予的激勵

鬱金香宇宙、宿遷鷹瞳及宿遷眾佑均為在中國成立的本公司員工激勵平台，且截至本中期報告日期，彼等分別於本公司已發行股份總數中擁有約3.58%、3.87%及2.24%的權益。有關員工激勵平台的更多詳情，請參閱招股章程。

2022年股權激勵計劃

於2023年1月13日，董事會議決採納2022年股權激勵計劃，該計劃其後經股東於本公司於2023年3月30日舉行的臨時股東大會上批准。2022年股權激勵計劃的更多詳情載於本公司日期為2023年3月10日的通函及2023年年報。2022年股權激勵計劃自2023年3月30日起五年內有效。根據2022年股權激勵計劃可授予的激勵股份的最大數量不得超過6,214,080股H股，將由受託人從公開市場購買的H股支付。

2024年股權激勵計劃

於2024年8月28日，董事會決議採納2024年股權激勵計劃，該計劃有待股東進一步批准。有關進一步詳情，請參閱本公司日期為2024年8月28日的公告。

OTHER INFORMATION

其他資料

Movements in incentives under the 2022 Equity Incentive Scheme

2022年股權激勵計劃項下激勵變動

Details of the incentives granted under the 2022 Equity Incentive Scheme and their movements during the six months ended June 30, 2024 are as follows:

2022年股權激勵計劃項下激勵及其於截至2024年6月30日六個月內的變動詳情如下：

Category and name of grantee	Position	Grant Date	Vesting period	Grant price	Number of Incentive Shares granted but not yet vested as of January 1, 2024 截至2024年1月1日 已授予但尚未歸屬的激勵股份數目	Number of Incentive Shares granted during the Reporting Period 報告期內 已授予激勵股份數目	Number of Incentive Shares vested during the Reporting Period 報告期內 已歸屬激勵股份數目	Number of Incentive Shares cancelled during the Reporting Period 報告期內 已註銷激勵股份數目	Number of Incentive Shares lapsed during the Reporting Period 報告期內 已失效激勵股份數目	Number of Incentive Shares granted but not yet vested as of June 30, 2024 截至2024年6月30日 已授予但尚未歸屬的激勵股份數目	Weighted average closing price of Incentive Shares vested during the Reporting Period 報告期內 已歸屬激勵股份的加權平均收市價 HK\$ 港元
Directors 董事											
Mr. Zhang 張先生	Executive Director and chief executive officer 執行董事兼首席執行官	April 3, 2023 April 24, 2024 2023年4月3日 2024年4月24日	Note (1) Note (2) 附註(1) 附註(2)	nil nil 無 無	2,330,280 —	— 1,306,743	— 179,676	— —	— —	2,330,280 980,058	— 14.88
Ms. WANG Lin (王林) 王林女士	Executive Director 執行董事	April 24, 2024 2024年4月24日	Note (2) 附註(2)	nil 無	—	100,000	25,000	—	—	75,000	14.88
Dr. HE Chao (和超) 和超博士	Executive Director 執行董事	April 24, 2024 2024年4月24日	Note (2) 附註(2)	nil 無	—	72,540	18,135	—	—	54,405	14.88
Mr. QIN Yong (秦勇) 秦勇先生	Executive Director 執行董事	April 24, 2024 2024年4月24日	Note (2) 附註(2)	nil 無	—	100,000	21,116	—	—	75,000	14.88
Senior Management 高級管理層											
Ms. YANG Wenting (楊文婷) 楊文婷女士	Joint Company Secretary and Chief financial officer 聯席公司秘書兼首席財務官	April 24, 2024 2024年4月24日	Note (2) 附註(2)	nil 無	—	100,000	21,116	—	—	75,000	14.88
Employees 僱員											
Other grantees 其他承授人	Note(3) 附註(3)	April 24, 2024 2024年4月24日	Note (4) 附註(4)	nil 無	—	1,427,757	306,936	—	3,392	1,117,429	14.88
Total 合計					2,330,280	3,107,040	726,756	—	3,392	4,707,172	

OTHER INFORMATION 其他資料

Notes:

- 25% of the Incentive Shares vested on December 31, 2023. On April 24, 2024, the Board resolved to accelerate the vesting schedule of the remaining 75% of the Incentive Shares, with all such Incentive Shares to vest on September 30, 2024. The Board considers that the reasons and basis for accelerating the vesting are to (i) recognize and appreciate Mr. Zhang's dedication, significant efforts, and outstanding contributions to the Group, particularly his leadership in guiding the Group to achieve its corporate and business development goals in 2023, (ii) encourage Mr. Zhang to leverage his industry expertise and extensive knowledge in product development and continue enhancing the value of the Company and its Shares for the benefit of the Company and its Shareholders as a whole, and (iii) strengthen the alignment of Mr. Zhang's long-term interests with those of the Company, thereby providing an incentive for his ongoing commitment and contribution to the Group's future growth.
- 25% of the Incentive Shares vested upon grant as a reward for leading the Company in achieving its business targets. The remaining 75% will vest in three annual installments on each anniversary of the grant date, subject to the fulfillment of certain performance targets related to business development as stipulated in the respective grant agreements.
- Other grantees are all employees of the Company (other than the Directors, Supervisors or senior management members) who entered into valid employment contracts with the Company.
- 25% of the Incentive Shares vested upon grant as a reward for leading the Company in achieving the business targets. The remaining 75% will vest in three annual installments on each anniversary of the grant date, subject to the fulfillment of certain performance targets related to business development, sales and marketing, or research and development milestones (as the case may be), as stipulated in the respective grant agreements.

Save as disclosed, the Company did not make any other grants under the 2022 Equity Incentive Scheme as of the date of this interim report.

As the Incentives were granted to the executive Directors pursuant to their service contracts with the Group and form part of their remuneration package thereunder, the grants of Incentives to the executive Directors are exempt from the reporting, announcement and independent Shareholders' approval requirements under Rules 14A.73(6) and 14A.95 of the Listing Rules.

附註：

- 25%的激勵股份於2023年12月31日歸屬。於2024年4月24日，董事會議決加快餘下75%激勵股份的歸屬時間表，所有該等激勵股份將於2024年9月30日歸屬。董事會認為，加速歸屬的原因及依據為(i)認同及贊賞張先生對本集團的奉獻精神、重大努力及傑出貢獻，尤其是其於指導本集團於2023年實現企業及業務發展目標方面的領導能力，(ii)鼓勵張先生利用其於產品開發方面的行業專長及豐富知識，繼續提升本公司及其股份的價值，以利本公司及其股東的整體利益，及(iii)加強張先生長期利益與本公司長期利益的一致性，從而激勵其為本集團的未來增長作出持續承諾及貢獻。
- 25%的激勵股份於授予時歸屬，作為引領本公司實現其業務目標的獎勵。餘下的75%將於授出日期的每個週年日分三年歸屬，前提是達成各項授予協議中規定的與業務發展相關的若干績效目標。
- 其他承授人均為與本公司簽訂有效僱傭合約的本公司僱員(董事、監事及高級管理層成員除外)。
- 25%的激勵股份於授予時歸屬，作為引領本公司實現業務目標的獎勵。餘下的75%將於授出日期的每個週年日分三年歸屬，前提是達成各項授予協議中規定的與業務發展、銷售與營銷或研發里程碑(視情況而定)相關的若干績效目標。

除所披露者外，本公司截至本中期報告日期並無根據2022年股權激勵計劃作出任何其他授予。

由於激勵乃根據執行董事與本集團簽訂的服務合約而授予，並構成其薪酬待遇的一部分，因此向執行董事授予激勵豁免遵守上市規則第14A.73(6)及14A.95條的申報、公告及獨立股東批准規定。

OTHER INFORMATION

其他資料

The number of Incentive Shares available for grant under the Scheme at the beginning of the Reporting Period and the end of the Reporting Period are 3,107,040 and nil, respectively. The number of Shares available for issue under the Scheme was nil as the Incentive Shares will be satisfied by the H Shares to be purchased on market by the trustee. In order to satisfy the 6,214,080 Incentive Shares granted, since the date of the Company's 2023 annual report, and up to the date of this interim report, the trustee purchased a total number of 2,880,100 H Shares in the open market.

As of the date of this interim report, save as disclosed above, the Company did not have any other share incentive scheme or make any grant that is subject to the disclosure requirements under Chapter 17 of the Listing Rules.

MATERIAL LITIGATION

The Company was not involved in any material litigation or arbitration for the six months ended June 30, 2024. The Directors are also not aware of any material litigation or claims that are pending or threatened against the Group during the six months ended June 30, 2024.

CHANGES IN THE INFORMATION OF THE DIRECTORS

Pursuant to Rule 13.51B of the Listing Rules, the changes in the information of the Directors since the date of the Company's 2023 annual report and up to the date of this interim report are set out below:

On August 28, 2024, Mr. Albert Ng resigned as an independent non-executive Director and ceased to be the chairman of the Audit Committee and a member of the remuneration and appraisal committee of the Company. For further information, please see the announcement of the Company dated August 28, 2024.

Save as disclosed above, no information is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

於報告期初及報告期末，根據該計劃可供授予的激勵股份數目分別為3,107,040股及零。由於受託人將從市場購買H股支付激勵股份，故根據該計劃可供發行的股份數目為零。為支付授出的6,214,080股激勵股份，自本公司2023年年度報告日期起直至本中期報告日期，受託人於公開市場購買合共2,880,100股H股。

截至本中期報告日期，除上文所披露者外，本公司並無任何其他須依據上市規則第十七章披露規定的股份激勵計劃或作出任何授予。

重大訴訟

截至2024年6月30日止六個月，本公司並無涉及任何重大訴訟或仲裁事項。於截至2024年6月30日止六個月內，董事亦不知悉任何尚未了結或本集團可能面臨的任何重大訴訟或索賠。

董事之資料變動

根據上市規則第13.51B條，自本公司2023年年度報告日期起及直至本中期報告日期止，董事資料之變動載列如下：

於2024年8月28日，吳先生辭任獨立非執行董事，並不再擔任本公司審核委員會的主席及薪酬與考核委員會的成員。有關進一步資料，請參閱本公司日期為2024年8月28日的公告。

除上文所披露者外，概無資料須根據上市規則第13.51B(1)條予以披露。

OTHER INFORMATION 其他資料

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

None of the Directors or any of their respective associates were granted by the Company or its subsidiaries any right to acquire shares in, or debentures of, the Company or its subsidiary, or had exercised any such right during the six months ended June 30, 2024.

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

The Company does not have any other disclosure obligations pursuant to Rules 13.20, 13.21 and 13.22 of the Listing Rules.

REVIEW OF FINANCIAL STATEMENTS

The Audit Committee comprises three independent non-executive Directors, namely Mr. NG Kong Ping Albert, Dr. HUANG Yanlin and Dr. WU Yangfeng. Mr. NG Kong Ping Albert, being the chairman of the committee, is appropriately qualified as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of the Company and overseeing the audit process. The Audit Committee has reviewed the interim results of the Group for the six months ended June 30, 2024 and has recommended for the Board's approval thereof. The Audit Committee has reviewed together with the management the accounting principles and policies adopted by the Company and discussed internal control and financial reporting matters (including the review of the unaudited interim results and interim report of the Group for the six months ended June 30, 2024) of the Group.

董事收購股份或債權證之權利

於截至2024年6月30日止六個月期間，本公司或其附屬公司均未授予董事或任何彼等各自的聯繫人收購本公司或其附屬公司股份或債權證的權利，或行使該等權利。

根據上市規則的持續披露責任

本公司並無根據上市規則第13.20條、13.21條及13.22條項下的任何其他披露責任。

審閱財務報表

審核委員會由三名獨立非執行董事組成，即吳港平先生、黃彥林博士及武陽豐博士。吳港平先生為委員會主席，具備上市規則第3.10(2)條及3.21條規定的合適資格。審核委員會的主要職責是協助董事會就本公司財務報告流程、內部控制及風險管理系統的有效性提供獨立意見，並監督審核程序。審核委員會已審閱本集團截至2024年6月30日止六個月的中期業績，並建議董事會批准。審核委員會已與管理層一同審閱本公司採納的會計原則及政策並討論本集團的內部控制及財務申報事宜(包括審閱本集團截至2024年6月30日止六個月的未經審核中期業績及中期報告)。

OTHER INFORMATION

其他資料

APPRECIATION

We wish to express our sincere gratitude to our shareholders and business partners for their continued support, and to our employees for their dedication and hard work.

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, August 28, 2024

致謝

我們謹此就股東和業務夥伴的持續支持以及我們僱員的恪盡職守及辛勤工作向彼等致以衷心感謝。

承董事會命
北京鷹瞳科技發展股份有限公司
董事會主席
張大磊先生

香港，2024年8月28日

INDEPENDENT REVIEW REPORT

獨立審閱報告



Ernst & Young
27/F, One Taikoo Place
979 King's Road
Quarry Bay, Hong Kong

安永會計師事務所
香港鰂魚涌英皇道979號
太古坊一座27樓

Tel 電話: +852 2846 9888
Fax 傳真: +852 2868 4432
ey.com

Independent review report

To the board of directors of Beijing Airdoc Technology Co., Ltd.

(Incorporated in the People's Republic of China with limited liability)

INTRODUCTION

We have reviewed the interim financial information set out on pages 61 to 99, which comprises the condensed consolidated statement of financial position of Beijing Airdoc Technology Co., Ltd. (the “**Company**”) and its subsidiaries (the “**Group**”) as at 30 June 2024 and the related condensed consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 *Interim Financial Reporting* (“**IAS 34**”) issued by the International Accounting Standards Board (“**IASB**”). The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34. Our responsibility is to express a conclusion on this interim financial information based on our review. Our report is made solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

獨立審閱報告

致北京鷹瞳科技發展股份有限公司董事會

(於中華人民共和國註冊成立的有限公司)

緒言

我們已審閱列載於61至99頁的中期財務資料，包括北京鷹瞳科技發展股份有限公司（「**貴公司**」）及其附屬公司（「**貴集團**」）截至2024年6月30日的簡明綜合財務狀況表以及截至該日止六個月期間的相關簡明綜合損益表、簡明綜合收益表、簡明綜合權益變動表及簡明綜合現金流量表以及解釋附註。《香港聯合交易所有限公司證券上市規則》規定，編製中期財務資料的報告須遵守其相關條文及國際會計準則理事會（「**國際會計準則理事會**」）頒佈的《國際會計準則》第34號「中期財務報告」（「**國際會計準則第34號**」）。**貴公司**董事負責根據國際會計準則第34號編製並呈列本中期財務資料。我們的責任是根據我們的審閱對中期財務資料作出結論，並按照協定的委聘條款僅向整體董事會作出報告，除此之外，我們的報告不可用作其他用途。我們不就本報告內容向任何其他人士負責或承擔責任。

INDEPENDENT REVIEW REPORT

獨立審閱報告

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Hong Kong Institute of Certified Public Accountants (“**HKICPA**”). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information is not prepared, in all material respects, in accordance with IAS 34.

Ernst & Young
Certified Public Accountants
Hong Kong

28 August 2024

審閱範圍

我們已根據香港會計師公會（「香港會計師公會」）發出的《香港審閱委聘準則》第2410號「實體的獨立核數師對中期財務資料的審閱」進行審閱。中期財務資料的審閱包括對主要負責財務及會計事務的人員作出詢問，並實施分析及其他審閱程序。審閱的範圍遠小於根據《香港審計準則》進行的審核，故無法保證我們會注意到所有可通過審核發現的重大事項。據此，我們不會發表審核意見。

結論

根據我們的審閱，我們並無發現任何事項，令我們相信，中期財務資料於所有重大方面未有按照國際會計準則第34號編製。

安永會計師事務所
執業會計師
香港

2024年8月28日

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

中期簡明綜合損益表

FOR THE SIX MONTHS ENDED 30 JUNE 2024 截至2024年6月30日止六個月

For the six months ended 30 June
截至6月30日止六個月

		Notes	2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
		附註		
REVENUE	收入	4	93,710	82,502
Cost of sales	銷售成本		(39,954)	(31,138)
Gross profit	毛利		53,756	51,364
Other income and gains	其他收入及收益	5	17,719	49,786
Selling and distribution expenses	銷售及分銷開支		(38,198)	(44,292)
Administrative expenses	行政開支		(41,988)	(39,175)
Impairment losses on financial assets, net	金融資產減值淨虧損		(24,817)	52
Research and development expenses	研發開支		(48,986)	(56,517)
Other losses	其他虧損	5	—	(1,472)
Finance costs	財務成本	6	(216)	(275)
LOSS BEFORE TAX	除稅前虧損	7	(82,730)	(40,529)
Income tax credit/(expense)	所得稅抵免/(開支)	8	1,242	(488)
LOSS FOR THE PERIOD	期內虧損		(81,488)	(41,017)
Attributable to:	以下人士應佔：			
Owners of the parent	母公司擁有人		(80,502)	(36,970)
Non-controlling interests	非控股權益		(986)	(4,047)
			(81,488)	(41,017)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	母公司普通權益持有人應佔的每股虧損	10		
Basic and diluted (expressed in RMB)	基本及攤薄 (以人民幣列示)		(0.79)	(0.36)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

中期簡明綜合收益表

FOR THE SIX MONTHS ENDED 30 JUNE 2024 截至2024年6月30日止六個月

For the six months ended 30 June
截至6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
LOSS FOR THE PERIOD	期內虧損	(81,488)	(41,017)
OTHER COMPREHENSIVE LOSS	其他綜合虧損		
Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:	其後可重新分類至損益的其他綜合虧損：		
Exchange differences on translation of the financial statements of a subsidiary	換算一家附屬公司的財務報表時所產生的匯兌差額	(87)	(268)
Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods:	其後不會重新分類至損益的其他綜合虧損：		
Equity investments designated at fair value through other comprehensive income:	指定為以公允價值計量且其變動計入其他綜合收益的權益投資：		
Changes in fair value	公允價值變動	(480)	(932)
OTHER COMPREHENSIVE LOSS FOR THE PERIOD, NET OF TAX	期內其他綜合虧損，經扣除稅項	(567)	(1,200)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	期內綜合虧損總額	(82,055)	(42,217)
Attributable to:	以下人士應佔：		
Owners of the parent	母公司擁有人	(81,039)	(38,094)
Non-controlling interests	非控股權益	(1,016)	(4,123)
		(82,055)	(42,217)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

中期簡明綜合財務狀況表

30 JUNE 2024 於2024年6月30日

		Notes 附註	30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
NON-CURRENT ASSETS	非流動資產			
Property, plant and equipment	物業、廠房及設備	11	20,237	17,994
Right-of-use assets	使用權資產		4,644	10,451
Goodwill	商譽		127,213	127,213
Other intangible assets	其他無形資產		88,917	93,934
Other financial assets	其他金融資產	14	284,202	148,413
Other non-current assets	其他非流動資產		4,536	4,980
Total non-current assets	非流動資產總值		529,749	402,985
CURRENT ASSETS	流動資產			
Inventories	存貨		28,197	40,134
Trade receivables	應收賬款	12	58,189	79,640
Prepayments, other receivables and other assets	預付款項、其他應收款項 及其他資產	13	22,816	17,439
Other financial assets	其他金融資產	14	342,068	163,837
Cash in transit for investment	用於投資的在途現金		—	49,579
Time deposits over three months	超過三個月的定期存款	15	18,587	37,519
Restricted bank deposits	受限制銀行存款	15	—	2,289
Cash and cash equivalents	現金及現金等價物	15	547,763	891,490
Total current assets	流動資產總值		1,017,620	1,281,927
CURRENT LIABILITIES	流動負債			
Trade payables	應付賬款	16	7,942	17,529
Other payables and accruals	其他應付款項及應計費用	17	37,853	60,016
Contract liabilities	合約負債		12,517	23,726
Lease liabilities	租賃負債		3,479	8,622
Tax payable	應付稅項		—	344
Total current liabilities	流動負債總額		61,791	110,237
NET CURRENT ASSETS	流動資產淨值		955,829	1,171,690
TOTAL ASSETS LESS CURRENT LIABILITIES	資產總值減流動負債		1,485,578	1,574,675

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

中期簡明綜合財務狀況表

30 JUNE 2024 於2024年6月30日

		Notes 附註	30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
NON-CURRENT LIABILITIES	非流動負債			
Deferred tax liabilities	遞延稅項負債		10,755	11,939
Lease liabilities	租賃負債		587	752
Deferred income	遞延收入		2,609	4,200
			<hr/> 13,951	<hr/> 16,891
Total non-current liabilities	非流動負債總額			
			<hr/> 13,951	<hr/> 16,891
Net assets	淨資產		<hr/> 1,471,627	<hr/> 1,557,784
			<hr/> 1,471,627	<hr/> 1,557,784
EQUITY	權益			
Equity attributable to owners of the parent	母公司擁有人應佔權益			
Share capital	股本	18	103,568	103,568
Treasury shares	庫存股份		(20,476)	(10,442)
Reserves	儲備		1,372,150	1,447,257
			<hr/> 1,455,242	<hr/> 1,540,383
Non-controlling interests	非控股權益		16,385	17,401
			<hr/> 1,471,627	<hr/> 1,557,784
Total equity	權益總額		<hr/> 1,471,627	<hr/> 1,557,784

Zhang Dalei
張大磊
Director
董事

Wang Lin
王林
Director
董事

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

中期簡明綜合權益變動表

FOR THE SIX MONTHS ENDED 30 JUNE 2024 截至2024年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔									
		Share capital	Treasury shares	Share premium	Exchange reserve	Fair value reserve (non-recycling) 公允價值儲備 (不可劃轉)	Other reserve	Accumulated losses	Total	Non-controlling interests	Total equity
		股本 RMB'000 人民幣千元	庫存股份 RMB'000 人民幣千元	股份溢價 RMB'000 人民幣千元	匯兌儲備 RMB'000 人民幣千元	公允價值儲備 (不可劃轉) RMB'000 人民幣千元	其他儲備 RMB'000 人民幣千元	累計虧損 RMB'000 人民幣千元	合計 RMB'000 人民幣千元	非控股權益 RMB'000 人民幣千元	權益總額 RMB'000 人民幣千元
At 1 January 2024 (audited)	於2024年1月1日 (經審核)	103,568	(10,442)	1,827,965	731	—	96,655	(478,094)	1,540,383	17,401	1,557,784
Loss for the period	期內虧損	—	—	—	—	—	—	(80,502)	(80,502)	(986)	(81,488)
Other comprehensive loss for the period:	期內其他綜合虧損：										
Change in fair value of equity investments at fair value through other comprehensive income, net of tax	以公允價值計量且其變動計入其他綜合收益的權益投資的公允價值變動 (扣除稅項)	—	—	—	—	(480)	—	—	(480)	—	(480)
Exchange differences on translation of foreign operations	換算境外營運的匯兌差額	—	—	—	(57)	—	—	—	(57)	(30)	(87)
Total comprehensive loss for the period	期內綜合虧損總額	—	—	—	(57)	(480)	—	(80,502)	(81,039)	(1,016)	(82,055)
Treasury shares purchased	已購買庫存股份	—	(26,691)	—	—	—	—	—	(26,691)	—	(26,691)
Equity-settled share-based transactions	以權益結算的股份支付交易	—	—	—	—	—	22,589	—	22,589	—	22,589
Exercise of restricted shares	行使受限制股份	—	16,657	4,185	—	—	(20,842)	—	—	—	—
At 30 June 2024 (unaudited)	於2024年6月30日 (未經審核)	103,568	(20,476)	1,832,150	674	(480)	98,402	(558,596)	1,455,242	16,385	1,471,627

		Attributable to owners of the parent 母公司擁有人應佔								
		Share capital	Share premium	Exchange reserve	Fair value reserve (non-recycling) 公允價值儲備 (不可劃轉)	Other reserve	Accumulated losses	Total	Non-controlling interests	Total equity
		股本 RMB'000 人民幣千元	股份溢價 RMB'000 人民幣千元	匯兌儲備 RMB'000 人民幣千元	公允價值儲備 (不可劃轉) RMB'000 人民幣千元	其他儲備 RMB'000 人民幣千元	累計虧損 RMB'000 人民幣千元	合計 RMB'000 人民幣千元	非控股權益 RMB'000 人民幣千元	權益總額 RMB'000 人民幣千元
At 1 January 2023 (audited)	於2023年1月1日 (經審核)	103,568	1,827,965	673	1,274	78,206	(345,561)	1,666,125	5,237	1,671,362
Loss for the period	期內虧損	—	—	—	—	—	(36,970)	(36,970)	(4,047)	(41,017)
Other comprehensive loss for the period:	期內其他綜合虧損：									
Change in fair value of equity investments at fair value through other comprehensive income, net of tax	以公允價值計量且其變動計入其他綜合收益的權益投資的公允價值變動 (扣除稅項)	—	—	—	(932)	—	—	(932)	—	(932)
Exchange differences on translation of foreign operations	換算境外營運的匯兌差額	—	—	(192)	—	—	—	(192)	(76)	(268)
Total comprehensive loss for the period	期內綜合虧損總額	—	—	(192)	(932)	—	(36,970)	(38,094)	(4,123)	(42,217)
Acquisition of subsidiaries	收購附屬公司	—	—	—	—	—	—	—	23,412	23,412
Contributions from a non-controlling shareholder	非控股股東出資	—	—	—	—	—	—	—	1,345	1,345
Equity-settled share-based transactions	以權益結算的股份支付交易	—	—	—	—	11,147	—	11,147	—	11,147
At 30 June 2023 (unaudited)	於2023年6月30日 (未經審核)	103,568	1,827,965	481	342	89,353	(382,531)	1,639,178	25,871	1,665,049

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

FOR THE SIX MONTHS ENDED 30 JUNE 2024 截至2024年6月30日止六個月

For the six months ended 30 June
截至6月30日止六個月

			2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
CASH FLOWS FROM	經營活動所得現金			
OPERATING ACTIVITIES	流量			
Loss before tax	稅前虧損		(82,730)	(40,529)
Adjustments for:	就以下各項進行調整：			
Finance costs	財務成本	6	216	275
Interest income	利息收入	5	(4,451)	(8,976)
Depreciation of property, plant and equipment	物業、廠房及設備折舊	7	4,916	8,412
Amortisation of other intangible assets	其他無形資產攤銷	7	5,017	941
Depreciation of right-of-use assets	使用權資產折舊	7	3,419	4,192
Write-down of inventories to net realisable value	存貨較可變現淨值的撇減	7	2,708	—
Gains on termination of the lease contracts	終止租賃合約的收益		(138)	—
(Gains)/loss on disposal of property, plant and equipment	出售物業、廠房及設備的(收益)/虧損		(48)	973
Provision for impairment of trade receivables	應收賬款減值撥備	7	24,691	2,840
Provision for impairment of other receivables	其他應收款項減值撥備	7	126	98
Foreign exchange gains, net	匯兌淨收益	5	(387)	(7,805)
Fair value gains on financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產的公允價值收益	5	(2,161)	(9,841)
Investment income from financial assets	金融資產投資收入	5	(6,406)	(22,588)
Equity-settled share-based transactions	以權益結算的股份支付交易	7	22,589	11,147

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

FOR THE SIX MONTHS ENDED 30 JUNE 2024 截至2024年6月30日止六個月

For the six months ended 30 June

截至6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Decrease/(increase) in inventories	存貨減少/(增加)	9,229	(14,041)
Increase in trade receivables	應收賬款增加	(3,241)	(16,764)
Increase in prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產增加	(5,503)	(7,549)
Decrease in other non-current assets	其他非流動資產減少	694	—
(Decrease)/increase in trade payables	應付賬款(減少)/增加	(9,587)	3,945
Decrease in other payables and accruals	其他應付款項及應計費用減少	(21,022)	(10,964)
(Decrease)/increase in contract liabilities	合約負債(減少)/增加	(11,209)	8,307
Decrease in deferred Income	遞延收入減少	(1,591)	—
Decrease in restricted bank deposits	受限制銀行存款減少	2,289	—
Cash used in operations	經營所用現金	(72,580)	(97,927)
Interest received	已收利息	4,119	3,001
Income taxes received	已收所得稅	75	—
Net cash flows used in operating activities	經營活動所用現金流量淨額	(68,386)	(94,926)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

FOR THE SIX MONTHS ENDED 30 JUNE 2024 截至2024年6月30日止六個月

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Net cash flows used in operating activities	經營活動所用現金流量淨額	(68,386)	(94,926)
CASH FLOWS FROM INVESTING ACTIVITIES	投資活動所得現金流量		
Proceeds from disposal of property, plant and equipment	出售物業、廠房及設備所得款項	805	163
Proceeds from disposal of other financial assets	出售其他金融資產所得款項	1,034,954	1,455,963
Proceeds from disposal of time deposits	出售定期存款所得款項	37,519	153,525
Purchases of items of property, plant and equipment	購買物業、廠房及設備項目	(7,917)	(2,161)
Purchases of other intangible assets	購買其他無形資產	(1,500)	—
Purchases of other financial assets	購買其他金融資產	(1,291,308)	(1,641,216)
Purchase of time deposits	購買定期存款	(18,255)	(90,698)
Prepayment for purchase of other long-term assets	購買其他長期資產的預付款項	(250)	(269)
Acquisition of subsidiaries	收購附屬公司	—	(176,810)
Net cash flows used in investing activities	投資活動所用現金流量淨額	(245,952)	(301,503)
CASH FLOWS FROM FINANCING ACTIVITIES	融資活動所得現金流量		
Principal portion of lease payments	租賃付款的本金部分	(2,998)	(4,342)
Contributions from a non-controlling shareholder	非控股股東出資	—	1,345
Purchases of treasury shares	購買庫存股份	(26,691)	—
Net cash flows used in financing activities	融資活動所用現金流量淨額	(29,689)	(2,997)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

FOR THE SIX MONTHS ENDED 30 JUNE 2024 截至2024年6月30日止六個月

		For the six months ended 30 June	
		截至6月30日止六個月	
		2024	2023
		2024年	2023年
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
		RMB'000	RMB'000
		人民幣千元	人民幣千元
	Notes 附註		
NET DECREASE IN CASH AND CASH EQUIVALENTS	現金及現金等價物 減少淨額	(344,027)	(399,426)
Cash and cash equivalents at beginning of period	期初現金及現金等價物	891,490	1,268,250
Effect of foreign exchange rate changes, net	外匯匯率變動的 影響，淨額	300	7,536
CASH AND CASH EQUIVALENTS AT END OF PERIOD	期末的現金及現金等價物	547,763	876,360
	15		
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS	現金及現金等價物 結餘分析		
Cash and bank balances	現金及銀行結餘	512,129	853,310
Non-pledged time deposits with original maturity of less than three months when acquired	購入時原到期日少於 三個月的無抵押定期存款	35,634	23,050
Cash and cash equivalents as stated in the interim condensed consolidated statement of financial position	呈列於中期簡明綜合 財務狀況表的現金 及現金等價物	547,763	876,360
Cash and cash equivalents as stated in the interim condensed consolidated statement of cash flows	呈列於中期簡明綜合 現金流量表的現金 及現金等價物	547,763	876,360

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

1. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2024 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2023.

Beijing Airdoc Technology Co., Ltd. (the “**Company**”) was established as a limited liability company in the People's Republic of China (the “**PRC**”) on 9 September 2015. The Company was converted from a limited liability company into a joint stock limited liability company on 28 December 2020. The Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 5 November 2021.

The Company and its subsidiaries (together, the “**Group**”) are primarily focusing on providing AI-empowered retina-based early detection, diagnosis and health risk assessment solutions.

1. 編製基準

截至2024年6月30日止六個月的中期簡明綜合財務資料已根據《國際會計準則》第34號「中期財務報告」編製。中期簡明綜合財務資料不包括年度財務報表規定的所有資料及披露，應與本集團截至2023年12月31日止年度的年度綜合財務報表一併閱讀。

北京鷹瞳科技發展股份有限公司（「**本公司**」）於2015年9月9日在中華人民共和國（「**中國**」）成立為有限責任公司。本公司於2020年12月28日由有限責任公司改制為股份有限公司。本公司於2021年11月5日在香港聯合交易所有限公司（「**聯交所**」）主板上市。

本公司及其附屬公司（統稱「**本集團**」）主要專注於提供人工智能視網膜影像識別的早期檢測、診斷及健康風險評估解決方案。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2023, except for the adoption of the following revised International Financial Reporting Standards (“IFRSs”) for the first time for the current period's financial information.

Amendments to IFRS 16	<i>Lease Liability in a Sale and Leaseback</i>
Amendments to IAS 1	<i>Classification of Liabilities as Current or Non-current (the “2020 Amendments”)</i>
Amendments to IAS 1	<i>Non-current Liabilities with Covenants (the “2022 Amendments”)</i>
Amendments to IAS 7 and IFRS 7	<i>Supplier Finance Arrangements</i>

2. 會計政策變動及披露

編製中期簡明綜合財務資料所採納的會計政策與編製本集團截至2023年12月31日止年度的年度綜合財務報表所應用者一致，惟於本期間財務資料首次採用以下經修訂《國際財務報告準則》（「《國際財務報告準則》」）除外。

《國際財務報告準則》第16號（修訂本）	出售及租回中的租賃負債
《國際會計準則》第1號（修訂本）	負債分類為流動或非流動（「2020年修訂」）
《國際會計準則》第1號（修訂本）	附帶契諾的非流動負債（「2022年修訂」）
《國際會計準則》第7號及《國際財務報告準則》第7號（修訂本）	供應商融資安排

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

The nature and impact of the revised IFRSs are described below:

- (a) Amendments to IFRS 16 specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains. Since the Group has no sale and leaseback transactions with variable lease payments that do not depend on an index or a rate occurring from the date of initial application of IFRS 16, the amendments did not have any impact on the financial position or performance of the Group.
- (b) The 2020 Amendments clarify the requirements for classifying liabilities as current or non-current, including what is meant by a right to defer settlement and that a right to defer must exist at the end of the reporting period. Classification of a liability is unaffected by the likelihood that the entity will exercise its right to defer settlement. The amendments also clarify that a liability can be settled in its own equity instruments, and that only if a conversion option in a convertible liability is itself accounted for as an equity instrument would the terms of a liability not impact its classification. The 2022 Amendments further clarify that, among covenants of a liability arising from a loan arrangement, only those with which an entity must comply on or before the reporting date affect the classification of that liability as current or non-current. Additional disclosures are required for non-current liabilities that are subject to the entity complying with future covenants within 12 months after the reporting period.

2. 會計政策變動及披露 (續)

經修訂《國際財務報告準則》的性質及影響如下所述：

- (a) 《國際財務報告準則》第16號(修訂本)訂明賣方 — 承租人於計量售後回租交易中產生的租賃負債時所採用的規定，以確保賣方 — 承租人不確認與其保留的使用權有關的任何損益。由於本集團自首次應用《國際財務報告準則》第16號之日起，不存在可變租賃付款不取決於指數或利率的售後回租交易，因此該等修訂本並未對本集團的財務狀況或表現產生任何影響。
- (b) 2020年修訂澄清劃分負債為流動或非流動的規定，包括推遲結算權的含義，以及推遲結算權須於報告期末存在。負債的分類不受實體行使其權利延遲清償的可能性的影響。修訂本亦澄清，負債可由其自身的權益工具結算，只有當可轉換負債中的轉換選擇權本身作為權益工具入賬時，負債的條款才不會影響其分類。2022年修訂進一步明確，在貸款安排產生的負債契約中，只有實體於報告日期或之前必須遵守的契約才會影響該負債的流動或非流動分類。對於實體於報告期後12個月內必須遵守未來契約的非流動負債，需要進行額外披露。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

(b) (continued)

The Group has reassessed the terms and conditions of its liabilities as at 1 January 2023 and 2024 and concluded that the classification of its liabilities as current or non-current remained unchanged upon initial application of the amendments. Accordingly, the amendments did not have any impact on the financial position or performance of the Group.

(c) Amendments to IAS 7 and IFRS 7 clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk. The disclosure of relevant information for supplier finance arrangements is not required for any interim reporting period during the first annual reporting period in which an entity applies the amendments. As the Group does not have supplier finance arrangements, the amendments did not have any impact on the interim condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

Since the Group's revenue and operating losses were mainly from the activities related to the development, production, marketing, and sale of integrated solutions of AI-based software and hardware in Chinese Mainland, and most of the Group's identifiable operating assets and liabilities are in Chinese Mainland, the Group only has one reportable operating segment.

2. 會計政策變動及披露(續)

(b) (續)

本集團已重新評估截至2023年1月1日和2024年1月1日的負債條款及條件，並得出結論，於首次應用修訂後，其負債分類為流動或非流動保持不變。因此，該等修訂本並未對本集團的財務狀況或表現產生任何影響。

(c) 《國際會計準則》第7號及《國際財務報告準則》第7號(修訂本)闡明供應商融資安排的特點，並要求對此類安排進行額外披露。修訂本中的披露要求旨在幫助財務報表使用者瞭解供應商融資安排對實體負債、現金流量及流動資金風險的影響。在實體實施修訂的首個年度報告期內，任何中期報告期間均無須披露供應商融資安排的相關信息。由於本集團並無供應商融資安排，因此該修訂本並未對中期簡明綜合財務資料產生任何影響。

3. 經營分部資料

由於本集團收入及經營虧損主要來自於中國內地的開發、生產、市場營銷及銷售人工智能軟硬件一體化解決方案的活動，而本集團大部分可識別經營資產及負債均位於中國內地，故本集團僅有一個須予報告的經營分部。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

3. OPERATING SEGMENT INFORMATION

(continued)

Geographical information

(a) Revenue from external customers

Chinese Mainland	中國內地	89,100	78,566
Other countries/regions	其他國家/地區	4,610	3,936
Total revenue from contracts with customers	來自客戶合約的收入總額	93,710	82,502

The revenue information above is based on the locations of the customers.

(b) Non-current assets

Chinese Mainland	中國內地	245,547	254,572
Total non-current assets	非流動資產總值	245,547	254,572

The non-current asset information above is based on the locations of the assets and excludes financial instruments and deferred tax assets.

3. 經營分部資料 (續)

地區資料

(a) 來自外部客戶的收入

For the six months ended
30 June

截至6月30日止六個月

2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
89,100	78,566
4,610	3,936
93,710	82,502

上述收入資料乃根據客戶之地點劃分。

(b) 非流動資產

30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
245,547	254,572
245,547	254,572

上述非流動資產資料乃根據資產(未計金融工具及遞延稅項資產)之地點劃分。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

3. OPERATING SEGMENT INFORMATION

(continued)

Information about a major customer

(a) Disaggregated revenue information

Revenue from each of the major customers (aggregated if under common control) which accounted for 10% or more of the Group's revenue during the period is set out below:

Customer A	客戶A
Customer B	客戶B
Customer C	客戶C
Total	總計

* The corresponding revenue of the customer is not disclosed as the revenue individually did not account for 10% or more of the Group's revenue for the period ended 30 June 2024.

** The corresponding revenue of the customer is not disclosed as the revenue individually did not account for 10% or more of the Group's revenue for the period ended 30 June 2023.

3. 經營分部資料 (續)

主要客戶之資料

(a) 分類收入資料

於期內來自佔本集團收入10%或以上的各個主要客戶的收入(如受共同控制則合併計算)載列如下:

For the six months ended

30 June

截至6月30日止六個月

2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
10,389	11,273
6,179	**
*	8,494
16,568	19,767

* 截至2024年6月30日止期間，由於個別計算的收入並不佔本集團的收入10%或以上，因此並無披露該客戶的相應收入。

** 截至2023年6月30日止期間，由於個別計算的收入並不佔本集團的收入10%或以上，因此並無披露該客戶的相應收入。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

4. REVENUE

An analysis of revenue is as follows:

4. 收入

收入的分析如下：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Revenue from contracts with customers	來自客戶合約的收入	93,710	82,502
Disaggregated revenue information for revenue from contracts with customers	來自客戶合約收入的分類收入資料		
Disaggregated by customer type	按客戶類型分類		
Integrated solution of AI-based software and hardware:	人工智能軟件及硬件一體化解決方案：		
Medical institutions (Airdoc Medical)	醫療機構（鷹瞳醫療）	36,450	29,845
Consumer healthcare environments (Airdoc Health)	大健康場景（鷹瞳健康）	19,270	21,693
Eye health management settings (Airdoc Eye Health)	眼健康管理場景（鷹瞳眼健康）	37,990	30,964
Total	總計	93,710	82,502
Disaggregated by geographical market	按地區市場分類		
Chinese Mainland	中國內地	89,100	78,566
Other countries/regions	其他國家／地區	4,610	3,936
Total	總計	93,710	82,502
Disaggregated by timing of revenue recognition	按收入確認的時間分類		
Goods or services transferred at a point in time	於某一時點轉讓的貨品或服務	85,742	69,000
Services transferred over time	隨時間推移轉讓的服務	7,968	13,502
Total	總計	93,710	82,502

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

5. OTHER INCOME AND GAINS/(LOSSES) 5. 其他收入及收益／(虧損)

An analysis of other income and gains/(losses) is as follows:

其他收入及收益／(虧損)的分析如下：

		For the six months ended	
		30 June	
		截至6月30日止六個月	
		2024	2023
		2024年	2023年
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Other income	其他收入		
Interest income from bank deposits	銀行存款利息收入	4,451	8,976
Investment income from financial assets	金融資產所得投資收入	6,406	22,588
Total other income	其他收入總額	10,857	31,564
Gains	收益		
Fair value gains on financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產的公允價值收益	2,161	9,841
Foreign exchange gains, net	匯兌收益淨額	387	7,805
Government grants	政府補助	2,695	237
Others	其他	1,619	339
Total gains	收益總額	6,862	18,222
Total other income and gains	其他收入及收益總額	17,719	49,786
Other losses	其他虧損		
Loss on disposal of items of property, plant and equipment	出售物業、廠房及設備項目的虧損	—	(973)
Donation expenses	捐贈開支	—	(499)
Total other losses	其他虧損總額	—	(1,472)

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

6. FINANCE COSTS

6. 財務成本

For the six months ended

30 June

截至6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Interest on lease liabilities	租賃負債利息	<u>216</u>	<u>275</u>

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

7. LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging/ (crediting):

7. 除稅前虧損

本集團除稅前虧損乃於扣除／(計入)以下各項後得出：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Cost of inventories sold	已售存貨成本	26,263	18,801
Write-down of inventories to net realisable value	存貨較可變現淨值的 撇減	2,708	—
Cost of AI-based software solutions provided	已提供人工智能軟件 解決方案成本	10,983	12,337
Total	總計	39,954	31,138
Depreciation of property, plant and equipment	物業、廠房及設備 折舊	4,916	8,412
Depreciation of right-of-use assets	使用權資產折舊	3,419	4,192
Amortisation of other intangible assets	其他無形資產攤銷	5,017	941
Impairment of financial assets, net:	金融資產減值淨額：		
Impairment of trade receivables, net	應收賬款減值淨額	24,691	2,840
Impairment of other receivables, net	其他應收款項減值 淨額	126	98
Reversal of impairment of a guarantee contract	擔保合約減值撥回	—	(2,990)
Employee benefit expense:	僱員福利開支：		
Salaries, wages and other benefits	薪金、工資及其他 福利	75,597	80,774
Pension scheme contributions (note 1)	退休金計劃供款 (附註1)	4,675	6,132
Share-based payments	股份支付	22,589	11,147
Total	總計	102,861	98,053

Note 1: There are no forfeited contributions that may be used by the Group as the employer to reduce the existing level of contributions.

附註1：本集團(作為僱主)並無可用於以降低現有供款水平的已沒收供款。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

8. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Pursuant to the relevant rules and regulations of the Cayman Islands, a subsidiary of the Group incorporated therein is not subject to any income tax in the Cayman Islands.

Hong Kong profits tax has been provided at the rate of 8.25% (2023: 8.25%) on the estimated assessable profits arising in Hong Kong during the period of one subsidiary of the Group which is a qualifying entity under the two-tiered profits tax rates regime.

Under the relevant PRC income tax law, entities qualified as high-technology enterprises are entitled to a preferential income tax rate of 15%. The Company and three subsidiaries were recognised as high-technology enterprises and are subject to income tax at 15%.

Under the relevant PRC income tax law, the PRC subsidiaries of the Group are subject to income tax at a rate of 25% on their respective taxable income except for the Company and three subsidiaries.

8. 所得稅

本集團的各個實體須就產生自或源自本集團成員公司所在及所經營的司法管轄區的溢利繳納所得稅。

根據開曼群島相關規則及法規，本集團在開曼群島註冊成立的一家附屬公司在開曼群島毋須繳納任何所得稅。

本集團一家附屬公司之香港利得稅乃根據期內於香港產生之估計應課稅溢利按8.25% (2023年：8.25%) 之稅率計提撥備，該公司為符合兩級制利得稅稅率制度的實體。

根據相關中國所得稅法，具有高新技術企業資格的實體有權享受15%的所得稅優惠稅率。本公司及三間附屬公司獲認定為高新技術企業，並按15%的稅率繳納所得稅。

根據相關中國所得稅法，除本公司及三家附屬公司外，本集團中國附屬公司須就其各自應課稅收入按25%的稅率繳納所得稅。

For the six months ended 30 June

截至6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Current	即期		
Charge for the period	期內扣除	17	488
Overprovision in prior periods	過往期間超額撥備	(75)	—
Deferred	遞延	(1,184)	—
Total tax (credit)/charge for the period	期內稅項(抵免)/ 扣除總額	<u>(1,242)</u>	<u>488</u>

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

9. DIVIDENDS

No dividends were declared or paid by the Company during the six months ended 30 June 2024 (six months ended 30 June 2023: Nil).

10. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amount is based on the loss for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 102,119,722 (2023: 103,568,000) in issue during the period.

No adjustment has been made to the basic loss per share amounts presented for the periods ended 30 June 2024 and 2023 in respect of a dilution as the impact of the restricted shares units and restricted shares outstanding had an anti-dilutive effect on the basic loss per share amounts presented.

The calculations of basic and diluted loss per share are based on:

9. 股息

截至2024年6月30日止六個月，本公司並無宣派或派付股息（截至2023年6月30日止六個月：無）。

10. 母公司普通權益持有人應佔每股虧損

每股基本虧損金額乃根據母公司普通權益持有人應佔期內虧損，以及期內已發行普通股加權平均數102,119,722股（2023年：103,568,000股）計算。

截至2024年及2023年6月30日止期間呈列的每股基本虧損金額並未就攤薄作出調整，因為限制性股份單位及發行在外的受限制股份的影響對所呈列的每股基本虧損金額具有反攤薄效應。

每股基本及攤薄虧損的計算乃基於：

For the six months ended
30 June
截至6月30日止六個月

		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Loss	虧損		
Loss attributable to ordinary equity holders of the parent, used in the basic and diluted loss per share calculations	母公司普通權益持有人應佔虧損，用以計算每股基本及攤薄虧損	80,502	36,970

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

10. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT *(continued)*

10. 母公司普通權益持有人應佔每股虧損(續)

		Number of shares 股份數目	
		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年	2023 2023年
Shares	股份		
Weighted average number of ordinary shares in issue during the period used in the basic and diluted loss per share calculations	期內已發行普通股加權平均數，用以計算每股基本及攤薄虧損	102,119,722	103,568,000

11. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2024, the Group acquired assets at a cost of RMB7,917,000 (30 June 2023: RMB2,161,000), excluding property, plant and equipment acquired through a business combination.

Assets with a net book value of RMB757,000 were disposed of by the Group during the six months ended 30 June 2024 (30 June 2023: RMB1,136,000), resulting in a net gain on disposal of RMB48,000 (30 June 2023: a net loss on disposal of RMB973,000).

11. 物業、廠房及設備

截至2024年6月30日止六個月，本集團以成本人民幣7,917,000元（2023年6月30日：人民幣2,161,000元）收購資產，不包括通過業務合併取得的物業、廠房及設備。

截至2024年6月30日止六個月，本集團處置賬面淨值為人民幣757,000元的資產（2023年6月30日：人民幣1,136,000元），所產生處置淨收益為人民幣48,000元（2023年6月30日：處置淨虧損為人民幣973,000元）。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

12. TRADE RECEIVABLES

		30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Trade receivables	應收賬款	99,092	95,852
Impairment	減值	(40,903)	(16,212)
Total	總計	58,189	79,640

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

		30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 6 months	6個月內	40,221	48,019
6 to 12 months	6至12個月	11,695	21,340
Over 12 months	12個月以上	6,273	10,281
Total	總計	58,189	79,640

In addition to the provision matrix, for certain customers whose credit risk increased significantly, the Group has made individual loss allowances. As at 30 June 2024, the accumulated individual loss allowances were RMB23,939,000 (31 December 2023: RMB4,395,000) with a carrying amount before loss allowances of RMB38,923,000 (31 December 2023: RMB4,595,000).

12. 應收賬款

於報告期末，按發票日期為基準及經扣除虧損撥備的應收賬款的賬齡分析如下：

除撥備矩陣外，就若干信貸風險顯著增加的客戶而言，本集團已作出個別虧損撥備。於2024年6月30日，累計個別損失準備為人民幣23,939,000元（2023年12月31日：人民幣4,395,000元），而扣除虧損撥備前賬面值為人民幣38,923,000元（2023年12月31日：人民幣4,595,000元）。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

13. PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS

13. 預付款項、其他應收款項及其他資產

		30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Deposits	按金	1,240	818
Prepayments to suppliers	向供應商支付的預付款項	6,048	7,311
Value-added tax recoverable	可收回增值稅	6,181	5,215
Others	其他	10,620	5,242
Total	總計	24,089	18,586
Impairment allowance	減值撥備	(1,273)	(1,147)
Total	總計	22,816	17,439

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

14. OTHER FINANCIAL ASSETS

14. 其他金融資產

		30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Financial assets measured at amortised cost	按攤銷成本計量的金融資產	178,987	43,355
Financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產	445,763	266,895
Equity investments designated at fair value through other comprehensive income	指定以公允價值計量且其變動計入其他綜合收益的權益投資	1,520	2,000
		626,270	312,250
Classified as:	歸類為：		
Current assets	流動資產	342,068	163,837
Non-current assets	非流動資產	284,202	148,413
Total	總計	626,270	312,250

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

15. CASH AND CASH EQUIVALENTS

		30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Cash and bank balances	現金及銀行結餘	566,350	931,298
Less: Time deposits over three months (note 1)	減：超過三個月的 定期存款 (附註1)	18,587	37,519
Restricted bank deposits	受限制銀行存款	—	2,289
Cash and cash equivalents	現金及現金等價物	547,763	891,490

Note 1: The original maturity of the time deposits was more than three months but less than one year.

15. 現金及現金等價物

		30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Cash and bank balances	現金及銀行結餘	566,350	931,298
Less: Time deposits over three months (note 1)	減：超過三個月的 定期存款 (附註1)	18,587	37,519
Restricted bank deposits	受限制銀行存款	—	2,289
Cash and cash equivalents	現金及現金等價物	547,763	891,490

附註1：定期存款的原到期日為超過三個月但少於一年。

16. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

		30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 6 months	6個月內	4,796	11,443
6 months to 1 year	6個月至1年	3,146	4,483
Over 1 year	1年以上	—	1,603
Total	總計	7,942	17,529

16. 應付賬款

於報告期末，應付賬款按發票日期的賬齡分析如下：

		30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 6 months	6個月內	4,796	11,443
6 months to 1 year	6個月至1年	3,146	4,483
Over 1 year	1年以上	—	1,603
Total	總計	7,942	17,529

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

17. OTHER PAYABLES AND ACCRUALS

17. 其他應付款項及應計費用

		30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Accrued payroll	應計薪金	8,393	19,289
Other taxes payable	其他應繳稅款	21,653	20,308
Accrued expenses	應計開支	6,155	15,424
Other payables	其他應付款項	1,652	4,995
Total	總計	37,853	60,016

18. SHARE CAPITAL

18. 股本

		30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Issued and fully paid:	已發行及繳足：		
103,568,000 (31 December 2023: 103,568,000) ordinary shares of RMB1 each	103,568,000股 (於2023年 12月31日： 103,568,000股) 每股面值人民幣 1元的普通股	103,568	103,568

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

19. EQUITY-SETTLED SHARE-BASED TRANSACTIONS

Incentives granted prior to the Listing

During the year ended 31 December 2021, 2,319,588 restricted share units were granted to a director and certain employees of the Group at a price of RMB13.87 per share unit. The restricted share units (“RSUs”) granted on 1 November 2021 will vest in tranches of 25% each at the end of the fourth month, the sixteenth month, the twenty-eighth month and the fortieth month, respectively, from the date of grant upon the achievement of service period condition. The restricted share units granted on 31 December 2021 are subject to a vesting scale in tranches of 25% each per annum from the date of grant upon the achievement of service period condition.

The number and movements of RSUs are as follows:

		RMB'000 人民幣千元
At 1 January 2023	於2023年1月1日	1,590,688
Forfeited during the year	於年內已失效	(746,807)
Vested during the year	於年內歸屬	(402,285)
At 31 December 2023 and 1 January 2024	於2023年12月31日及 2024年1月1日	441,596
Forfeited during the period	於期內已失效	(836)
Vested during the period	於期內歸屬	(84,499)
At 30 June 2024 (unaudited)	於2024年6月30日(未經審核)	356,261

19. 以權益結算的股份支付交易

於上市前授予的激勵

截至2021年12月31日止年度，本集團以每股份單位人民幣13.87元的價格向一位董事及若干僱員授出2,319,588份受限制股份單位。於2021年11月1日授予的受限制股份單位(「受限制股份單位」)將於達成服務期限條件後分別自授出日期起的第4個月末、第16個月末、第28個月末和第40個月末按每批25%的比例歸屬。於2021年12月31日授出的受限制股份單位將於達成服務期限條件後自授出日期起，按每年每批25%的比例歸屬。

受限制股份單位的數目及變動如下：

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

19. EQUITY-SETTLED SHARE-BASED TRANSACTIONS (continued)

Incentives granted prior to the Listing (continued)

As at 30 June 2024, 356,261 RSUs remained unvested. The grant date fair values of the RSUs granted on 1 November 2021 and on 31 December 2021 were determined based on the difference between the market share price at the grant date and the price of the RSUs payable by the grantee of RMB13.87 per share unit. The weighted average grant date fair values of these RSUs issued on 1 November 2021 and 31 December 2021 are RMB61.73 and RMB31.40 per share unit, respectively.

2022 Equity Incentive Scheme

On 30 March 2023, the Group granted 3,107,040 restricted shares at the price of RMB0.00 per share to Mr. Zhang Dalei and the restricted shares will vest in tranches of 25% each at the end of the ninth month, the twenty-first month, the thirty-third month and forty-fifth month, respectively, from the date of grant.

On 24 April 2024, the Group granted 3,107,040 restricted shares at the price of RMB0.00 per share to forty-two employees. Among them, 2,907,040 restricted shares granted will be vested in 25% on the grant date, and the remaining 75% will be assessed through certain performance conditions and vested at the end of the 12th, 24th and 36th months, respectively, from the grant date. Another 200,000 restricted shares granted will be vested in batches upon the achievement of the performance appraisal milestones as agreed in the grant agreement.

19. 以權益結算的股份支付交易 (續)

於上市前授予的激勵 (續)

於2024年6月30日，仍有356,261份受限制股份單位尚未歸屬。於2021年11月1日及2021年12月31日授予的受限制股份單位的授予日公允價值按授出日期的市場股價與承授人應付的受限制股份單位價格每股份單位人民幣13.87元的差額釐定。於2021年11月1日及2021年12月31日發行之此等受限制股份單位的授予日加權平均公允價值分別為每股份單位人民幣61.73元及人民幣31.40元。

2022年股權激勵計劃

於2023年3月30日，本集團以每股人民幣0.00元的價格向張大磊先生授出3,107,040股受限制股份，且受限制股份將分別於授予日期起第9個月末、第21個月末、第33個月末和第45個月末按每批25%的比例歸屬。

於2024年4月24日，本集團以每股人民幣0.00元的價格向42名員工授出3,107,040股受限制股份。其中，2,907,040股受限制股份將於授予日歸屬25%，其餘75%將通過若干業績條件評估，分別於授予日起第12個月末、第24個月末及第36個月末歸屬。另外已授出之200,000股受限制股份將於達到授予協議中約定的績效考核里程碑後分批歸屬。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

19. EQUITY-SETTLED SHARE-BASED TRANSACTIONS (continued)

2022 Equity Incentive Scheme (continued)

The number and movements of restricted shares are as follows:

19. 以權益結算的股份支付交易 (續)

2022年股權激勵計劃 (續)

受限制股份的數目及變動如下：

		RMB'000 人民幣千元
At 1 January 2023	於2023年1月1日	—
Granted during the year	於年內授予	3,107,040
Vested during the year	於年內歸屬	(776,760)
At 31 December 2023 and 1 January 2024	於2023年12月31日及 2024年1月1日	<u>2,330,280</u>
Granted during the period	於期內授予	3,107,040
Vested during the period	於期內歸屬	(726,760)
Forfeited during the period	於期內已失效	(3,392)
At 30 June 2024 (unaudited)	於2024年6月30日 (未經審核)	<u>4,707,168</u>

As at 30 June 2024, 4,707,168 restricted shares remained unvested. The grant date fair values of the restricted shares granted on 30 March 2023 and 24 April 2024 were determined based on the market share price at the grant date of RMB13.34 and RMB13.49, respectively.

於2024年6月30日，4,707,168股受限制股份仍未歸屬。於2023年3月30日及2024年4月24日授予的受限制股份的授予日公允價值分別按授出日期的市場股價人民幣13.34元及人民幣13.49元釐定。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

20. COMMITMENTS

The Group had the following contractual commitments at the end of the reporting period:

20. 承擔

本集團於報告期末的合約承擔如下：

		30 June 2024 於2024年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2023 於2023年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Purchase of other financial assets (note 1)	購買其他金融資產 (附註1)	12,625	14,176
Capital contributions (note 2)	出資額(附註2)	25,000	35,000
Total	總計	37,625	49,176

Note 1: The Group has committed to purchase several fund investments of USD1,772,000 (equivalent to RMB12,625,000) as at 30 June 2024 (31 December 2023: USD2,002,000 (equivalent to RMB14,176,000)).

附註1：於2024年6月30日，本集團已承諾購買若干基金投資1,772,000美元(相當於人民幣12,625,000元)(2023年12月31日：2,002,000美元(相當於人民幣14,176,000元))。

Note 2: In addition, in April 2024, the Group signed a partnership agreement to invest in a fund and the total capital contribution amounted to RMB25,000,000.

附註2：此外，本集團於2024年4月簽署合夥協議以投資基金，出資總額達人民幣25,000,000元。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

21. RELATED PARTY TRANSACTIONS

(a) Transactions with related parties

The Group had the following transactions with related parties during the period:

Revenue from the provision of AI-based software solutions:	提供人工智能軟件解決方案的收入：
Fellow subsidiaries of a minority shareholder	一名少數股東的同系附屬公司

2024	2023
2024年	2023年
RMB'000	RMB'000
人民幣千元	人民幣千元
(Unaudited)	(Unaudited)
(未經審核)	(未經審核)

For the six months ended

30 June

截至6月30日止六個月

1,066

4

(b) Outstanding balances with related parties

Amounts due from related parties:	應收關聯方款項：
Fellow subsidiaries of a minority shareholder	一名少數股東的同系附屬公司

30 June	31 December
2024	2023
於2024年	於2023年
6月30日	12月31日
RMB'000	RMB'000
人民幣千元	人民幣千元
(Unaudited)	(Audited)
(未經審核)	(經審核)

1,984

2,624

21. 關聯方交易

(a) 與關聯方的交易

於本期間，本集團與關聯方進行的交易如下：

(b) 與關聯方的未償還結餘

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

21. RELATED PARTY TRANSACTIONS

(continued)

(c) Compensation of key management personnel of the Group:

21. 關聯方交易 (續)

(c) 本集團關鍵管理人員酬金：

		For the six months ended 30 June 截至6月30日止六個月	
		2024 2024年 (Unaudited) (未經審核) RMB'000 人民幣千元	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元
Salaries, bonuses, allowances and benefits in kind	薪金、花紅、津貼及實物福利	2,695	3,298
Pension scheme contributions	退休金計劃供款	196	168
Share-based payments	股份支付	13,394	7,110
Total compensation paid to key management personnel	已付關鍵管理人員之酬金總額	16,285	10,576

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

Management has assessed that the fair values of cash and cash equivalents, time deposits, restricted bank deposits, trade receivables, trade payables, financial assets included in prepayments, other receivables and other assets, financial liabilities included in other payables and accruals approximate to their carrying amounts largely due to the short term maturities of these instruments.

The Group's finance department headed by the chief financial officer is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the chief financial officer and the audit committee. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer. The valuation process and results are discussed with the audit committee twice a year for interim and annual financial reporting.

The fair values of the financial assets are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values of those financial assets.

22. 金融工具公允價值和公允價值等級

管理層評定，現金及現金等價物、定期存款、受限制銀行存款、應收賬款、應付賬款、計入預付款項、其他應收款項及其他資產的金融資產以及計入其他應付款項及應計費用的金融負債的公允價值與其賬面值相若，主要由於該等工具於短期內到期。

本集團由首席財務官領導之財務部門負責釐定金融工具公允價值計量的政策及程序。財務經理直接向首席財務官及審核委員會呈報。於各報告日期，財務部門分析金融工具的價值變動並釐定應用於估值的主要輸入數據。估值由首席財務官審核及批准。估值過程及結果與審核委員會每年討論兩次以進行中期及年度財務申報。

金融資產的公允價值按自願方之間的當前交易（強迫或清算銷售除外）中可交換工具的金額列賬。於估計該等金融資產的公允價值時已採用以下方式及假設。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS *(continued)*

The fair values of unlisted equity investments designated at fair value through other comprehensive income have been estimated using a market-based valuation technique based on assumptions. The valuation requires the directors to determine comparable public companies (peers) based on industry, size, leverage and strategy, and to calculate an appropriate price multiple, for each comparable company identified. The multiple is calculated by dividing the market capitalization of the comparable company by sales measure. The trading multiple is then discounted for considerations between the comparable companies based on company-specific facts and circumstances. The discounted multiple is applied to the corresponding earnings measure of the unlisted equity investments to measure the fair value. The directors believe that the estimated fair values resulting from the valuation technique, which are recorded in the interim condensed consolidated statement of financial position, and the related changes in fair values, which are recorded in other comprehensive income, are reasonable, and that they were the most appropriate values at the end of the reporting period.

The Group invests in unlisted investments in the British Virgin Islands, fund investments issued by financial institutions in the Cayman Islands and other regions and wealth management products issued by banks in Chinese Mainland China. The Group has estimated the fair values of these financial products and unlisted investments by using a discounted cash flow valuation model based on the market interest rates of instruments with similar terms and risks.

22. 金融工具公允價值和公允價值等級 *(續)*

指定以公允價值計量且其變動計入其他綜合收益的非上市權益投資的公允價值已使用市場估值法，根據假設進行估計。估值須董事根據行業、規模、槓桿比率及策略確定可資比較公眾公司（同業），並就所識別的各可資比較公司計算合適價格倍數。倍數乃將可資比較公司之市值除以銷量計量而計算。隨後，交易倍數將在考慮可資比較公司的差異後根據公司特定事實及情況作出折讓。經折讓倍數將應用於非上市權益投資的相應盈利計量以計量公允價值。董事相信，由估值方法產生的估計公允價值（已於中期簡明綜合財務狀況表入賬）及相關公允價值變動（已於其他綜合收益入賬）乃屬合理，且其為於報告期末的最適當價值。

本集團投資於英屬處女群島的非上市投資、開曼群島及其他地區金融機構發行的基金投資及中國內地銀行發行的理財產品。本集團已根據具有類似條款及風險的工具的市場利率採用貼現現金流估值模式估計該等金融產品及非上市投資的公允價值。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

For the fair value of the unlisted equity investments at fair value through other comprehensive income, management has estimated the potential effect of using reasonably possible alternatives as inputs to the valuation model.

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 30 June 2024

22. 金融工具公允價值和公允價值等級 (續)

就以公允價值計量且其變動計入其他綜合收益的非上市權益投資的公允價值而言，管理層已對在估值模型中運用合理可能的替代輸入數據的潛在影響作出估計。

公允價值等級

下表闡明本集團金融工具公允價值計量等級：

按公允價值計量的資產：

於2024年6月30日

		Fair value measurement using 公允價值計量採用以下基準			
		Quoted prices in active markets (Level 1) (第一層級) RMB'000 (Unaudited) (未經審核)	Significant observable inputs (Level 2) (第二層級) RMB'000 (Unaudited) (未經審核)	Significant unobservable inputs (Level 3) (第三層級) RMB'000 (Unaudited) (未經審核)	Total 總計 RMB'000 (Unaudited) (未經審核)
Equity investments designated at fair value through other comprehensive income	指定為以公允價值計量且其變動計入其他綜合收益的權益投資	—	1,520	—	1,520
Financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產	—	140,505	305,258	445,763
Total	總計	—	142,025	305,258	447,283

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

Fair value hierarchy (continued)

Assets measured at fair value: (continued)

As at 31 December 2023

22. 金融工具公允價值和公允價值等級 (續)

公允價值等級 (續)

按公允價值計量的資產：(續)

於2023年12月31日

Fair value measurement using
公允價值計量採用以下基準

		Quoted prices in active markets	Significant observable inputs	Significant unobservable inputs 重大影響的 不可觀察 輸入數據	Total 總計
		(Level 1) RMB'000 人民幣千元 (Unaudited) (未經審核)	(Level 2) RMB'000 人民幣千元 (Unaudited) (未經審核)	(Level 3) RMB'000 人民幣千元 (Unaudited) (未經審核)	(Level 3) RMB'000 人民幣千元 (Unaudited) (未經審核)
Equity investments designated at fair value through other comprehensive income	指定為以公允價值計量且其變動計入其他綜合收益的權益投資	—	2,000	—	2,000
Financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產	—	—	266,895	266,895
Total	總計	—	2,000	266,895	268,895

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

Fair value hierarchy (continued)

Assets measured at fair value: (continued)

The movements in fair value measurements within Level 3 during the period are as follows:

22. 金融工具公允價值和公允價值等級 (續)

公允價值等級 (續)

按公允價值計量的資產：(續)

期內，第三層級中的公允價值計量變動如下：

		2024 2024年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Financial assets at fair value through profit or loss:	以公允價值計量且其變動計入當期損益的金融資產：		
At 1 January	於1月1日	266,895	126,186
Total gains recognised in other income and gains in the interim condensed consolidated statement of profit or loss	於中期簡明綜合損益表的其他收入及收益確認的收益總額	1,656	9,841
Purchases	購買	86,214	224,350
Redemption	贖回	(49,507)	(17,045)
At 30 June	於6月30日	<u>305,258</u>	<u>343,332</u>

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 JUNE 2024 於2024年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS *(continued)*

Fair value hierarchy *(continued)*

Liabilities measured at fair value:

The Group did not have any financial liabilities measured at fair value as at 30 June 2024 and 31 December 2023.

During the period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for financial assets (six months ended 30 June 2023: Nil).

23. EVENTS AFTER THE REPORTING PERIOD

- On 1 July 2024, the Company paid in capital contributions of RMB25,000,000 based on a partnership agreement which was signed in April 2024. Details about the capital contributions are given in note 20.
- On 28 August 2024, the Board resolved to adopt the 2024 Equity Incentive Scheme, which is subject to consideration and approval by the Shareholders at the extraordinary general meeting.

24. COMPARATIVE AMOUNTS

The Group separately presented impairment losses on financial assets and other losses. Accordingly, comparative amounts have been reclassified to conform with the current period's presentation and disclosures. The reclassification did not have any significant impact on the Group's financial statements for the six months ended 30 June 2023.

22. 金融工具公允價值和公允價值等級 *(續)*

公允價值等級 *(續)*

按公允價值計量的負債：

於2024年6月30日及2023年12月31日，本集團並無任何按公允價值計量的金融負債。

於期內，金融資產在第一層級與第二層級之間並無公允價值層級轉撥，亦無轉至或轉出第三層級（截至2023年6月30日止六個月：無）。

23. 報告期後事項

- 於2024年7月1日，本公司根據於2024年4月簽署的合夥協議實繳出資人民幣25,000,000元。有關出資的詳情載於附註20。
- 於2024年8月28日，董事會議決採納2024年股權激勵計劃，該計劃須待股東於臨時股東大會上審議及批准後，方可作實。

24. 可比較金額

本集團單獨呈列金融資產減值虧損及其他虧損。因此，可比較金額已重新分類以符合本期間之呈列及披露。重新分類對本集團截至2023年6月30日止六個月的財務報表並無任何重大影響。

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術詞彙表

<p>“2022 Equity Incentive Scheme”</p> <p>「2022年股權激勵計劃」</p>	<p>the equity incentive scheme adopted by the Board in accordance with the rules thereof on January 13, 2023 and approved by the Shareholders on the extraordinary general meeting of the Company held on March 30, 2023, the details of which are set out in the circular of the Company dated March 10, 2023</p> <p>指 董事會於2023年1月13日根據其規則採納之股權激勵計劃，並經股東於本公司於2023年3月30日舉行的臨時股東大會上批准，其詳情載於本公司日期為2023年3月10日之通函</p>
<p>“AI”</p> <p>「人工智能」</p>	<p>artificial intelligence</p> <p>指 人工智能</p>
<p>“Airdoc”, “Group”, “we” or “us”</p> <p>「鷹瞳」、「本集團」或「我們」</p>	<p>our Company and all of our subsidiaries or, where the context so requires, in respect of the period before our Company became the holding company of its present subsidiaries, the businesses operated by such subsidiaries or their predecessors (as the case may be)</p> <p>指 本公司及我們的所有附屬公司，或倘文義指明，就本公司成為其目前附屬公司的控股公司之前的期間而言，指由該等附屬公司或其前身(視情況而定)所經營的業務</p>
<p>“Airdoc Beijing”</p> <p>「北京鷹瞳」</p>	<p>Beijing Airdoc Health Technology Co., Ltd.* (北京鷹瞳健康科技有限公司), a company established in the PRC with limited liability on August 30, 2018 and an indirect wholly owned subsidiary of our Company</p> <p>指 北京鷹瞳健康科技有限公司，一家於2018年8月30日在中國成立的有限責任公司，為本公司的間接全資附屬公司</p>
<p>“Airdoc Universe”</p> <p>「鬱金香宇宙」</p>	<p>Beijing Airdoc Universe Technology Center L.P.* (北京鬱金香宇宙科技中心(有限合夥)), a limited partnership established in the PRC on February 22, 2016, an employee incentive platform of our Group and a member of our single largest group of Shareholders</p> <p>指 北京鬱金香宇宙科技中心(有限合夥)，一家於2016年2月22日在中國成立的有限合夥公司，為本集團僱員激勵平台，及單一最大股東集團成員</p>
<p>“Articles of Association”</p> <p>「組織章程細則」</p>	<p>the articles of association of the Company adopted on May 12, 2021, which will become effective upon the Listing Date, as amended from time to time</p> <p>指 本公司於2021年5月12日採納的經不時修訂並將於上市日期後生效的組織章程細則</p>

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術詞彙表

“ASCVD” 「ASCVD」	atherosclerotic cardiovascular disease 指 動脈粥樣硬化性心血管疾病
“associate(s)” 「聯繫人」	has the meaning ascribed to it under the Listing Rules 指 具有上市規則所賦予的涵義
“AUC” 「AUC」	area under the receiver operating characteristic curve (ROC curve), a measurement of the ability of a model to distinguish between positive and negative cases 指 受試者工作特徵曲線(ROC曲線)下方的面積，衡量模型區分陽性和陰性病例的能力
“Audit Committee” 「審核委員會」	the audit committee of the Board 指 董事會審核委員會
“Board” or “Board of Directors” 「董事會」	the board of directors of our Company 指 本公司董事會
“Board of Supervisors” 「監事會」	the board of supervisors of the Company 指 本公司監事會
“Business Day” 「營業日」	any day (other than a Saturday, Sunday or public holiday in Hong Kong and any day on which tropical cyclone warning no. 8 or above or a black rainstorm warning signal is hoisted in Hong Kong) on which banks in Hong Kong are generally open for normal banking business 指 香港銀行一般開門辦理常規銀行業務的任何日子(星期六、星期日或香港公眾假期，及香港懸掛八號或以上熱帶氣旋警告或黑色暴雨警告訊號的任何日子除外)
“CAGR” 「年複合增長率」	compound annual growth rate 指 年複合增長率
“CDR” 「CDR」	cup to disc ratio, a measurement used in ophthalmology and optometry to assess the progression of glaucoma 指 杯盤比，在眼科和驗光中用於評估青光眼進展的一種測量方法

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術詞彙表

“CG Code”	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
「企業管治守則」	指 上市規則附錄C1所載企業管治守則
“China” or “the PRC”	the People’s Republic of China but for the purpose of this interim report and for geographical reference only and except where the context requires, references in this interim report to “China” and the “PRC” do not include Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
「中國」	指 中華人民共和國，除文義另有所指外，就本中期報告及僅就地域參考而言，本中期報告提及的「中國」不包括中國香港、澳門特別行政區及台灣
“Class III medical device”	medical devices with relatively high risks, which shall be strictly controlled and administered through special measures to ensure their safety and effectiveness under the Regulation on the Supervision and Administration of Medical Devices (《醫療器械監督管理條例》)
「第三類醫療器械」	指 根據《醫療器械監督管理條例》，具有相對較高風險，需要採取特別措施嚴格控制管理以保證其安全有效的醫療器械
“CNIPA”	the National Intellectual Property Administration of the PRC (國家知識產權局)
「國家知識產權局」	指 中國國家知識產權局
“Companies Ordinance”	the Companies Ordinance, Chapter 622 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
「公司條例」	指 香港法例第622章公司條例(經不時修訂、補充或以其他方式修改)
“Company”, “our Company” or “the Company”	Beijing Airdoc Technology Co., Ltd. (北京鷹瞳科技發展股份有限公司), a joint stock company incorporated in the PRC with limited liability on September 9, 2015
「本公司」	指 北京鷹瞳科技發展股份有限公司，一家於2015年9月9日在中國註冊成立的股份有限公司

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術詞彙表

“Concert Party Agreement”	the agreement entered into between Mr. Zhang, Mr. Chen and Mr. Gao on October 14, 2016, pursuant to which Mr. Chen and Mr. Gao have undertaken to, among other things, vote unanimously with Mr. Zhang for any resolutions proposed at any Board and Shareholders’ meetings of our Company
「一致行動人士協議」	指 根據張先生、陳先生及高先生於2016年10月14日達成的協議，陳先生及高先生已承諾（其中包括）就於本公司任何董事會及股東大會上提出的任何決議案與張先生一致投票
“connected person”	has the meaning ascribed thereto under the Listing Rules
「關連人士」	指 具有上市規則所賦予的涵義
“connected transaction”	has the meaning ascribed thereto under the Listing Rules
「關連交易」	指 具有上市規則所賦予的涵義
“core connected person”	has the meaning ascribed thereto under the Listing Rules
「核心關連人士」	指 具有上市規則所賦予的涵義
“Core Product(s)”	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purpose of this prospectus, our Core Product refers to our Airdoc-AIFUNDUS
「核心產品」	指 具有上市規則第18A章所賦予的涵義；就本招股章程而言，我們的 核心產品指Airdoc-AIFUNDUS
“COVID-19”	a viral respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
「COVID-19」	指 由嚴重急性呼吸綜合症冠狀病毒2(SARS-CoV-2)引發的病毒性呼吸道疾病
“CSDC”	China Securities Depository and Clearing Co., Ltd. (中國證券登記結算有限責任公司)
「中國結算」	指 中國證券登記結算有限責任公司
“CSRC”	China Securities Regulatory Commission (中國證券監督管理委員會), a regulatory body responsible for the supervision and regulation of the PRC national securities markets
「中國證監會」	指 中國證券監督管理委員會，負責監督及規管中國國家證券市場的監管機構

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術詞彙表

<p>“Director(s)” [董事]</p>	<p>the director(s) of our Company, including all executive, non-executive and independent non-executive directors 指 本公司董事，包括所有執行董事、非執行董事及獨立非執行董事</p>
<p>“EIT Law” [《企業所得稅法》]</p>	<p>the Enterprise Income Tax Law of the PRC (《中華人民共和國企業所得稅法》), as amended, supplemented or otherwise modified from time to time 指 《中華人民共和國企業所得稅法》(經不時修訂、補充或以其他方式修改)</p>
<p>“Global Offering” [全球發售]</p>	<p>the Hong Kong Public Offering and the International Offering 指 香港公開發售及國際發售</p>
<p>“Greater China” [大中華區]</p>	<p>PRC, Hong Kong, Macau and Taiwan 指 中國、香港、澳門及台灣</p>
<p>“Guowei Jian’an” [國衛健安]</p>	<p>Beijing Guowei Jian’an Technology Co., Ltd.* (北京國衛健安科技有限公司), a company established in the PRC with limited liability on January 23, 2018 and a subsidiary of our Company 指 北京國衛健安科技有限公司，一家於2018年1月23日在中國成立的有限責任公司，為本公司的附屬公司</p>
<p>“H Share(s)” [H股]</p>	<p>overseas listed foreign share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are to be listed on the Stock Exchange and traded in Hong Kong dollars 指 指本公司股本中每股面值人民幣1.00元的境外上市外資股，將於聯交所上市並以港元交易</p>
<p>“H Share Registrar” [H股證券登記處]</p>	<p>Tricor Investor Services Limited 指 卓佳證券登記有限公司</p>
<p>“HK\$” or “Hong Kong Dollars” [港元]</p>	<p>Hong Kong dollars, the lawful currency of Hong Kong 指 港元，香港法定貨幣</p>
<p>“Hong Kong” [香港]</p>	<p>the Hong Kong Special Administrative Region of the PRC 指 中國香港特別行政區</p>
<p>“IASB” [國際會計準則理事會]</p>	<p>International Accounting Standards Board 指 國際會計準則理事會</p>

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術詞彙表

“ICVD”	ischemic cardiovascular disease, including myocardial infarction and cerebral infarction
「ICVD」	指 缺血性心血管疾病，包括心肌梗塞及腦梗塞
“IFRS”	International Financial Reporting Standards
「國際財務報告準則」	指 國際財務報告準則
“Incentive Shares”	H Shares underlying the incentives to be granted to the selected participants in the 2022 Equity Incentive Scheme
「激勵股份」	指 將向2022年股權激勵計劃選定激勵對象授予的激勵相關H股
“Listing” or “IPO”	the listing of our Shares on the Stock Exchange
「上市」或「首次公開發售」	指 我們的股份於聯交所上市
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
「上市規則」	指 聯交所證券上市規則(經不時修訂或補充)
“Main Board”	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the Growth Enterprise Market of the Stock Exchange. For the avoidance of doubt, the Main Board excludes the Growth Enterprise Market of the Stock Exchange
「主板」	指 由聯交所運營的股票交易所(不包括期權市場)，乃獨立於聯交所GEM並與其並行運作。為免生疑問，主板不包括聯交所GEM
“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 of the Listing Rules
「標準守則」	指 上市規則附錄C3所載的上市發行人董事進行證券交易的標準守則
“Mr. Chen”	Mr. Chen Mingqiang (陳明強), one of our co-founders and a member of the single largest group of Shareholders
「陳先生」	指 陳明強先生，乃我們的聯合創始人之一及單一最大股東集團成員
“Mr. Gao”	Mr. Gao Fei (高斐), one of our co-founders, and a member of the single largest group of Shareholders
「高先生」	指 高斐先生，乃我們的聯合創始人之一及單一最大股東集團成員
“Mr. Zhang”	Mr. Zhang Dalei (張大磊), our founder, the chairman of the Board, an executive Director and a member of the single largest group of Shareholders
「張先生」	指 張大磊先生，乃我們的創始人、董事會主席、執行董事及單一最大股東集團成員

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術詞彙表

“NASDAQ” 「納斯達克」	the Nasdaq Stock Market 指 納斯達克股票市場
“NMPA” 「國家藥監局」	the National Medical Products Administration of China (國家藥品監督管理局) or, where the context so requires, its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局), or CFDA 指 國家藥品監督管理局(或按文義所指其前身國家食品藥品監督管理總局(又稱CFDA))
“Nomination Committee” 「提名委員會」	the nomination committee of the Board 指 董事會提名委員會
“OEM” 「原設備製造商」	acronym for original equipment manufacturer, a business that manufactures goods or equipment for branding and release by others 指 原設備製造商(縮寫為OEM)，製造貨品或設備供他人創建品牌或發佈產品的企業
“Ping An Healthtech” 「平安醫療科技」	Ping An Healthtech Co., Ltd. (平安醫療科技有限公司), a company established in the PRC with limited liability on September 28, 2017 指 平安醫療科技有限公司，一家於2017年9月28日在中國成立的有限責任公司
“pricing guidance” 「定價指引」	a guidance issued by governmental authorities, which is a prerequisite for the public hospitals to set specific charging items for medical service and charge patients accordingly 指 政府機關發佈的指引，為公共醫院為醫療服務設置特定收費項目，並據此作為向患者收費的先決條件
“Prospectus” 「招股章程」	the prospectus issued by the Company dated October 26, 2021 指 本公司於2021年10月26日發佈的招股章程
“R&D” 「研發」	Research and Development 指 研究及開發
“Remuneration and Appraisal Committee” 「薪酬與考核委員會」	the remuneration and appraisal committee of the Board 指 董事會薪酬與考核委員會
“Renminbi” or “RMB” 「人民幣」	Renminbi Yuan, the lawful currency of China 指 中國的法定貨幣人民幣

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術詞彙表

“Reporting Period” 「報告期」	the six months ended June 30, 2024 指 截至2024年6月30日止六個月
“SaMD(s)” 「SaMD」	Software as a Medical Device, a class of medical software designed to carry out one or more medical functions without the need for actual hardware 指 作為醫療器械的軟件，是一類無需實際硬件即可用於執行一種或多種醫療功能的醫療軟件
“SFO” 「證券及期貨條例」	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended or supplemented from time to time 指 香港法例第571章證券及期貨條例(經不時修訂或補充)
“Shanghai Zhongyou” 「上海眾佑」	Shanghai Zhongyou Intelligent Technology Co., Ltd.* (上海眾佑智能科技有限公司), a company established in the PRC with limited liability on July 25, 2017 and a wholly owned subsidiary of our Company 指 上海眾佑智能科技有限公司，一家於2017年7月25日在中國成立的有限責任公司，為本公司的全資附屬公司
“Share(s)” 「股份」	shares in the share capital of our Company, with a nominal value of RMB1.00 each, comprising Unlisted Shares and H Shares 指 本公司股本中每股面值人民幣1.00元的股份，包括非上市股份及H股
“Shareholder(s)” 「股東」	holder(s) of the Share(s) 指 股份的持有人
“Stock Exchange” 「聯交所」	The Stock Exchange of Hong Kong Limited 指 香港聯合交易所有限公司
“Strategy Committee” 「戰略委員會」	the strategy committee of the Board 指 董事會戰略委員會
“subsidiary(ies)” 「附屬公司」	has the meaning ascribed to it in section 15 of the Companies Ordinance 指 具有公司條例第15條所賦予的涵義
“Substantial Shareholder(s)” 「主要股東」	has the meaning ascribed to it under the Listing Rules 指 具有上市規則所賦予的涵義
“Supervisor(s)” 「監事」	supervisor(s) of our Company 指 本公司監事

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術詞彙表

“Suqian Airdoc”	Suqian Airdoc Technology Center (Limited Partnership)* (宿遷鷹瞳科技中心(有限合夥)), a limited partnership established in the PRC on October 13, 2020 and an employee incentive platform of our Group
「宿遷鷹瞳」	指 宿遷鷹瞳科技中心(有限合夥)，一家於2020年10月13日在中國成立的有限合夥企業，且為本集團僱員激勵平台
“Suqian Zhongyou”	Suqian Zhongyou Technology Center (Limited Partnership)* (宿遷眾佑科技中心(有限合夥)), a limited partnership established in the PRC on November 10, 2020 and an employee incentive platform of our Group
「宿遷眾佑」	指 宿遷眾佑科技中心(有限合夥)，一家於2020年11月10日在中國成立的有限合夥企業，且為本集團僱員激勵平台
“U.S.” or “United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
「美國」	指 美利堅合眾國，其領土、屬地及受其司法管轄的所有地區
“U.S. dollars” or “US\$”	United States dollars, the lawful currency of the United States
「美元」	指 美元，美國法定貨幣
“Unlisted Share(s)”	domestic share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is(are) subscribed for and paid up in RMB by domestic investors and currently not listed on any stock exchange
「未上市股份」	指 本公司股本中每股面值人民幣1.00元的內資股，由境內投資者以人民幣認購並繳足，目前並未於任何證券交易所上市
“Yadong Beichen”	Yadong Beichen Venture Investment Co., Ltd.* (亞東北辰創業投資有限公司), previously known as Yadong Beichen Investment Management Co., Ltd.* (亞東北辰投資管理有限公司), a company established in the PRC with limited liability on August 2, 2013
「亞東北辰」	指 亞東北辰創業投資有限公司(前稱亞東北辰投資管理有限公司)，一家於2013年8月2日在中國成立的有限責任公司

For the purpose of this interim report, references to “provinces” of China include provinces, municipalities under direct administration of the central government and provincial-level, autonomous regions.

就本中期報告而言，提及中國的「省」包括省、中央政府直接管理的直轄市及省級自治區。



Airdoc 鹰瞳